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Summary 
 
 Phenylketonuria (PKU) is an autosomal recessive human inborn error of metabolism caused 
by dysfunction of the liver homotetrameric/homodimeric enzyme phenylalanine hydroxylase 
(hPAH), which results in increased levels of L-phenylalanine (L-Phe) in the blood and if 
untreated causes severe mental retardation. More than 550 mutations have been identified to 
date, with three quarters of PKU patients being compound heterozygous, leading to a high 
phenotypic diversity. Inconsistencies in some genotype-phenotype correlations with more severe 
phenotypes than the ones expected and lack of response to cofactor ((6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4)) supplementation in patients with two known responsive mutations 
have raised the possibility of interallelic complementation (IC). We have shown that mutations 
involved in inconsistencies (I65T, R261Q, R270K and V338M) display a negative IC, with 
reduced enzymatic activity when mimicking the heteroallelic state of compound heterozygous 
PKU patients. Moreover, using wild-type and truncated mutants forms we were able to isolate an 
heterotetrameric hPAH form, WT/∆N102-hPAH, that resulted from the assembly of two 
homodimers, since heterodimers did not form. This hybrid species revealed kinetic and 
regulatory properties that were influenced by interactions between the two homodimers within 
the heterotetramer. 
 Phenylketonuria is considered a protein misfolding disease with loss of function, as a large 
number of point mutations result in decreased stability, aggregation and accelerated protein 
degradation. The deleterious effects seem to particularly affect the R-domain of hPAH that 
contains an ACT module found in a large number of multimeric proteins with complex allosteric 
regulation. Here we have studied the effect of the missense mutation G46S in the R-domain that 
promotes self-association and fibril formation in vitro. The mutation seems to extend α-helix 1 
and thus perturbs the α-β sandwich of the ACT module in the R-domain. We were able to 
modulate in vitro the mutant self-association process by chemical, pharmacological and 
molecular chaperones. The mutant G46S dimer also self-associates forming fibrils and an 
enhancement in the self-association was observed in the presence of WT dimer, due to hybrid 
formation (WT/G46S). However, only amorphous aggregates were observed and L-Phe binding 
precludes the self-association of the WT dimer, since the wild-type and mutant tetramer ↔ 
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dimer equilibrium responds differently to the presence of L-Phe, thus explaining the phenotype 
of WT/G46S carriers, as none of the PKU heterozygous shows any clinical phenotype.  
The R-domain of full-length hPAH is particularly unstable and when isolated it self-associates 
even in its WT form. This self-association was inhibited stereospecifically by L-Phe, pointing to 
a regulatory binding site that has been disputed over the years. It seems now evident that the 
isolated R-domain is able to bind L-Phe as we and other groups have observed, but the full-length 
enzyme has lost this ability with the simultaneously acquiring of complex regulatory 
mechanisms. 
One of these regulatory mechanisms comprises the catalytic activation by the substrate. In the 
resting state hPAH is inhibited by the cofactor BH4. Binding of L-Phe triggers a series of 
conformational changes that resulted in the activation of the enzyme. Crystal structures of hPAH 
with bound cofactor and substrate have revealed a large displacement of Tyr138 in a highly 
flexible loop, from a surface position to a partial buried position at the active site upon substrate 
binding. Here we have found an important functional role for Tyr138 displacement in positioning 
substrates for catalysis and in the L-Phe triggered conformational isomerization that results in 
catalytic activation of the enzyme. 
 
 
 
Keywords: human phenylalanine hydroxylase; phenylketonuria; interallelic complementation; 
hybrid protein; misfolding; self-association; ACT domain; substrate activation. 
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A fenilcetonúria (PKU; OMIM 261600) é uma doença autossómica recessiva do 
metabolismo, causada por uma deficiente actividade da enzima homotetramérica/homodimérica 
fenilalanina hidroxilase (hPAH; EC 1.14.16.1). A enzima existe maioritariamente nos 
hepatócitos, onde é responsável pela hidroxilação da L-fenilalanina (L-Phe) em L-tirosina (L-Tyr) 
na presença do cofactor (6R)-L-eritro-5,6,7,8-tetrahidrobiopterina (BH4) e oxigénio. Nesta 
reacção ocorre simultaneamente a hidroxilação do cofactor, que posteriormente é regenerado 
pela acção da enzima dihidrobiopterina reductase. A fenilalanina hidroxilase é responsável pela 
homeostase da L-Phe, de forma a impedir o aumento dos níveis deste aminoácido, que são 
tóxicos para o cérebro, e simultaneamente evitar a sua completa depleção, comprometendo a 
síntese proteica. Deste modo, a enzima sofre uma regulação complexa, que envolve a activação 
catalítica pelo substrato L-Phe, com cooperatividade positiva e fosforilação do resíduo Ser16. A 
enzima é também regulada pelo cofactor BH4, que provoca a sua inibição e estabilização num 
estado inactivo, na ausência de L-Phe. 
Mais de 550 mutações foram identificadas no gene PAH humano, resultando em proteínas 
mutantes com baixa actividade e/ou estabilidade e consequente aparecimento da doença. Esta é 
caracterizada pelo aumento dos níveis de fenilalanina plasmática (hiperfenilalaninémia; HPA) e 
pela diminuição do teor de tirosina circulante. Na ausência de tratamento, a PKU resulta em 
atraso mental profundo. A terapêutica actual consiste na detecção da doença através do rastreio 
neonatal e na implementação imediata de uma dieta pobre em L-Phe, com controlo da tolerância 
ao aminoácido, a qual tem de ser mantida para a vida. Recentemente verificou-se que algumas 
mutações respondem à administração oral do cofactor BH4 (suplementação com BH4), 
especialmente as formas menos graves da doença, permitindo o aumento da actividade 
enzimática e consequente relaxamento da dieta. Este encontra-se já comercialmente disponível 
na forma sintética do isómero 6R do BH4 (cloreto de sapropterina, Kuvan). 
 Devido à heterogeneidade da doença, mais de 75% dos doentes são heterozigóticos compostos 
(portadores de duas diferentes mutações). Em alguns destes doentes foram verificadas 
inconsistências tanto ao nível da correlação genotipo-fenótipo do récem-nascido HPA, quer ao 
nível da resposta à suplementação com BH4. A correlação genótipo/fenótipo bioquímico tem 
sido efectuada com base na actividade residual prevista (PRA), calculada pela média das 
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actividades determinadas in vitro de cada uma das proteínas mutantes associadas ao genótipo do 
doente. Em alguns doentes heterozigóticos compostos foram descritos fenótipos mais severos do 
que os previstos pela determinação da PRA. Particularmente, correlações genótipo-fenótipo em 
doentes HPA Portugueses envolvendo as mutações I65T, R261Q, R270K e V338M revelaram 
inconsistências. 
No que diz respeito à suplementação com BH4, alguns heterozigóticos compostos não 
revelaram uma resposta positiva ao tratamento, embora as duas mutações presentes no seu 
genótipo se encontrem descritas como respondendo ao BH4 em doentes homozigóticos para as 
mesmas. Curiosamente, algumas dessas mutações estão relacionadas com as inconsistências 
detectadas ao nível de correlações genótipo-fenótipo (e.g. I65T e R261Q). De forma a explicar 
estas observações clínicas foi proposta a existência de fenómenos de complementação inter-
alélica, a qual terá como base interacções entre as diferentes subunidades mutantes da enzima 
multimérica, originando uma proteína com menor actividade/estabilidade do que a prevista pela 
PRA (neste caso uma complementação inter-alélica negativa). 
De forma a estudar este fenómeno desenvolvemos sistemas de expressão procariótica de 
forma a produzir e isolar os possíveis híbridos. Utilizando um sistema de expressão dupla foi 
possível reproduzir bioquimicamente a situação de um heterozigótico composto (tetrâmeros, 
heterotetrâmeros e dímeros) com as combinações das mutações descritas anteriormente. Todas 
estas mutações revelaram uma diminuição da actividade enzimática quando comparada com a 
prevista pela PRA, demonstrando a existência de fenómenos de complementação inter-alélica 
negativa. Com a utilização da forma selvagem (WT) e mutantes de deleção num sistema 
bicistrónico foi possível isolar pela primeira vez um híbrido da hPAH, neste caso um 
heterotetrâmero WT/∆N102-hPAH. Nestes estudos, a existência de heterodímeros foi excluída, 
explicando o facto da hPAH selvagem ser isolada como tetrâmeros e dímeros, mas nunca como 
monómeros. O heterotetrâmero isolado apresenta propriedades cinéticas e reguladoras que 
demonstram a existência de interacções entre os dois dímeros na proteína híbrida. Estes 
resultados foram corroborados pela formação de heterotetrâmeros a partir de homodímeros pré-
formados da forma selvagem e de um mutante com uma elevada propensão para agregar 
(WT/G46S). A presença do mutante leva à agregação da proteína WT, processo este dependente 
da presença de L-Phe, pois o equilíbrio entre as diferentes formas oligoméricas responde de 
forma diferente à presença do substrato. 
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 A vasta maioria das mutações que afectam a proteína hPAH levam a uma diminuição da 
eficiência do folding proteico e/ou na redução da estabilidade da enzima, resultando na sua 
agregação e/ou rápida degradação. O domínio regulador da enzima revela uma reduzida 
estabilidade e o seu envolvimento no processo de misfolding tem sido evidenviado nos últimos 
anos. O estudo da mutação G46S, localizada no domínio regulador e que resulta na forma mais 
grave da doença, permitiu avaliar o processo de misfolding de um mutante envolvendo este 
domínio. Em estudos in vitro, a proteína mutante agrega, levando à formação de fibrilas. Este 
processo foi inibido parcialmente pela utilização de glicerol (chaperone químico), 3-amino-2-
benzil-7-nitro-4-(2-quinolil)-1,2-dihidroisoquinolina-1-ona (um chaperone farmacológico 
recentemente proposto) e pelos chaperones moleculares Hsp70/Hsp40 e Hsp90. 
O domínio regulador da hPAH apresenta um módulo ACT, que ocorre em várias enzimas 
multiméricas com complexos modos de regulação. Os módulos ACT formam normalmente 
dímeros e estão envolvidos na ligação de aminoácidos nas interfaces entre as duas subunidades. 
A instabilidade do domínio regulador da hPAH, onde não é possível existir a formação de 
dímeros entre os módulos ACT, foi também analisada pelo estudo deste na sua forma isolada. 
Curiosamente, tanto o domínio regulador mutante como o selvagem revelam tendência para 
agregar. No entanto, a agregação é inibida estereo-especificamente na forma selvagem pela 
fenilalanina, indicando que o domínio regulador na forma isolada consegue ligar o substrato, 
embora na enzima full-length, essa capacidade tenha sido perdida. 
 A ligação do substrato L-Phe ao sítio activo da enzima resulta num processo reversível de 
isomerização que ocorre numa escala de segundos a minutos. Este processo converte a enzima de 
um estado de baixa actividade/afinidade para um estado de alta actividade/afinidade, resultando 
na activação da enzima e na existência de cooperatividade positiva. Dado a inexistência da 
estrutura cristalográfica da enzima full-length, não foi possível até ao momento estabelecer o 
circuito de alterações conformacionais que levam à activação da enzima. No entanto, a existência 
de estruturas proteicas de formas truncadas do domínio catalítico da enzima em complexos 
binários (hPAH·(Fe(II)-cofactor) e ternários (hPAH·(Fe(II)-cofactor-substrato) permitiram 
verificar a existência de alterações conformacionais ao nível do domínio catalítico. Uma dessas 
alterações envolve o reposicionamento de um loop flexível da superfície da enzima para uma 
posição mais hidrofóbica no sítio activo da proteína. A maior alteração envolve o resíduo 
Tyr138, cuja cadeia lateral sofre uma deslocação de ∼21 Å. De forma a compreender a função 
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desempenhada por este loop e em particular o papel desempenhado pela Tyr138, o resíduo foi 
mutado e o seu efeito avaliado ao nível do impacto na actividade enzimática e eficiência de 
coupling (co-hidroxilação de substrato e cofactor), bem como na isomerização da proteína. Estes 
resultados permitiram identificar que a Tyr138 desempenha um papel ao nível do 
reposicionamento dos substratos para catálise, mas sem afectar o coupling da reacção. No 
entanto, o resíduo Tyr138 também desempenha um papel regulador na isomerização 
conformacional desencadeada pela ligação do substrato no sítio activo, preenchendo mais uma 
lacuna no objectivo de compreender o processo de activação catalítica na fenilalanina hidroxilase 
humana. 
 
 
 
Palavras-chave: fenilalanina hidroxilase humana, fenilcetónuria, complementação inter-alélica, 
proteínas híbridas, misfolding, polimerização, domínio ACT, activação catalítica. 
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1. The aromatic amino acid hydroxylase (AAAH) family 
The aromatic amino acid hydroxylase (AAAHs) family comprises the structurally and 
functionally related enzymes phenylalanine hydroxylase (PAH; EC 1.14.16.1), tyrosine 
hydroxylase (TH; EC 1.14.16.2) and tryptophan hydroxylase 1 and 2 (TPH1 and TPH2, EC 
1.14.16.4), that use the (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4) as cofactor. These 
enzymes are non-heme iron mono-oxygenases that in vivo catalyze the hydroxylation of the 
respective aromatic amino acid L-phenylalanine (L-Phe), L-tyrosine (L-Tyr) and L-tryptophan (L-
Trp). The three enzymes share a high degree of sequence homology and domain organization, 
namely an N-terminal regulatory domain (R-domain), a catalytic core domain (C-domain) and a 
C-terminal oligomerization domain (O-domain) (Fig. 1). They also present an overall common 
catalytic mechanism involving the non-heme iron coordinated to a 2-His-1-carboxylate facial 
triad, the cofactor BH4 and dioxygen (Kappock and Caradonna 1996; Fitzpatrick 1999; Flatmark 
and Stevens 1999; Fitzpatrick 2000; Fitzpatrick 2003; Teigen et al. 2007) (Fig. 2). The catalytic 
reaction involves the incorporation of one oxygen atom into the amino acid substrate, while the 
other oxygen atom is incorporated into the cofactor BH4, yielding the corresponding 
hydroxylated amino acid and pterin 4a-carbinolamine (4a-OH-BH4), respectively. Although BH4 
is usually referred to as a cofactor, it is in fact a co-substrate being hydroxylated during catalysis, 
and needs to be regenerated by other enzymes. The resulting compound 4a-OH-BH4 has to be 
rapidly converted back to the reduced active form BH4, since a spontaneous non-enzymatic 
conversion can occur (e.g. formation of primapterin) (Curtius et al. 1990; Davis et al. 1991). BH4 
recycling occurs through the BH4-regeneration system which involves the enzyme pteridin 4a-
carbinolamine dehydratase (PCD) and the NADH-dependent enzyme dihydropteridine reductase 
(DHPR), via the intermediate quinonoid dihydrobiopterin (q-BH2). This compound can also 
isomerize to L-erythro-7,8-dihydrobiopterin (BH2) which is converted back to BH4 by 
dihydrofolate reductase (DHFR) (Kappock and Caradonna 1996) (Fig. 2). 
BH4 has a ubiquitous distribution in higher organisms, being an essential cofactor in several 
enzymatic reactions other than those involving AAAHs (Thöny et al. 2000). The pathway for the 
de novo synthesis of BH4 from the precursor guanosine triphosphate (GTP) includes the enzymes 
GTP cyclohydrodrolase (GTP-CH), 6-pyruvoyl-tetrahydropterin synthase (6-PTPS) and 
sepiapterin reductase (SR) (Thöny et al. 2000) (Fig. 2). 
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Figure 1. Sequence alignment of human phenylalanine hydroxylase (hPAH) (SWISS-PROT 
P00439), human tyrosine hydroxylase (hTH) isoform 2 (SWISS-PROT P07101-3), human 
tryptophan hydroxylase 1 (hTPH1) (SWISS-PROT P17752) and human tryptophan hydroxylase 2 
(hTPH2) (SWISS-PROT Q8IWU9). The sequences were aligned using Clustal W and the figure was 
prepared using BioEdit (Hall 1999). The secondary structure assignment of hPAH is represented above 
the sequence and was obtained from the coordinates of the full-length PAH model constructed from rPAH 
(PDB ID: 1PHM) and hPAH (2PAH) crystal structures, and shown as α-helices (blue), 3/10-helices 
(purple) and β-strands (green). The symbols below the sequences correspond to clustal consensus results 
with asterisks indicating identity, and two dots or one dot denoting homolog properties, depending on the 
degree of similarity of the residues. Residues involved in iron coordination at the active site are marked 
with #. 
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Figure 2. Overview of the BH4-dependent aromatic amino acid hydroxylase system. Phenylalanine 
hydroxylase (PAH), tyrosine hydroxylase (TH) and tryptophan hydroxylase (TPH) catalyze the 
hydroxylation of the aromatic amino acids L-phenylalanine (L-Phe), L-tyrosine (L-Tyr) and L-tryptophan 
(L-Trp), respectively, using dioxygen and the cofactor (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin (BH4). 
The BH4 biosynthetic and regeneration pathways are also shown. The regeneration system involves the 
dehydratation of tetrahydropterin-4a-carbinolamine (4a-OH-BH4) by the enzyme pteridin 4a-
carbinolamine dehydratase (PCD) and the conversion of the quinonoid dihydrobiopterin (q-BH2) into 
BH4, by the NADH-dependent enzyme dihydropteridine reductase (DHPR). The q-BH2 form can 
alternatively isomerize to BH2, which is reduced back to BH4 by the enzyme dihydrofolate reductase 
(DHFR). The de novo BH4 biosynthetic pathway from guanosine triphosphate involves the enzymes GTP 
cyclohydrolase (GTP-CH), 6-pyruvoyl-tetrahydropterin synthase (6-PTPS) and sepiapterin reductase 
(SR). 
 
The AAAHs also display some distinct characteristics such as cellular localization, substrate 
specificity, regulation and cofactor structural preferences (Wang et al. 2002; Teigen et al. 2007). 
In contrast to the high degree of homology found in the catalytic core domain, the regulatory N-
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terminal domains are highly variable in length and topology, reflecting different regulatory 
modes that are related to the specific function of the three enzymes (Hufton et al. 1995). 
Phenylalanine hydroxylase (PAH) catalyzes the conversion of L-Phe into L-Tyr, the first and 
rate-limiting step in the catabolism of L-Phe in the liver (Fig. 2). A large number of mutations 
have been identified in the human PAH gene resulting in phenylketonuria (PKU) and 
hyperphenylalaninemia (HPA), the most common inborn error of metabolism (Surtees and Blau 
2000). PAH is regulated positively by L-Phe and phosphorylation of Ser16 and negatively by 
BH4 (Flatmark and Stevens 1999) (see Part I, sections 2 and 3). 
Tyrosine hydroxylase (TH) catalyzes the hydroxylation of L-Tyr into L-3,4-
dihydroxyphenylalanine (L-DOPA), the first step in the biosynthesis of cathecolamine 
neurotransmitters such as dopamine, noradrenaline and adrenaline (Fitzpatrick 1999; Flatmark 
and Stevens 1999) (Fig. 2). This reaction occurs in dopaminergic and noradrenergic neurons in 
the brain, in the peripheral sympathetic nervous system and in chromaffin cells in the adrenal 
medulla (Hufton et al. 1995; Kaufman 1995; Flatmark and Stevens 1999; Fitzpatrick 2000; 
Flatmark et al. 2002). The enzyme exists in at least four isoforms created by alternative splicing 
(Grima et al. 1987; Kaneda et al. 1987) and it is regulated essentially by feedback inhibition by 
catecholamines, phosphorylation at several serine residues in the R-domain (Kaufman 1995; 
Dunkley et al. 2004) and interaction with 14-3-3 proteins (Halskau Jr. et al. 2009). Additional 
regulatory mechanisms involve substrate inhibition (Quinsey et al. 1998) and negative 
cooperativity for the cofactor BH4 (Flatmark et al. 1999). 
Tryptophan hydroxylase (TPH) converts L-Trp into 5-hydroxytryptophan (5-OH-Trp), the 
first step of the biosynthesis of the neurotransmitter serotonin (5-hydroxytryptamine) and the 
hormone melatonin. Two individual isoforms with different properties and localization were 
identified (Walther et al. 2003). TPH1 is abundant in the peripheral tissues (e.g. gut, spleen and 
thymus) and pineal gland, whereas THP2, the central or neuronal form, is localized in the brain 
stem (Walther and Bader 2003; McKinney et al. 2005; Sakowski et al. 2006). The TPH enzyme 
is the less well understood member of the AAAHs family in terms of molecular, functional and 
regulatory properties. Nonetheless, TPH seems to be activated by phosphorylation and 
interaction with 14-3-3 proteins (Banik et al. 1997; Winge et al. 2008) and inhibited by 
catecholamines, but not by serotonin (Johansen et al. 1991; Martínez et al. 2001). 
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In contrast to PAH, few mutations have been identified in the genes encoding TH, TPH1 and 
TPH2 (Haavik et al. 2008). Nevertheless, dysfunction of human TH and TPH has been 
implicated in the pathogenesis of neurodegenerative and neuropsychiatric disorders (Haavik et 
al. 2008). TH mutant proteins are associated with autosomal recessive inherit forms of L-DOPA-
responsive dystonia (DDR), juvenile parkinsonism and progressive infantile encephalopathy with 
L-DOPA-nonresponsive dystonia (Knappskog et al. 1995; Lüdecke et al. 1996; Haavik and 
Toska 1998; Ichinose et al. 1999; Swaans et al. 2000; Hoffmann et al. 2003; Kobayashi and 
Nagatsu 2005). Mutations and single nucleotide polymorphisms (SNPs) in the intronic and 
untranslated regions (UTRs) in the human TPH genes have been associated with psychiatric 
disorders like unipolar depression, bipolar disorder, suicidal behavior, attention-
deficit/hyperactive disorder (ADHD) and anxiety (Boldrini et al. 2005; Sheehan et al. 2005; 
Zhang et al. 2005; Bach-Mizrachi et al. 2006; Li and He 2006b; Li and He 2006a; Chen et al. 
2008; Cichon et al. 2008; McKinney et al. 2008; Porter et al. 2008). Additionally, impaired 
TPH1 enzyme activity has been implicated in disturbances of melatonin biosynthesis, sleep and 
immune system disorders, and gastrointestinal dysfunction (Ekwall et al. 1998; Walther and 
Bader 2003; Teigen et al. 2007). 
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2. Human phenylalanine hydroxylase (hPAH) 
Human phenylalanine hydroxylase (hPAH) is a homotetrameric enzyme (in equilibrium with 
a dimeric form) with a polypeptide chain of 452 amino acids and a subunit molecular mass of 
∼52 kDa. Human PAH is a cytoplasmic enzyme present mainly in the liver (Kaufman 1971), but 
is also expressed in some extent in the kidney (Tessari et al. 1999; Møller et al. 2000) and 
epidermis (Schallreuter et al. 2005). Loss or severely reduced activity of hPAH has been shown 
to result in the metabolic disorder phenylketonuria (PKU), that if untreated will result in brain 
damage (see Part I, section 3). 
 
2.1. The molecular genetics of hPAH 
The human PAH gene is located on chromosome 12q23.2 (Woo et al. 1983; Lidksy et al. 
1984; Scriver 2007) and consists of 13 exons spreading over 90 kb, representing 3% of the 
genomic sequence (Scriver et al. 2003), with introns varying from 1 to 20 kb (Kappock and 
Caradonna 1996). Only one hPAH isoform is produced. The 5′ UTR of hPAH gene lacks a 
proximal TATA box, but contains several consensus sequences for different response elements, 
suggesting that hPAH may be continuously expressed in the target tissues and multiple 
transcription factors may be involve in the regulation of its expression (Konecki et al. 1992). 
 
2.2. The physiological function of hPAH 
Human PAH is considered a catabolic enzyme due to its role in the degradation of L-Phe from 
food, contrasting to hTH and hTPH that are considered anabolic enzymes. However, hPAH also 
provides an endogenous source of L-Tyr to the organism by converting L-Phe, an essential amino 
acid that has to be include in the diet (Kalhan and Bier 2008), into L-Tyr which therefore is a 
non-essential amino acid. 
The main pathway for disposal of L-Phe in a healthy human is the hydroxylation reaction 
catalyzed by hPAH, the initial and rate-limiting step in the complete catabolism of L-Phe to 
carbon dioxide and water. An alternative pathway for phenylalanine breakdown leads to the 
formation of toxic phenylketones. This pathway is initiated by transamination of phenylalanine 
to phenylpyruvate, followed by conversion of the latter compound to metabolites such as 
phenyllactate, phenylacetate and o-hydroxyphenylacetate, which are excreted in the urine 
(Kaufman 1999). 
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2.3. The structure of phenylalanine hydroxylase 
2.3.1. The protomer and oligomeric forms of PAH 
The first high resolution 3D structures of truncated forms of hPAH (Erlandsen et al. 1997) 
and rTH (Goodwill et al. 1997) were resolved in the 1990s, but until today no crystal structure 
has been obtained for the full-length mammalian PAH. So far, several crystal structures of 
truncated forms of hPAH in complex with ligands, such as adrenaline, noradrenaline, dopamine, 
L-DOPA, 3-(2-thienyl)-L-alanine (THA) and L-norleucine (NLE), have been described. 
However, from the determined structures only one (∆C24-rPAH) includes the regulatory domain 
(Kobe et al. 1999), which has been difficult to study in all AAAHs. The structural studies 
together with site-directed mutagenesis and limited proteolysis have shown that the hPAH 
protomer is organized in a three domain structure: (i) a N-terminal regulatory domain (Ser2-
Thr117); (ii) a catalytic domain (Val118-Phe410), enclosing the active site iron, the binding sites 
for substrate, cofactor and catecholamine inhibitors; and (iii) an oligomerization domain 
(Ser411-Lys452) containing motifs for dimerization and tetramerization (Fusetti et al. 1998; 
Flatmark and Stevens 1999; Kobe et al. 1999) (Fig. 3).  
Human PAH exists in an equilibrium of homotetramers and homodimers, along with some 
higher oligomeric forms (Martínez et al. 1995; Bjørgo et al. 2001), while TH and TPH exist as 
homotetramers in solution (Kappock and Caradonna 1996; Flatmark and Stevens 1999). The 
tetramer is the high activity form of the enzyme, and reveals different properties when compared 
with the dimer, at the level of cooperativity, substrate affinity and activation (Martínez et al. 
1995; Bjørgo et al. 2001). The hPAH tetramer ↔ dimer equilibrium is dependent on pH 
(Kappock et al. 1995) and L-Phe concentration (Martínez et al. 1995; Bjørgo et al. 2001). A 
decrease of pH and L-Phe binding to the enzyme shifts the equilibrium towards the tetrameric 
form.  
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Figure 3. Domain organization and structure of hPAH. (A) Schematic representation of the functional 
domain structure of hPAH: regulatory domain (RD), catalytic domain (CD) and oligomerization domain 
(OD). The N-terminal intrinsic autoregulatory sequence (IARS) together with the Ser16 phosphorylation 
site is indicated. (B and C) Models of the full-length monomer (B) and tetramer (C) of hPAH generated 
by combining the crystal structure of a C-terminal truncated dimeric rPAH (∆C24-rPAH, PDB ID: 
2PHM) and the N-terminal truncated tetrameric hPAH (∆N102-hPAH, PDB ID: 2PAH). The monomer in 
B is represented with the same color code as in the schematic representation in A, with the regulatory 
domain in red, the catalytic domain in blue and the oligomerization domain in green. One monomer in C 
is represented with the same color code as in B, while the other monomers are shown in gray, purple and 
orange. Iron atoms are shown as yellow spheres. Figures B and C were prepared using the program UCSF 
Chimera (Pettersen et al. 2004). 
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2.3.2. Structural and functional domains in PAH 
2.3.2.1. The N-terminal regulatory domain 
The regulatory domain of hPAH has a common αβ-sandwich, frequently observed in other 
regulatory domains of allosteric proteins, assembled from a βαββαβ-motif, and being classified 
as an ACT domain (see below) (Siltberg-Liberles and Martínez 2009), consisting of a four-
stranded anti-parallel β-sheet flanked on one side by two α-helices (one α-helix and a combined 
3/10- and α-helix) and on the other side by the catalytic domain (Kobe et al. 1999). This 
topology gives rise to a flexible structure, consistent with thermal denaturation studies that have 
shown that the R-domain unfolds at a lower temperature than the more compact C-domain 
(Thórólfsson et al. 2002). 
While the R-domain core is located far from the active site in the C-domain, the N-terminal 
residues referred as the intrinsic autoregulatory sequence (IARS; residues 1-33) extends over the 
active site in the catalytic domain (Fig. 3B). The IARS forms a lid that partly controls the access 
of the solvent and substrates to the active site (Kobe et al. 1999; Kobe and Kemp 1999; Horne et 
al. 2002). The hinge bending region that separates the regulatory from the catalytic domain, 
around sequence 111-117, is involved in domain movements occurring upon activation by the 
substrate (Stokka et al. 2004; Li et al. 2010). The IARS also includes the phosphorylation site 
(Ser16), which is involved in the activation of the enzyme (see below, section 2.5.1). 
The ACT domain (from aspartokinase, chorismate mutase and prephenate dehydrogenase, 
three proteins from the domain family) was first identified as a regulatory module found in a 
number of diverse proteins (Fig. 4) (Aravind and Koonin 1999). The ACT domain is a small 
molecule-binding domain (SMBD) with a high sequence divergence and evolutionary mobility 
(Anantharaman et al. 2001). ACT domains are usually found in allosteric proteins (e.g. 
Escherichia coli D-3-phosphoglycerate dehydrogenase) where they have a regulatory role, 
forming dimers (or higher-order oligomers) and binding small ligands (typically amino acids and 
pyrimidines) at their dimer interface (Aravind and Koonin 1999; Chipman and Shaanan 2001; 
Liberles et al. 2005; Grant 2006; Siltberg-Liberles and Martínez 2009). 
The ACT domain in hPAH differs from the others archetypal ACT domain proteins by the 
fact that there are no contacts between the four ACT domains in the hPAH tetramer, and 
consequently no dimer interface is established (Flatmark and Stevens 1999; Kobe and Kemp 
1999; Siltberg-Liberles and Martínez 2009). The putative L-Phe binding at the regulatory ACT 
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domain has therefore being challenged with evidence that the full-length hPAH enzyme is not 
able to bind L-Phe at the R-domain (Martínez et al. 1990; Martínez et al. 1991; Thórólfsson et al. 
2002; Flydal et al. 2010), but the isolated R-domain seems to have the ability to bind the amino 
acid (Gjetting et al. 2001a; Li et al. 2011). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The prototypal ACT domain fold. (A) A single ACT domain from E. coli D-3-
phosphoglycerate dehydrogenase displaying the βαββαβ motif. In the schematic representation below, 
the triangles pointing up or down indicate the direction of the strand in the β sheet, with numbers starting 
from the N-terminus. (B) The E. coli D-3-phosphoglycerate dehydrogenase tetramer (PDB ID: 1PSD), 
with the subunits in green and gray and ACT domains colored blue and red. The arrows indicate the 
location of the ACT domains in the structure, with the ligand (L-Ser) binding at the dimer interface in 
CPK format. Figure from Grant 2006. 
 
2.3.2.2. The catalytic core domain 
The catalytic domain of hPAH consists predominantly of α-helices. The domain has a basket-
like organization with a total of 13 α-helices, two 3/10-helices, 6 short β-strands and loops of 
variable length connecting the secondary elements, with the catalytic iron at the bottom 
(Erlandsen et al. 1997). The active site is a 13 Å deep and 10 Å wide pocket. A 16 Å long and 8 
Å wide channel connected to the active site pocket is most likely the entrance of solvent and 
ligands into the active site (Erlandsen et al. 1997). A 2-His-1-carboxylate facial triad motif 
anchored the catalytic mononuclear iron at the intersection of the channel and the active site 
pocket, 10 Å below the surface (Erlandsen et al. 1997), a structural motif that has been found in 
A B 
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other non-heme iron enzymes (Hegg and Que 1997; Lange and Que Jr. 1998; Que Jr. 2000; 
Koehntop et al. 2005). The active Fe(II) form in the binary cofactor complex displays an 
octahedral geometry interacting with the enzyme through His285 (N···2.12 Å), His290 (N···2.13 
Å) and Glu330 (O···2.06 Å), and three water molecules (Fig. 5). 
 
 
Figure 5. Close-up of the iron binding site in hPAH. The iron atom (Fe(II) form) is shown as a yellow 
sphere hexa-coordinated to His295, His290, Glu330 (in stick model) and three water molecules (Wat1, 
Wat2 and Wat3) represented as red spheres, in an octahedral geometry. The cofactor BH4 is also 
represented in stick model. The catalytic domain is shown in blue and the oligomerization domain in 
green. The figure was prepared using the crystal structure of the binary cofactor complex (∆N102/∆C24-
hPAH-Fe(II)·BH4) (PDB ID: 1J8U) and the program UCSF Chimera (Pettersen et al. 2004). 
 
The cofactor BH4 binds at the active site, in the vicinity of the iron atom, where it makes 
stacking interactions with Phe254. The amino group at C2 and N3 hydrogen bonds with the 
carboxylic group of the conserved glutamate residue Glu286 (Teigen et al. 1999; Teigen et al. 
2004). From the binary crystal structures (Erlandsen et al. 2000; Andersen et al. 2001; Andersen 
et al. 2002), BH4 binds in the iron second coordination sphere, by an induced fit mechanism with 
the carbonyl oxygen (O4) located 3.67−4.18 Å from the iron. Local conformational changes as 
well as changes in the dihydroxypropyl side-chain were observed (Andersen et al. 2001). From 
the ternary crystal structures (Andersen et al. 2002; Andersen et al. 2003), the cofactor was 
found to bind closer to the iron, with the carbonyl oxygen distance to the iron ranging from 
3.12−3.53 Å (Olsson et al. 2010b).  
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In the ternary crystal structures of substrate analogs, THA and NLE, the substrate was also 
found to bind in the second coordination sphere of the iron atom with the aromatic ring stacking 
against the imidazole group of the iron-bound His285 (Andersen et al. 2002; Andersen et al. 
2003). The substrate was found to interact through hydrogen bonds to Arg270, Thr278 and 
Ser349, and water-mediate H-bonds to Tyr277, Ser350 and Glu353. Additionally hydrophobic 
interactions are observed with the phenyl group close to a cluster of aromatic amino acids 
(Phe331, Trp326) and Pro281 (Andersen et al. 2002). 
Superposition of the binary and ternary complexes (Andersen et al. 2003) and studies of 
hydrogen/deuterium exchange mass spectrometry (HXMS) (Li et al. 2010) revealed that 
substrate binding results in structural changes at the catalytic domain, but also in the entire 
protomer, with a re-orientation of the regulatory and catalytic domains through hinge-bending 
regions (Stokka et al. 2004). A large displacement observed upon L-Phe binding was the 
refolding of a surface loop (residues 134-139) to a partially buried position at active site, with a 
backbone displacement of 9.6 Å for Tyr138 (Andersen et al. 2003). 
 
2.3.2.3. The C-terminal oligomerization domain 
The oligomerization domain consists of a dimerization (411-427) and a tetramerization (428-
452) motifs. The dimerization motif consists of two β-strands (Tβ12 and Tβ13) held together by 
a loop (Figs. 1 and 3). The dimerization of the two protomers is mediated by van der Waals 
interactions and four H-bonds between the two loops. Additionally the two protomers interact 
across the dimerization interface with a buried area of 440 Å2 (Erlandsen et al. 1997). The last 24 
C-terminal amino acids (428-452) constitute the tetramerization motif, a 40 Å long α-helix 
(Tα16) (Fig.1). The helix is a conserved heptad repeat of hydrophobic residues and this leucine 
zipper plays an important role in the tetramerization domain swapping mechanism, where the 
helices from each monomer form an antiparallel coiled-coil structure in the middle of the 
tetramer (Fusetti et al. 1998). The hPAH tetramer is not completely symmetrical, and is 
considered a dimer of two conformationally dimers (Fusetti et al. 1998). The two dimers within 
the tetramer adopt a different relative orientation, due to rotation around the hinge region 
Asp425-Gln429 (at Thr427) that connects the dimerization and tetramerization motifs, followed 
by an another rotation around Gly442 in the C-terminal tetramerization helix (Fusetti et al. 
1998). 
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2.4. The catalytic mechanism of L-Phe hydroxylation  
 The catalytic mechanism of hPAH, as well as all AAAHs, requires the substrate (L-Phe in 
hPAH), cofactor (co-substrate) BH4, molecular dyoxygen as well as a non-heme iron in the 
ferrous form (Fe(II)) at the active site (Fisher et al. 1972; Gottschall et al. 1982). The PAH 
catalytic mechanism is not fully understood. In the monomeric bacterial Chromobacterium 
violaceum phenylalanine hydroxylase (CvPAH) the steady-state reaction mechanism was shown 
to be sequential and fully ordered with binding of pterin cofactor, L-Phe and finally dioxygen in 
consecutive order, prior to catalysis and release of any intermediate or product (Volner et al. 
2003). In mammalian PAHs there is no consensus about the order of binding to form the 
quaternary complex (PAH-Fe(II)·BH4·L-Phe·O2), with different enzymes revealing different 
preferences for binding order (Fitzpatrick 2003; Costas et al. 2004).  
The PAH catalytic mechanism can be divided in two parts: the first one involving the 
molecular oxygen activation by iron to form an iron-bound peroxopterin intermediate 
(Fe(II)−O−O−BH4) and a second one where the oxygen-oxygen heterolytic bond cleavage leads 
to the formation of a oxyferryl (Fe(IV)=O) species which catalyzes the hydroxylation of L-Phe 
(Dix and Benkovic 1985; Dix et al. 1985; Feig and Lippard 1994; Kemsley et al. 1999; 
Fitzpatrick 2003; Eser et al. 2007; Pavon and Fitzpatrick 2009; Olsson et al. 2010a). A catalytic 
mechanism based on crystallographic studies of the ternary complex ∆N102/∆C24-hPAH-
Fe(II)⋅BH4·THA (PDB ID: 1KW0) and modeling of dioxygen into the active site has been 
proposed (Andersen et al. 2002) (Fig. 6). In the resting state of PAH, the iron atom is in the 
ferric form (Fe(III)), which is reduced by BH4 to the active ferrous form (Fe(II)) in a reaction 
independent of L-Phe (reductive activation of PAH) (Marota and Shiman 1984; Wallick et al. 
1984; Shiman et al. 1994; Hagedoorn et al. 2001) (Fig. 6, Step 1).  
The cofactor BH4 binding at the active site of the pre-reduced enzyme results in a hexa-
coordinated iron with three water molecules (Erlandsen et al. 2000; Andersen et al. 2001) (Fig. 
6, Step 2). The direct binding of cofactor to iron during catalysis is still an open mechanistic 
question (Pember et al. 1987; Teigen et al. 1999; Teigen et al. 2005; Olsson et al. 2010a; Olsson 
et al. 2011). Subsequently, L-Phe binding to the binary complex results in a penta-coordinated 
square-pyramidal arrangement of the iron atom (Kemsley et al. 1999; Andersen et al. 2002), 
different from the hexa-coordinated octahedral geometry found in the unliganded ∆N102/∆C24-
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hPAH-Fe(III) or inactive binary ∆N102/∆C24-hPAH-Fe(III)⋅BH2 (Erlandsen et al. 2000) and 
active binary ∆N102/∆C24-hPAH-Fe(II)⋅BH4 complexes (Andersen et al. 2001).  
The ternary complex formation results from the removal of two water molecules (Wat1 and 
Wat3), and in the re-orientation of Glu330, that becomes bidentate coordinated to the iron 
(Andersen et al. 2002) (Fig. 6, Step 3). These rearrangements create an available coordination 
position on the iron for dioxygen activation and the generation of the putative Fe(II)−O−O−BH4 
intermediate, with release of the last water molecule (Wat2) (Fig. 6, Step 4). Using density 
functional theory (DFT), the water dissociation process was shown to be remarkable facile in a 
gas-phase cluster model of the active site (∆G = 1.5 kcal/mol) (Olsson et al. 2010a). A water-free 
first coordination sphere is also suggested from observations from electron paramagnetic 
resonance and ultraviolet-visible studies (Han et al. 2006). A less hydrophilic environment 
around the iron seems to stabilize the Fe(II)−O−O complex and reduce the risk of hydrogen 
peroxide formation, a mechanism that was also observed in other enzymes (Olsson et al. 2010a).  
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Figure 6. Proposed catalytic mechanism for the L-Phe hydroxylation by PAH. BH4 reduces the 
Fe(III) form to the catalytic active Fe(II) form (Step 1). Reversible binding of BH4 results in a hexa-
coordinate Fe(II), with a change in the coordination of Glu330 and an increase in the electron density of 
water 1 and 2 (W1 and W2 in brackets) (Step 2). The reversible binding of L-Phe results in a highly 
distorted square pyramidal penta-coordinated Fe(II) with a bidentate coordination of Glu330 (Step 3). The 
reversible binding of dioxygen leads to the formation of the putative Fe(II)−O−O−BH4 intermediate (Step 
4), and heterolytic cleavage of the O−O bond leads to the formation of 4a-OH-BH4 and a ferryl species, 
Fe(IV)=O (Step 5), which is responsible by the hydroxylation of L-Phe into L-Tyr, with subsequently 
released of the products (Step 6). Figure from Andersen et al. 2002. 
 
The complete mechanism of dioxygen activation and the formation of Fe(II)−O−O−BH4 
intermediate still remain elusive (Costas et al. 2004; Abu-Omar et al. 2005). A stepwise binding 
has been proposed with three possible mechanisms: (i) an initial binding of dioxygen to Fe(II) 
forming an Fe(III)−O2- species that subsequently binds to BH4 (metal catalyzed pathway); (ii) 
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dyoxygen binding to the cofactor forming a pterin hydroxyperoxide which then coordinates to 
the iron (metal-free pathway); or (iii) a concerted addition of dioxygen to both iron and cofactor 
(Costas et al. 2004; Abu-Omar et al. 2005). Heterolytic cleavage of the oxygen-oxygen bond of 
the Fe(II)−O−O complex resulting in the formation of the hydroxylated cofactor (4a-OH-BH4) 
and a highly active oxygen intermediate Fe(IV)=O was proposed (Dix and Benkovic 1988; 
Bassan et al. 2003b; Bassan et al. 2003a; Fitzpatrick 2003; Eser and Fitzpatrick 2010) (Fig. 6, 
Step 5), that will ultimately hydroxylate the aromatic ring of L-Phe by an electrophilic aromatic 
substitution mechanism (Fig. 6, Step 6), returning the iron to the Fe(II) form (Pavon and 
Fitzpatrick 2006; Panay and Fitzpatrick 2008). Consequently, the dyoxygen atoms would be in 
fact incorporated into both substrate and cofactor (Dix and Benkovic 1988; Siegmund and 
Kaufman 1991). A high-spin Fe(IV) species have been directly observed in the TH catalytic 
reaction (Eser et al. 2007) and more recently in the catalytic cycle of a bacterial PAH (CvPAH) 
(Panay et al. 2011), which might correspond to the Fe(IV)=O intermediate. It has been proposed 
that 4a-OH-BH4 will be released from the active site because this compound will present a 
decreased affinity due to the sp3 configuration of the 4a position and to the bending in the pterin 
ring that impairs the stacking with Phe254 (Teigen et al. 1999). The release of the product (L-
Tyr) may occur due to steric hindrance by Glu330 and Trp326 (Teigen et al. 1999; Andersen et 
al. 2002). 
 
2.5. Regulatory properties of phenylalanine hydroxylase  
 Human PAH is tightly regulated in the human body in order to maintain the correct levels of 
L-Phe in the blood. High levels of L-Phe are toxic to the brain, while low levels can hamper 
protein synthesis, as hepatic levels of fully activated hPAH are enough to remove all L-Phe from 
the bloodstream within minutes (Shiman et al. 1982). In vivo, hPAH is regulated by three main 
mechanisms: (i) activation by substrate (Shiman and Gray 1980; Shiman et al. 1990), (ii) 
phosphorylation of Ser16 (Døskeland et al. 1996) and (iii) inhibition by the pterin cofactor 
(Shiman and Gray 1980; Xia et al. 1994). In vitro, hPAH can be artificially activated by 
chymotrypsin limited proteolysis (Iwaki et al. 1986), alkylation of the sulfhydryl group of 
Cys237 (Parniak and Kaufman 1981; Gibbs and Benkovic 1991) and interaction with ionic 
detergents, such as lysolecithin (Fisher and Kaufman 1973; Abita et al. 1984; Kaufman 1993). 
Removal of a N-terminal fragment by limited proteolysis activates the enzyme, and an 
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autoinhibitory effect by the R-domain was then proposed (Iwaki et al. 1986). The only available 
crystal structure of the regulatory PAH domain (dimeric ∆C24-rPAH) has confirmed the role of 
the R-domain, especially the N-terminal autoregulatory sequence (IARS) that partly covers the 
active site (Kobe et al. 1999). Studies on truncated forms of hPAH lacking part or the full R-
domain and chimeric PAH with a R-domain from TH, all have shown that the enzyme is already 
in an activated state (Knappskog et al. 1996b; Daubner et al. 1997) and is not inhibited by the 
cofactor BH4 (Jennings et al. 2001), properties that are not exhibited by the full-length enzyme. 
 
2.5.1. Activation by substrate and phosphorylation 
The substrate L-Phe is an allosteric activator of the hPAH enzyme, inducing conformational 
changes that result in two related effects (Kaufman 1993). The first one is associated with the 
activation of the enzyme. Preincubation with L-Phe results in a 5- to 6- fold activation of full-
length hPAH (1.6-fold for the dimeric form) (Solstad and Flatmark 2000; Bjørgo et al. 2001), a 
process caused by conformational changes in the tetrameric/dimeric enzyme (Flatmark and 
Stevens 1999; Flatmark et al. 2001; Stokka and Flatmark 2003; Stokka et al. 2004; Li et al. 
2010). Movements of the R-domain with displacement of the IARS seem to be involved, with an 
increased accessibility to the active site, as N-terminal truncated mutants are already in an 
activated state (Knappskog et al. 1996b; Stokka and Flatmark 2003). This L-Phe triggered 
activation is a slow (second-to-minutes) transition of the enzyme from a low activity, low 
affinity state “T”-state to a high activity “R”-state (Shiman and Gray 1980; Shiman et al. 1990), 
a characteristic of a hysteretic enzyme (Flatmark et al. 1999). 
The second effect related to substrate binding is cooperativity. The full-length tetrameric form 
of hPAH binds the substrate L-Phe with positive cooperativity (the dimeric form does not display 
cooperativity), a major regulatory mechanism that involves all four monomers (Shiman and Gray 
1980; Shiman et al. 1990; Bjørgo et al. 2001). Human PAH shows a non-hyperbolic (sigmoidal) 
dependence on substrate concentration for its equilibrium binding (Parniak and Kaufman 1981) 
and steady-state kinetics (Kaufman 1993). This process is thought to result from a homotropic 
cooperative mechanism triggered by L-Phe binding at the active site, consistent with only one L-
Phe binding site per protomer, at least to elicit the positive cooperativity process (Martínez et al. 
1990; Martínez et al. 1991; Martínez et al. 1993; Stokka and Flatmark 2003). The substrate L-
Phe binds with an affinity (S0.5) of ∼150 µM for eukaryotic PAH and a Hill coefficient (nH) of ∼2 
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(Kaufman 1993; Teigen et al. 2007) and the physiological L-Phe level in healthy individuals is 
less than 120 µM (Pey and Martínez 2005; Blau et al. 2010b). The positive cooperative binding 
of L-Phe is considered to be physiologically important as a protection mechanism when the 
serum L-Phe concentration increases above normal levels. The mechanism allows L-Phe 
homeostasis in the blood by preventing HPA, but allowing a continuous supply of L-Tyr for 
protein synthesis (Kappock and Caradonna 1996; Olsson et al. 2010b). The activation and 
positive cooperativity mechanism of the full-length hPAH enzyme is a complex process that is 
still not completely understood. 
Phosphorylation at Ser16 by the cyclic AMP dependent protein kinase A (PKA) is a post-
translational modification that acts synergistically with L-Phe activation. The phosphorylated 
enzyme requires a lower L-Phe concentration for full catalytic activation while L-Phe levels 
increase the rate of phosphorylation by PKA (Døskeland et al. 1984; Phillips and Kaufman 1984; 
Kaufman 1993; Døskeland et al. 1996). In contrast, BH4 reduces the rate of phosphorylation, but 
this inhibition is prevented in the presence of L-Phe (Døskeland et al. 1996). Phosphorylation 
seems to induce a local conformational change at Ser16 in the IARS, which facilitates the access 
of L-Phe to the active site (Miranda et al. 2002; Miranda et al. 2004). 
 
2.5.2. Inhibition by cofactor 
The cofactor BH4 plays a role as co-substrate in the catalytic reaction, but has also a 
regulatory role in hPAH. BH4 inhibits the enzyme by inducing a low-activity conformational 
state (the binary hPAH·BH4 complex), inhibits L-Phe activation and reduces the rate of 
phosphorylation at Ser16 (Xia et al. 1994; Døskeland et al. 1996; Solstad et al. 2003; Teigen and 
Martínez 2003; Pey et al. 2004a; Pey et al. 2004b). The cofactor BH4 inhibits hPAH in the 
absence of L-Phe (resting state) by protecting the enzyme from unfolding and degradation 
(Mitnaul and Shiman 1995), a stabilization process that plays a major role in the BH4-responsive 
PKU (see below Section 3.2.1) (Martínez et al. 2008). The regulatory properties of the cofactor 
are dependent on the dihydroxypropyl side-chain at position C6 of the cofactor, as functional 
analogues such as 6-methyl-5,6,7,8-tetrahydropterin (6MPH4) and 6,7-dimethyl-5,6,7,8-
tetrahydropterin (DMPH4) are able to substitute the natural cofactor in catalysis but do not 
induce the regulatory properties (Phillips and Kaufman 1984; Kaufman 1993; Kappock and 
Caradonna 1996; Pey et al. 2004b). The Km value of PAH for BH4 is in the range of 15−40 µM 
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(Olsson et al. 2010b). In a healthy individual the concentration of BH4 in liver hepatocytes is 
approximately 5−10 µM (Pey and Martínez 2005) and hPAH subunit concentration is postulated 
to be equimolar. Therefore, the majority of hPAH is converted in the inactive but stable 
hPAH·BH4 complex (Mitnaul and Shiman 1995), whose inhibitory effect is reversed by 
increasing levels of L-Phe in the blood. The BH4 dependent activity of the non-activated enzyme 
is characterized by a Michaelis-Menten kinetics (Knappskog et al. 1996b), whereas the L-Phe 
activated form displays a positive cooperativity towards BH4 binding (Gersting et al. 2010b). 
 
2.6. Post-translational modifications in hPAH 
The only known post-translational modifications to occur in hPAH in vivo are 
phosphorylation (discussed in the above section) and non-enzymatic deamidation of hPAH. The 
deamidation of labile amide groups of Asn (and Gln, although to a lesser degree) to Asp or L-
isoaspartic acid, or to a lesser extent to D-isoaspartic acid, are in general related to mechanisms 
of aging and cellular turnover of proteins (Robinson et al. 1970; Robinson and Robinson 2001). 
The function of deamidation in hPAH is not completely clear, but a similar role is expected. 
Two-dimensional gel electrophoresis of different PAH preparations has revealed a 
microheterogeneity that corresponds to PAH forms with different degrees of deamidation 
(Solstad and Flatmark 2000). Asn32 in the R-domain and Asn376 in the C-domain were found to 
be the most determinant residues for the regulatory and functional differences observed in the 
deamidated proteins (Carvalho et al. 2003). Highly deamidated forms of hPAH are more 
susceptible to limited proteolysis, display an increased catalytic efficiency and substrate affinity 
(Solstad and Flatmark 2000). 
Human PAH was also shown to be a substrate for the ubiquitin-conjugating enzyme system in 
an in vitro system (Døskeland and Flatmark 1996; Døskeland and Flatmark 2001), pointing to a 
degradation by the proteasome degradation machinery, at least to some extent. Turnover rates of 
hPAH have been reported to be approximately 8.4 h in cultured hepatoma cells (Baker and 
Shiman 1979) and in vitro cell-free coupled transcription-translation system (Waters et al. 
1998a; Gámez et al. 2000). Several misfolding PKU mutations have been associated with 
increased protein turnover rates (Waters et al. 1998a; Waters et al. 1999; Gámez et al. 2000), and 
the degradation of the mutants might involve different proteolytic pathways (Waters 2003), 
including the ubiquitin-proteasome system. 
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3. Phenylketonuria (PKU) 
 Phenylketonuria (PKU; OMIM 216600) was the first inborn error of metabolism shown to be 
associated to neuropsychological symptoms. It was first described in 1934 by Dr. Asbjørn 
Følling following his studies of mentally retarded children who excreted phenylketonuric acid in 
their urine. Asbjørn Følling suggested that a metabolic anomaly with a pattern of an autosomal 
recessive genetic disease, apparently caused by an inherited defect in the metabolism of 
phenylalanine, was the cause of neuropsychological deficits (Følling 1934). In 1947 Jervis 
suggested that the metabolic error described by Følling was an inability to convert L-Phe into L-
Tyr (Jervis 1947), and an hepatic system was soon thereafter discovered to be responsible for this 
conversion (Udenfriend and Cooper 1952), and the underlying cause pinned down to the 
deficient conversion of L-Phe to L-Tyr in the liver by phenylalanine hydroxylase (Jervis 1953). In 
the early 1950s, Dr. Horst Bickel successfully introduced a low-phenylalanine diet that resulted 
in reduced plasma L-Phe levels and disappearance of phenylpyruvic acid from urine, and also 
resulted in an improvement of physical development and behavior performance, (Bickel et al. 
1953; Bickel et al. 1954; Armstrong and Tyler 1955; Woolf et al. 1955) if started within the first 
weeks of life (Bickel et al. 1954; Armstrong and Low 1957; Clader 1957). In the 1960s Robert 
Guthrie introduced a simple blood screening method for detection of high levels of plasma L-Phe 
in newborns (the Guthrie test) (Guthrie and Susi 1963). 
 
3.1. PKU mutations and clinical outcome 
 Phenylketonuria is caused by a deficiency of the hepatic phenylalanine hydroxylase enzyme, 
due to mutations in the PAH gene. The failure to metabolize L-Phe results in its accumulation in 
blood and toxic levels in the brain. In untreated PKU, the high levels of L-Phe together with the 
presence of phenylketones (formed from the transaminase pathway) give rise to neurotoxicity 
and results in severe mental retardation or impaired cognitive development, growth abnormalities 
and behavioral difficulties (Scriver and Kaufman 2001; Blau et al. 2010b; Feillet et al. 2010; 
Mazur et al. 2010). Additional symptoms can include microcephaly, eczematous rash, autism, 
ADHD symptoms, agoraphobia, seizures and motor dysfunction (Waisbren and Levy 1991; 
Arnold et al. 1998; Antshel and Waisbren 2003; Baieli et al. 2003; Blau et al. 2010b; Mazur et 
al. 2010). 
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PKU is inherited in an autosomal recessive fashion, when both alleles are mutated. At present, 
more than 550 disease-causing mutations in the PAH gene have been identified and registered in 
the Human PAH Mutation Knowledgebase (hPAHdb; www.pahdb.mcgill.ca/) (Hoang et al. 
1996; Scriver et al. 2003; Scriver 2007). The current spectrum of PKU mutations consists of 
~60% missense mutations; ~13% deletions; ~11% splice mutations; ~6% silent mutations; ~5% 
nonsense mutations and ~2% insertions. Mutations have been identified in all 13 exons, but the 
majority are found in the 3′-half of the gene, namely between exon 5 and 12 (Waters et al. 
1998b). Due to the large number of mutations, most of the patients (approximately 75%) are 
heteroallelic for PAH mutations being classified as compound heterozygous (Scriver and Waters 
1999) 
In Caucasians the frequency of PKU is approximately 1 per 10,000 but this value can 
fluctuate by geographical region and among ethnic groups (Blau et al. 2010b). Although the 
majority of the HPA cases resulted from mutations in the PAH gene, approximately 1−2% of 
HPA resulted from mutations in genes coding for the enzymes involved in the de novo synthesis 
of BH4 from GTP and in the regeneration system of BH4 (Part I, section 1) (HPA secondary to 
BH4 deficiency) (Thöny and Blau 2006; Blau et al. 2010b). Differential diagnosis of PKU versus 
BH4 deficiency is carried out by blood or urinary pterin analyses or blood DHPR activity (Blau 
et al. 2003). 
Expression and characterization analyses of several PAH missense mutations in 
complementary in vitro systems (for review, see the PAH Mutation Analysis Consortium 
database) (Hoang et al. 1996) and computational studies have identified at least three main 
groups of enzymatic phenotypes which differ in their kinetic behaviour and/or stability, i.e. (i) 
structurally stable mutations with altered kinetic properties, e.g. mutations at residues involved in 
substrate (L-Phe) or the pterin cofactor (BH4) binding; (ii) mutations with normal or almost 
normal kinetic properties, but reduced stability both in vitro and in vivo; and (iii) mutations 
affecting both kinetic and stability properties of the enzyme (Knappskog et al. 1996a; Flatmark 
et al. 1997; Bjørgo et al. 1998; Waters et al. 1998a; Waters et al. 1999; Waters et al. 2000; 
Gjetting et al. 2001b; Waters 2003; Pey et al. 2007; Gersting et al. 2008). From these studies it 
emerged that a decrease in protein stability is the main molecular pathogenic mechanism (Pey et 
al. 2007), with PKU being considered a protein misfolded disease (Gregersen et al. 2001; 
Gregersen 2006; Gregersen et al. 2006; Martínez et al. 2008).  
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The PAH gene mutations lead to a wide spectrum of clinical and biochemical phenotypes with 
different degrees of severity, ranging from classical or severe PKU (reduced or no enzymatic 
activity), to mild PKU and mild HPA (considerable hPAH activity). The classification of PKU 
severity is based on blood phenylalanine concentration before treatment and/or dietary Phe 
intake tolerance, at five years of age, in order to maintain L-Phe plasmatic levels below 360 µM. 
The classic PKU form is associated with blood Phe concentrations above 1200 µM before 
treatment and a dietary Phe tolerance of less than 20 mg/kg of body weight; mild PKU is linked 
with blood Phe concentrations between 600-1200 µM and a dietary Phe tolerance between 20-25 
mg/kg of body weight; and mild HPA (MHP) is associated with blood Phe concentrations 
between 120-600 µM, when the patient is on a normal diet and a dietary Phe tolerance greater 
than 25 mg/kg of body weight (Güttler and Guldberg 1994; Blau 2010; Blau et al. 2010b; Feillet 
et al. 2010). It must be emphasized that the blood Phe concentration in a healthy person varies 
from 50−110 µM. Individuals with mild HPA have a much lower risk of impaired cognitive 
development in the absence of treatment, although some might have decreased executive 
functioning (Gassió et al. 2005). 
Elevated levels of blood L-Phe are associated with neuropsychological impairment, especially 
in the first years of life through several mechanisms, particularly dysmyelination and dopamine 
and serotonin depletion (Fig. 7) (Surtees and Blau 2000; Gassió et al. 2005; Feillet et al. 2010). 
HPA has been shown to cause white-matter lesions and increase myelin turnover, with delayed 
or reduced myelination in children and loss of myelin in adults. However, the causal link 
between dysmyelination and neuropsychological deficit has not been clearly demonstrated (Blau 
et al. 2010b; Feillet et al. 2010). Nonetheless, a relation between the white-matter abnormalities 
in PKU patients and neuropsychological impairment was established (Huttenlocher 2000; 
Anderson et al. 2007).  
Hyperphenylalaninemia also affects the neurotransmitters function in the brain, due to 
depletion of L-Tyr levels. The L-Phe transport across the blood brain barrier (BBB) is mediated 
by the L-amino acid transporter 1 (LAT1). This carrier is also responsible for the transport of the 
two other large, neutral amino acids (LNAA), L-Tyr (precursor of dopamine and noradrenaline) 
and L-Trp (precursor of serotonin) (Part I, section 1) (Pietz et al. 1999). Therefore, L-Phe 
competes with the other aromatic amino acids for their transport into the brain. Consequently, in 
PKU patients the supply of L-Tyr and L-Trp for protein synthesis (Kalsner et al. 2001; Hoeksma 
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et al. 2009) as well as the level of essential neurotransmitters can be dramatically reduced (van 
Spronsen et al. 2009).  
 
 
Figure 7. Potential mechanisms of neurocognitive impairment by hyperphenylalaninemia (HPA). 
BBB indicates blood-brain barrier; L-Phe, L-phenylalanine; BH4, (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin; 4a-OH-BH4, tetrahydropterin-4a-carbinolamine; L-Tyr, L-tyrosine; LNAA, large, 
neutral amino acid; LAT1, L-amino acid transporter 1; HMG-CoA, 3-hydroxy-3-methylglutaryl-
coenzyme; TH, tyrosine hydroxylase; TPH, tryptophan hydroxylase; L-Trp, L-tryptophan. Adapted from 
Feillet et al. 2010. 
 
Other possible mechanisms involved in brain function impairment include disturbed 
glutamatergic synaptic transmission (Martynyuk et al. 2005), cholesterol biosynthetic pathway 
(through a moderately inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) 
(Shefer et al. 2000), glucose metabolism (inhibition of pyruvate kinase) (Hörster et al. 2006; 
Wasserstein et al. 2006) and reduced function of the monoamine oxidase B as a modifying gene 
(Ghozlan et al. 2004). DNA damage and oxidative stress may also play a role on PKU 
pathogenesis (Sitta et al. 2006; Sitta et al. 2009). 
In recent years, the importance of blood phenylalanine variability has been a topic of major 
discussion. It has been proposed that not only the mean lifetime blood L-Phe level, but also the 
degree of fluctuation of L-Phe concentration during long-term dietary management could be of 
clinical importance, affecting the cognitive outcome (Burgard et al. 1996; Arnold et al. 1998; 
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Anastasoaie et al. 2008). Thus, in addition to maintain average L-Phe levels, the stability of 
blood L-Phe over time (homeostasis) might be an important goal in the treatment strategy (Blau 
et al. 2010b). 
Another important health concern related to PKU pathogenesis is the relation between 
prenatal L-Phe exposure and the offspring outcome. Women with PKU that have discontinue the 
Phe-free diet and become pregnant may develop maternal PKU. When maternal L-Phe 
concentrations are above 360 µM, normally defined as the critical threshold, the fetus is exposed 
to teratogenic concentrations of the amino acid (Koch et al. 2003a; Waisbren and Azen 2003; 
Widaman and Azen 2003). In that case, newborns may manifest severe mental retardation, 
microcephaly, developmental delay, facial dysmorphisms, low birth weight and congenital heart 
disease (Lenke and Levy 1980; Levy and Waisbren 1983; Hoeks et al. 2009; Blau 2010). 
Therefore, in PKU women maintenance of maternal blood L-Phe levels within a range of 
100−250 µM and minimization of L-Phe variation, before conception and during pregnancy is 
essential to achieve the best possible offspring outcome (Maillot et al. 2008). 
 
3.2. The treatment of PKU 
The main treatment goals for PKU are to maintain L-Phe concentration within safe limits 
(120−360 µM and 120−240 µM for pregnant PKU women) to prevent the onset or aggravation of 
neuropsychological symptoms and to ensure a normal growth and healthy life throughout 
adulthood (Giovannini et al. 2007). 
At present, the routine detection of hyperphenylalaninemia by Neonatal Screening Programs 
(the Guthrie test or modern systems based in tandem mass spectrometry) leads to the 
identification of PKU patients within the first days of life, allowing that a low L-Phe diet can be 
started early, and thus avoiding the development of severe clinical symptoms (Smith et al. 1990). 
Nowadays, this low-protein diet, supplemented with L-Phe-free mixture of amino acids, 
vitamins, minerals and other nutrients remains the most effective treatment for PKU (Giovannini 
et al. 2007; Blau et al. 2010b).  
A strict dietary control management is recommend in early childhood, and although it can be 
relaxed in older children and adults, a life-long management is currently recommend to avoid 
any harmful neurological effects (Blau 2010). However, the compliance to this life-long 
restriction diet is difficult, and usually it erodes as patients get older, with up to 75% of PKU 
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patients becoming essentially non-adherent in adulthood (Koch et al. 2002; Walter et al. 2002; 
Walter and White 2004; Blau et al. 2010b). Although an early reduction of L-Phe concentration 
can avoid the most serious deleterious effects, if there is a poor metabolic control of the L-Phe 
levels over time, it can result in persistent consequences such as lower intelligence quotient, 
impair executive function (e.g. planning, working memory, information processing, problem 
solving, sustained attention, abstract reasoning), delayed speech and behavioral problems 
(National Institutes of Health Consensus Development Panel 2001; Huijbregts et al. 2002; 
Arnold et al. 2004; Leuzzi et al. 2004; Channon et al. 2007; VanZutphen et al. 2007; Albrecht et 
al. 2009; Blau 2010). A discontinuation of the dietary treatment in early-treated adults can also 
result in vitamin deficiencies, osteoporosis, neurological and psychological decline, including 
spastic paresis, late-onset epilepsy, ataxia, tremor and problems such as neuroses, depression and 
anxiety (Hoeks et al. 2009; Blau 2010). The absence of a clear management of PKU in adult 
patients, together with inconsistencies in the definition of the mild HPA phenotype and 
management discrepancies between countries can also contribute to a long-term outcome less 
than optimal in PKU patients (Ahring et al. 2009; Blau et al. 2010a; Feillet et al. 2010). 
Although compliance with a restrictive Phe-free diet prevents most of the harmful effects of 
PKU, it may lead to insufficiencies of essential nutrients (such as tyrosine, iron, trace elements or 
long-chain polyunsaturated fatty acids), and abnormal energy supply, due to reduced intake of 
carbohydrates and fats (Przyrembel and Bremer 2000; Acosta et al. 2004). The clinical 
manifestation of these nutritional deficits comprise decrease bone density, overweight and 
growth retardation (Przyrembel and Bremer 2000; Acosta et al. 2003; Koletzko et al. 2007; 
Modan-Moses et al. 2007). The strict L-Phe diet has also been associated with selenium and 
coenzyme Q10 deficiencies that may alter the antioxidant status, especially with increase patient 
age (van Bakel et al. 2000; Artuch et al. 2004). Therefore, in the last years new approaches to 
substitute or alleviate the restrictive L-Phe-free diet and improve clinical outcomes are emerging. 
Recent developments include: BH4 or large neutral amino acid supplementation, 
glycomacropeptide as protein source, enzyme therapy (replacement and substitution), gene 
therapy (Sarkissian et al. 2009) and repopulation of hepatic PAH activity by liver cell 
transplantation (Harding 2008). Among these strategies the cofactor BH4 supplementation is 
already successfully used in the treatment of a large number of PKU patients (see below, section 
3.2.1) (Levy et al. 2007). 
Part I 
28 
The glycomacropeptide is a protein derivative from cheese whey that in its purified form is 
naturally free of aromatic amino acids, but is rich in other essential amino acids (Etzel 2004; 
Laclair et al. 2009). This protein could be a useful adjunct to the low-Phe diet, when in a purified 
form and when supplemented with the missing limiting amino acids. Glycomacropeptide is 
therefore an alternative source of dietary protein, improving the dietary compliance and 
metabolic control in PKU patients (Lim et al. 2007; Ney et al. 2009; van Calcar et al. 2009). 
The supplementation with large neutral amino acids is a strategy based on the fact that 
LNAAs compete and inhibit the L-Phe transport across the blood-brain barrier (section 3.1) and 
L-Phe uptake via intestinal absorption at the gastrointestinal tract, with cationic amino acids also 
inhibiting the uptake (Matalon et al. 2003; Matalon et al. 2006). LNAAs have been shown to 
significantly reduce blood (Matalon et al. 2006; Matalon et al. 2007) and brain L-Phe levels 
(Pietz et al. 1999), and to increase blood L-Tyr and L-Trp concentration (Koch et al. 2003b), 
improving the executive functioning (Schindeler et al. 2007). Long-term studies of the efficacy 
and safety of LNAAs supplementation are still necessary, but their use in off-diet and non-
compliant diet patients seems recommend (Rocha and Martel 2009). 
Enzyme substitution therapy with the plant derived phenylalanine ammonia lyase (PAL, E. C. 
4.3.1.5) is an additional approach to treat PKU that is currently in phase II clinical trials 
(ClinicalTrials.gov 2010). PAL is a stable L-Phe degrading enzyme from plants and yeasts that 
unlike PAH does not require a cofactor. However, L-Tyr is not a product of PAL catalytic 
reaction where phenylalanine is converted to metabolically insignificant amounts of ammonia 
and trans-cinnamic acid, a harmless metabolite converted to benzoic acid and excreted in urine 
as hippurate (Sarkissian et al. 1999). Nevertheless, the first PAL formulations presented a very 
short half-life and were highly immunogenic in parenteral therapy (Gámez et al. 2005; Ikeda et 
al. 2005). To overcome these problems pegylated forms of PAL were developed (Sarkissian et 
al. 2008) and the results from subcutaneous administration phase I clinical trials demonstrated a 
reduction of ∼60% of the mean blood L-Phe level without serious adverse effects (BioMarin 
Pharmaceutical Inc. 2009). An oral formulation of PAL is also under evaluation (Kang et al. 
2010). 
Enzyme replacement therapy with recombinant wild-type human phenylalanine hydroxylase 
is another alternative to treat PKU. In this case no L-Tyr supplementation would be required. The 
major drawbacks of the therapy are the difficulty to obtain a stable form of hPAH for 
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formulation and the cofactor requirement (Gámez et al. 2004; Kim et al. 2004). Studies 
involving hPAH fusions proteins to HIV-transactivator of transcription peptide and human 
hepatocyte growth factor, to target the enzyme specifically to the liver are also under way (Eavri 
and Lorberboum-Galski 2007). 
The PKU somatic gene therapy requires the use of DNA-based gene transfer methodologies in 
order to replace the mutant gene by a functional PAH gene in the liver, consequently restoring 
hPAH enzymatic activity. Several reports using viral and non-viral delivery gene systems in 
murine PKU models have shown to correct the HPA phenotype (Harding 2008; Jung et al. 2008; 
Rebuffat et al. 2010; Yagi et al. 2011). An alternative strategy of gene therapy includes the 
expression of PAH gene in a heterologous tissue (e.g. skeletal muscle), with enzymes from the 
BH4 biosynthetic pathway (Ding et al. 2008). Another complementary gene therapy approach 
involves transplantation of cells with a complete PAH hydroxylase system (Harding 2008). 
However, all these gene therapy approaches are still far from reaching clinical use. 
 
3.2.1. The BH4-responsive mutations 
A significant number of PKU mutations result in phenotypes that are responsive to 
pharmacologic administration of the cofactor BH4 (Zurflüh et al. 2008). Treatment of those 
patients with exogenous BH4 results in an increased hepatic activity of hPAH and decreased 
hyperphenylalaninemia, opening a new strategy in PKU treatment and management (Kure et al. 
1999; Muntau et al. 2002; Fiege and Blau 2007; Zurflüh et al. 2008; Blau et al. 2009). Mild PKU 
mutations, with considerable residual activity, are more likely to respond to BH4 intake while 
non-responders, usually classic PKU, present two inactive alleles (Bernegger and Blau 2002; 
Muntau et al. 2002). Although BH4-responsiveness can in some cases be predicted from the 
presence of specific mutations, it seems that the full genotype is more important. A database that 
contains the current list of BH4-responsive genotypes can be found at http://www.bh4.org. 
Nonetheless, in PKU management the genotype should always be combined with a 
tetrahydrobiopterin-loading test followed by a 1 to 4-week trial of sapropterin dihydrochloride, a 
commercial formulation of BH4, and the dose adjusted according to the response (Blau et al. 
2009; Karačić et al. 2009; Feillet et al. 2010). In Europe, BH4 is given orally to newborns at 20 
mg/kg bodyweight per day (48-h loading test) and the blood L-Phe concentration measured at 0, 
8, 16 and 24 h after the load (Blau et al. 2009; Blau et al. 2010a). BH4-reponsiveness is normally 
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defined as an observed reduction of blood L-Phe of at least 30% (Bernegger and Blau 2002; 
Fiege and Blau 2007). A drastically L-Phe reduction (>85%) usually indicates a deficiency in the 
recycling and biosynthesis of the cofactor and a non-responder usually shows a reduction of less 
than 20% (Blau 2008; Blau et al. 2010b). 
The molecular basis of BH4-reponsiveness are multifactorial (Blau and Erlandsen 2004), but 
the main mechanisms appear to involve the correction of catalytic defects (decreased affinity for 
cofactor) and a natural chaperone effect with the stabilization of the mutant protein against 
misfolding/aggregation/degradation (Erlandsen et al. 2004; Pey et al. 2004a; Scavelli et al. 2005; 
Aguado et al. 2006; Gersting et al. 2010a). 
The commercial form of the natural BH4, sapropterin dihydrochloride (KuvanTM, BioMarin 
Pharmaceutical Inc, CA, USA), a soluble tablet formulation, has passed the clinical trials with 
approximately 20−50% of PKU patients reaching a reduction of >30% of blood L-Phe level 
(Burton et al. 2007; Levy et al. 2007; Blau et al. 2009; Trefz et al. 2009a). The overall frequency 
of BH4-responsiveness is estimated to be ∼50−60%, based on genetic allelic data (Zurflüh et al. 
2008; Blau 2010). Sapropterin dihydrochloride was approved by the US Food and Drug 
Administration (FDA), European Medicines Agency (EMEA) and in Japan. In Europe it is 
indicate for the treatment of HPA in adult patients and PKU children (>4 years old) or BH4 
deficiency (Blau et al. 2009). The most frequent side effects are mild and include: upper 
respiratory tract infection, headache, vomiting, pharyngo-laryngeal pain, nasopharyngitis and 
diarrhea (Levy et al. 2007; Lee et al. 2008). Sapropterin dihydrochloride can provide a good L-
Phe control in some patients, increasing their dietary L-Phe tolerance and opening the possibility 
to make adjustments towards a less restrictive diet (Blau 2010). However, data related to 
neurocognitive outcomes in long-term BH4 treated patients is still scarce (Gassió et al. 2010). 
 
3.2.2. Natural, chemical and pharmacological chaperones in PKU treatment 
Several human genetic diseases are misfolding diseases caused by defects in protein folding 
or trafficking that results in the accumulation or degradation of the proteins by cellular protein 
quality control systems (Gregersen et al. 2006). This group of proteins is a likely candidate to 
new therapeutic strategies using small chemical compounds such as cofactors, protein inhibitors, 
osmolytes and ligands, the so called natural/chemical/pharmacological chaperones, in order to 
rescue the misfolded unstable mutant protein from degradation (loss of function) or aggregation 
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(gain of function), and thereby restoring protein function (Cohen and Kelly 2003; Kolter and 
Wendeler 2003; Loo and Clarke 2007; Leandro and Gomes 2008). The use of these compounds 
have been evaluated in several human diseases including neurodegenerative and metabolic 
disorders (Leandro and Gomes 2008), e.g. several pharmacological chaperones are already in 
clinical evaluation for treatment of some lysosomal storage diseases as Gaucher, Fabry and 
Pompe disease (Parenti 2009). 
In PKU a large number of the identified missense mutations result in misfolded proteins and 
increased protein turnover, with PKU being considered a conformational disease with loss of 
function due to decrease conformational stability (Pey et al. 2007; Gersting et al. 2008). Natural 
chaperoning in PKU with cofactor BH4 is an already approved treatment for a subset of PKU 
mutations (see section above). Chemical chaperoning of hPAH with osmolytes (glycerol, 
trimethylamine N-oxide (TMAO), mannitol) has been shown to increase the catalytic activity 
and stability of the wild-type and mutant forms of the protein (Leandro et al. 2001; Nascimento 
et al. 2008; Nascimento et al. 2010), opening new perspectives to the identification of low-
molecular-weight compounds that increase enzyme activity/stability, which may also be useful in 
future enzyme replacement therapy formulation. Recently, a screening of over 1000 
pharmacological agents has identified small-molecule binders that efficiently enhanced the 
thermal stability of wild-type and misfolded mutant forms, significantly increased the activity 
and steady-state PAH protein levels in transiently transfected cells and raised the PAH activity in 
mouse liver (Pey et al. 2008). Similar studies were extended to other AAAHs, namely tyrosine 
hydroxylase and tryptophan hydroxylase 2, with promising results (Calvo et al. 2010). These 
studies open a potential treatment strategy for PKU and other AAAHs related diseases by 
pharmacological chaperoning. 
 
3.3. Interallelic complementation 
A unique property of homo-oligomeric enzymes associated with human genetic disorders is 
their potential ability to exhibit interallelic complementation (IC), a phenomenon that occurs 
when a multimeric protein is formed from subunits produced by different mutant alleles of a 
gene, and particular combinations of two alleles, at a given locus, produce a less (positive IC) or 
a more (negative IC) severe phenotype than their homoallelic counterparts. IC is observed in 
homomeric enzymes where the protomers exhibit interactions resulting in hybrid proteins with 
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functional or stability properties deviating significantly from the average of the parental 
enzymes. 
Interallelic complementation has been implicated in several human diseases (Veitia 2009), 
including neurodegenerative disorders such as familial amyloid polyneuropathy (Hammarström 
et al. 2003; Keetch et al. 2005), cancer (Nicholls et al. 2002; Dridi et al. 2003; Dong et al. 2007; 
Lee and Sabapathy 2008) and metabolic disorders such as, argininosuccinic aciduria (McInnes et 
al. 1984; Howell et al. 1998; Yu et al. 2001), erythropoietic protoporphyria (Ohgari et al. 2005), 
galactosemia (Elsevier and Fridovich-Keil 1996; Christacos and Fridovich-Keil 2002) and PKU 
(Kaufman et al. 1975).  
In PKU the IC phenomenon was first pointed out in 1975, when Kaufman and Max (Kaufman 
et al. 1975) observed deviations from proportionality in PAH activity of parents of PKU patients 
(obligate heterozygous). They introduced the term negative interallelic complementation to 
illustrate the negative effects of protein-protein interactions occurring between the mutant 
subunits in the tetrameric hPAH enzyme. Additional clinical evidence lending support to a 
negative IC in some compound heterozygous PKU patients has been obtained from genotype-
phenotype correlations studies, where some patients present a more severe phenotype than the 
anticipated by the predicted residual activity (PRA), based on in vitro assays of recombinant 
proteins (Burgard et al. 1996; Kayaalp et al. 1997; Guldberg et al. 1998; Rivera et al. 2000), and 
from clinical data of BH4-loading tests where some patients displayed an absence or only a 
partial response to BH4, although carrying two BH4-responsive alleles (Karačić et al. 2009; Trefz 
et al. 2009b). Interactions between different hPAH protomers have been demonstrated by the 
yeast two-hybrid system (Waters et al. 2001), but the molecular mechanism of negative IC and 
its role in PKU pathogenesis is still far from being solved. 
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 Since the first report in 1934, by Asbjørn Følling, PKU has been the subject of extensive 
research. However, beyond the knowledge accumulated along these years there are still diverse 
aspects that have remained largely overlooked and others that owing to the increase awareness of 
their importance demand a more thoroughly study. In this perspective, the main goal of this 
thesis was to further elucidate those aspects, namely the phenomenon of interallelic 
complementation (IC) (Part III); the study of misfolding mutants involving the R-domain of 
phenylalanine hydroxylase (Part IV) and the identification of the structure-function role of amino 
acids residues in catalysis and catalytic activation of hPAH, particularly those localized in the 
highly flexible loop 131-155 (Part V). 
The negative interallelic complementation phenomenon in PKU was first proposed by 
Seymour Kaufman in 1975. Although the majority of PKU patients are compound heterozygous 
(~75%) with a high genotypic heterogeneity (>550 mutations identified to date), raising the 
importance of IC in PKU pathogenesis, this phenomenon has been largely neglected. The first 
experimental evidence lending support to a negative interallelic complementation in some 
compound heterozygous PKU patients had been obtained from the first metanalysis of genotype-
phenotype correlation studies and more recently from inconsistencies observed in the treatment 
with cofactor BH4. Therefore, due to the increase understanding that the characterization of the 
interactions between wild-type and mutant protomers and between different mutant protomers is 
clinically relevant, as they will contribute to a better understanding of the metabolic phenotype in 
PKU/HPA patients and BH4-responsiveness and will also be essential in the development of new 
emerging therapies (e.g. pharmacological chaperones), in Part III of this work the molecular 
basis of interallelic complementation in human phenylalanine hydroxylase was addressed.  
Interactions between different hPAH protomers have been demonstrated by the yeast two-
hybrid system. However, the molecular mechanism of interallelic complementation and its role 
in PKU pathogenesis remained elusive since heteromeric forms of hPAH have never been 
isolated and characterized biochemically. The conventional expressions studies of recombinant 
hPAH initiated in the 1990s led to the characterization of more than 100 hPAH mutant forms in 
the homoallelic state. Nevertheless, they did not allow the characterization of heteroallelic states. 
Hence, our first aim was the development of a dual vector prokaryotic expression system 
producing two different hPAH subunits, mimicking the natural heteroallelic state in 
heterozygous or in compound heterozygous patients (Part III, section 1; Paper I). The mutations 
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analyzed, namely the I65T, R261Q, R270K and V388M, were selected due to the observed 
inconsistencies in genotype-phenotype correlation studies of Portuguese hyperphenylalaninemic 
compound heterozygous patients and thus likely candidates of negative IC. Albeit the produced 
recombinant proteins resembled the heteroallelic state observed in compound heterozygous, with 
mixed populations of hetero-/homo-oligomers (i.e. homo-oligomer-1 + homo-oligomer-2 + 
hetero-oligomer-1/2) in addition to some dimers, the expression system did not allowed the 
isolation of individual hetero-oligomeric species. Therefore, our next challenge was the 
development of a bicistronic system (Part III, section 2; Paper II) to express wild-type and 
truncated forms of hPAH, allowing the isolation of pure heteromeric forms and to answer to 
some fundamental questions related to the assembly of hybrid forms (existence of hetero-
tetramers and/or hetero-dimers), and the formation of heteromeric species with different 
functional domains.  
Phenylketonuria is considered a protein misfolding disease with loss of function. Human PAH 
has a small margin of stability and a high frequency of misfolding hPAH mutations are 
associated with PKU/HPA, resulting in enzymes with a propensity to self-associate and to form 
higher-order oligomers (when overexpressed in prokaryotic systems) and to be rapidly degraded 
(when expressed in eukaryotic cells). This group of mutations does not directly affect the 
catalytic function, but impairs molecular motions involved in regulatory processes, substrate and 
cofactor binding and oligomerization assembly. Particularly the N-terminal regulatory domain 
(R-domain) seems to play a crucial role in the instability and misfolding of the protein. 
Therefore, we aimed to comprehensively study in vitro the missense mutation G46S in the R-
domain of hPAH, associated with the severe form of PKU, which is rapidly degraded when 
expressed in HEK293 cells (Part IV, section 1, Paper III). The experimental approach with the 
putative maltose binding protein (MBP) as fusion partner allowed the recovery of the mutant in a 
metastable conformational state, and cleavage of fusion protein enabled the study of the 
molecular mechanism of the self-association and the structural properties of the higher-order 
oligomers, as well as the effect of molecular/chemical/pharmacological chaperones. We also 
aimed to extend the studies of this misfolded mutant and the wild-type (WT) to truncated forms 
of the R-domain (residues 2-120). These forms were analyzed (Part IV, section 2; Paper IV) 
using a similar experimental approach, and the WT R-domain self-association propensity was 
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further explored in terms of the controversial allosteric regulatory binding site for L-
phenylalanine in the R-domain of hPAH. 
 The substrate L-Phe triggered activation of hPAH, a key regulatory property of the enzyme, is 
characterized by a reversible transition from a low activity/affinity state (T-state) to a high 
activity/affinity state (R-state). There is no crystal structure of the full-length enzyme, but high-
resolution structures of a truncated dimeric form of the binary cofactor complex (ΔN102/ΔC24-
hPAH-Fe(II)·BH4) and ternary cofactor-substrate analog complex (ΔN102/ΔC24-hPAH-
Fe(II)·BH4·THA) have provided insights into the roles of active site residues and conformational 
changes in substrate recognition and catalysis, leading to the proposal of a catalytic mechanism 
for PAH. Moreover, these structures have revealed that substrate binding triggers a 
conformational isomerization, including a Cα displacement of ~10 Å for Tyr138 and ~21 Å of 
its side-chain hydroxyl group from a surface position in a flexible loop to a partially buried 
position within a hydrophobic core at the active site. In the closely related rTH, a homologous 
flexible loop seems to be involved in the rate-limiting step of the TH reaction. In hPAH the 
functional importance of the L-Phe-induced displacement observed for the flexible surface loop 
(conserved in mammalian PAHs) and relocation of the Y138 hydroxyl group was addressed 
experimentally (Part V, section 1, Paper V), by mutation of the residue (Y138F/A/E/K) in the 
dimeric catalytic core domain (ΔN102/ΔC24-hPAH) and in the full-length tetrameric hPAH. 
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To study the interaction between two different subunits of the heteromeric human phenylalanine hydroxylase (hPAH), present in
hyperphenylalaninemic (HPA) compound heterozygous patients, heteroallelic hPAH enzymes were produced. A dual vector expression system
was used (PRO™ Bacterial Expression System) in which each mutant subunit was expressed from a separate compatible vector, with different
epitope tags, in a single bacterial host. Experimental conditions were selected in order that each plasmid produced equivalent levels of mutant
subunits. In this study, we demonstrated that both subunits were expressed and that the purified heteroallelic enzymes, were catalytically active. As
expected, the produced proteins displayed enzymatic activities levels lower than the predicted catalytic activity, calculated by averaging in vitro
PAH activities from both alleles, and were strongly dependent on the proteins subunit composition. The obtained data suggest that interactions
between the studied hPAH subunits, namely the I65T, R261Q, R270K and V388M, and the wild-type protein occurred. As postulated, this
phenomenon could be a source of phenotypic variation in genetic diseases involving multimeric proteins.
© 2006 Elsevier B.V. All rights reserved.Keywords: Heteroallelic human phenylalanine hydroxylase; Dual expression system; Interallelic complementation1. Introduction
Human phenylalanine hydroxylase (hPAH; E.C. 1.14.16.1)
is a homotetrameric non-heme iron dependent enzyme that
hydroxylates phenylalanine (L-Phe) to tyrosine (L-Tyr). In man,
hPAH dysfunction leads to phenylketonuria (PKU; OMIM
261600) and related forms of hyperphenylalaninemia (HPA)
[1]. The enzymatic phenotype of this recessive metabolic
disease results from the combined expression of the two mutant
alleles. Most HPA patients are heteroallelic for PAH mutations
being classified as compound heterozygous [2].
There is now considerable direct evidence indicating that it
is possible to establish genotype/phenotype correlations [3,4]
in the homoallelic state and in most cases of functional
hemizygous patients (resulting from the combination with a
“null” allele that completely abolishes PAH activity) [5].⁎ Corresponding author. Tel.: +351 217946400; fax: +351 217946491.
E-mail address: aleandro@ff.ul.pt (P. Leandro).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.02.001However, in the heteroallelic state inconsistencies exist
between the observed metabolic phenotype and the “predicted
residual activity” (PRA) [6], as calculated from the mean of
the monoallelic in vitro PAH enzyme activities for each
mutation comprising the genotype [3]. In these patients, the
presence of several mutations, namely the I65T, R261Q and
V388M mutations, associated either among each other or with
other mutations gives rise to more severe phenotypes than
those anticipated by the PRA [6]. This phenomenon was
already known since 1975 when Kaufman and Max [7]
observed, in parents of PKU patients (obligate heterozygous),
a deviation from proportionality in the determined PAH
activity. These authors introduced the term negative interal-
lelic complementation to illustrate the protein–protein inter-
actions occurring between the subunits of the multimeric
hPAH enzyme.
Recently, using a yeast two-hybrid approach [8,9], it was
demonstrated that the wild-type hPAH subunits interact with
different hPAH mutant subunits, thus, indicating the production
of heteromeric PAH enzymes. However, a central question
545J. Leandro et al. / Biochimica et Biophysica Acta 1762 (2006) 544–550remains concerning the enzymatic activity of the postulated
produced hybrid hPAH proteins. Till now, the use of
conventional expression systems had never allowed to test for
the hypothesis of a negative impact of a particular mutation on
the activity of a heteromeric hPAH, since in these systems, a
single mutant allele is expressed, thus, producing a homoallelic
protein phenotype.
Using a dual vector expression strategy, for the co-
production of two mutant hPAH subunits, we were able to
mimic the natural heteroallelic state occurring in heterozygous
individuals and compound heterozygous patients. Two different
subunits were simultaneously produced in equivalent amounts
in the same bacterial host, using two different plasmids (PRO™
Bacterial Expression System). The studied mutations included
the I65T, R261Q, R270K and V388M mutant forms, which
contribute mostly for the observed genotype/phenotype incon-
sistencies in the Portuguese PKU population [10].
The determined enzymatic activities showed that when co-
expressed the produced mutant enzymes presented lower
catalytic activities than the predicted by individual expression
of the mutant subunits. The obtained results were in full
accordance with the postulated phenomenon of negative
interallelic complementation.
2. Material and methods
2.1. Materials
The PRO™ Bacterial Expression System was from Clontech (Clontech
Laboratories, Palo Alto, USA). The synthetic cofactor 6-methyl-tetrahydropterin
(6-MPH4), L-Phe, HEPES and dithiothreitol (DTT) were from Sigma Chemical
Co (St. Louis, USA). Catalase was purchased from Roche Diagnostics GmbH
(Mannheim, Germany). All reagents were of analytical grade.
2.2. Construction of recombinant dual expression vectors
The PRO™ Bacterial Expression System comprises two expression
vectors developed by Lutz and Bujard [11], namely the pPROLar and
pPROTet. These vectors present different replication origins, a Myc epitope
(–Glu–Gln–Lys–Leu–Ile–Ser–Glu–Glu–Asp–Leu–) and encode resistance
to different antibiotics such that only cells expressing both vectors would be
resistant to both kanamycin (pPROLar) and chloramphenicol (pPROTet).
The pPROLar vector contains the Plac/ara-1 promoter, induced by
isopropylthio-β-D-galactoside (IPTG) and arabinose (Ara), and the pPROTet
vector includes the PLtetO-1 promoter, induced in response to anhydrote-Table 1
Oligonucleotides used for site directed mutagenesis
Primers Position a Sequence (5′
6xHis–tag F pPROTet 96–131; pROLar 122–158 AGAAAGGT
6xHis–tagR GCTGATCA
I65T-F cDNA 183–203 CTAGATTC
I65T-R CCTGACCC
R261Q-F cDNA 772–792 GTGGAAGA
R261-R CTGGCCTT
V388M-F cDNA 1152–1172 CTCTCTGC
V388M-R CCTGTATTA
R270K-F cDNA 799–819 CAGTACAT
R270K-R GGATCCAT
a Nucleotide positions refer to Konecki-Kwok PAH cDNA (PAH Mutation Anal
positions are underlined.tracycline (aTc). A recombinant-deficient host (DH5αPRO; Clontech
Laboratories, Palo Alto, USA) was used to minimize recombination
between plasmids.
The original vectors were subjected to Site Directed Mutagenesis
(Quikchange II; Stratagene, La Jolla, USA) in order to introduce a 6xHis
purification tag (Table 1). Moreover, the pPROLar Myc-tag was removed and
the Xpress epitope (–Asp–Leu–Tyr–Asp–Asp–Asp–Asp–Lys–) was intro-
duced. The pPROLar–XPress–His and pPROTet–Myc–His expression vectors
were obtained. The enterokinase (EK) recognition sequence was maintained just
before the hPAH coding sequence in order to be possible to remove the 6xHis
tag. However, the EK treatment it is not necessary, since we have demonstrated
previously that these tags did not interfere with the activity of the recombinant
protein [12].
For prokaryotic expression the coding sequence of hPAH [13] (GenBank
accession U49897) was introduced in the BamHI site of pPROLar–XPress–His
and pPROTet–Myc–His expression vectors, in frame with the start codon.
Using the mutagenic oligonucleotides described in Table 1, the studied
mutations were introduced by Site Directed Mutagenesis (Quikchange II).
The obtained constructs were sequenced to confirm the introduction of the
desired modifications and were used to transform competent DH5αPRO cells.
Propagation of pPROTet–Myc–His constructs was performed in LB plates
supplemented with spectinomycin (50 μg/ml, final concentration) and
chloramphenicol (34 μg/ml, final concentration). The pPROLar–XPress–His
constructs were propagated in LB plates supplemented with spectinomycin and
kanamycin (both at 50 μg/ml, final concentration).
The strategy to achieve dual vector expression was to transform E. coli host
cells simultaneously with two different hPAH subunits, each cloned in a
different vector. To select the co-expressed constructs, LB plates supplemented
with spectinomycin, kanamycin (both at 50 μg/ml final concentration) and
chloramphenicol (34 μg/ml, final concentration) were used.
2.3. Co-expression of recombinant hPAH subunits
The protein expression was initially optimised, for each system individually,
by testing the optimal inducers concentration and induction time. Final
concentrations of aTc from 1 to 100 ng/ml were used for induction of
pPROTet–Myc–His constructs. The pPROLar–XPress –His constructs were
assayed for induction with a constant IPTG concentration (1 mM) and variable
amounts of arabinose in the culture medium (0 to 0.2%). Kinetic induction
studies were performed with an incubation period of 12 hours, with samples
collected at 0, 1, 2, 3, 4, 5 and 12 hours after induction.
For the co-production of two different 6xHis–hPAH subunits, fresh
overnight cultures were diluted 1:100 in LB medium containing 34 μg/ml of
chloramphenicol, 50 μg/ml of spectinomycin and 50 μg/ml of kanamycin. Cells
were grown at 37 °C with expression induced by addition of the optimised
amounts of IPTG, arabinose and aTc when the A600 was about 0.6.
Simultaneously 0.1 mM ferrous ammonium sulfate (Fe2+) was added to the
culture. Induction was performed for a period determined to maximize the
prokaryotic expression of the heteroallelic hPAH enzyme forms under
investigation.–3′)
ACCCATGGGTCATCATCATCATCATCATGAACAGAAACTGATCAGC
GTTTCTGTTCATGATGATGATGATGATGATGACCCATGGGTACCTTTCT
AGTGTGGGTCAGG
ACACTGAATCTAG
CTTGGAAGGCCAG
CCAAGTCTTCCAC
CATGTAATACAGG
CATGGCAGAGAG
GAAACATGGATCC
GTTTGATGTACTG
ysis Consortium Database; http://www.mcgill.ca/pahdb). Nucleotide mismatch
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4 °C. The pellets (stored at −20 °C until used) were resuspended (40%, w/v) in
lysis buffer (50 mM potassium phosphate; 300 mMNaCl, pH 7.8; 10% glycerol)
containing 1 mM phenylmethanesulphonyl fluoride (PMSF) and 1 mg/ml
lysozyme. After a 30 min incubation at 4 °C, cells were disrupted by passage
through a Carver Press (Model C, from F.S. Carver Inc., Wabash, IN, USA) at
4000 psi. The crude extract was then centrifuged at 10,000×g at 4 °C for 20 min.
The concentrations of imidazole and β-mercaptoethanol (β-ME) in the
supernatants were adjusted to 10 mM and processed immediately.
The recombinant 6xHis–hPAH proteins expressed from the pPROLar–
XPress–His and pPROTet–Myc–His vectors were designated 6xHis–hPAHLar
and 6xHis–hPAHTet, respectively. Expression of heteroallelic proteins was
always carried out with both possible combinations (e.g. wtLar/V388MTet and
wtTet/V388MLar).
2.4. Purification and analysis of recombinant proteins
The presence of the 6xHis tag allowed the purification of the recombinant
protein by IMAC using a Ni-chelating resin (Ni-NTA-Resin; Qiagen, Valencia,
USA), as previously described [12]. Aliquots of the purified enzyme samples
were analysed by SDS-PAGE (10% gel) after Coomassie brilliant blue R
staining. Western immuno-analysis was performed according to standard
methods [14] using the anti-Myc or the anti-Xpress as the primary antibodies
(Invitrogen; Carlsbad, USA) and the anti-mouse IgG-HRP (Cell Signalling;
Beverly, USA) as the secondary antibody. Protein concentrations were
determined by the method of Bradford [15] using bovine serum albumin
(BSA) as standard. Protein purity was assessed by densitometric scanning of
destained gels or membrane blots followed by analysis using the Gel-Pro
Analyzer (version 2.0) software (Media Cybernetics).
2.5. Assay of enzymatic activity
Enzyme assays were performed with the purified fusion proteins, essentially
as described by Martinez et al [16] with some minor modifications [12]. The
PAH activity was assayed using the synthetic cofactor 6-methyl-tetrahydropterin
(6-MPH4) and the substrate (L-Phe) at final concentrations of 500 μM and
1 mM, respectively. All stages of protein purification, analysis and enzyme
assays were performed without intervening freeze–thaw cycles.
2.6. Cleavage of the fusion peptide
The leader fusion peptide 6xHis was excised from the recombinant fusion
protein by cleavage with EK (Invitrogen, Carlsbad, USA). In this assay 50 μg of
purified enzyme were incubated with 1 U of EK in 50 mM Tris–HCl pH 8.0,
1 mM CaCl2 (ratio EK: fusion protein about 1:30) for 5 h at 4 °C.Fig. 1. Regulation of wild-type 6xHis–hPAH expression from the PLtetO-1 (A)
and PLac/ara-1 (B) promoters. Assays were performed with 500 ml of growth
medium and 4-h incubation. Each value represents the mean of two independent
analysis. Arabinose induction was performed with a constant 1 mM IPTG
concentration.3. Results
The wild-type and mutant hPAH cDNAs were cloned into
the pPROLar–XPress–His and pPROTet–Myc–His expres-
sion vectors. Western Blot analysis of crude cell lysates
revealed the presence of a single fusion protein band with a
molecular mass of about 55 kDa. Assuming a molecular mass
of 3 kDa for the fusion peptide [12] the 52-kDa protein
corresponds to the expected full-length hPAH wild-type or
mutant forms [17,18].
Expression conditions, including inducers concentration and
induction time, were analysed in order to achieve equimolecular
levels of each subunit comprising the hPAH heteroallelic state.
Regulation of wild-type hPAH expression from the PLtetO-1 and
Plac/ara-1 promoters showed that the highest and equivalent
protein levels were reached using 100 ng/ml of aTc, for the
pPROTet–Myc–His construct, and 0.2% arabinose/1 mM IPTGfor the pPROLar–Xpress–His construct (Fig. 1). Using the
above inducers concentration maximum yields of recombinant
proteins were obtained between 4 and 5 h, for the wild-type
form and at 4 h induction for the studied mutant forms (Fig. 2).
After these time points, a decrease in the protein production was
observed. Based on these observations, a 4-h induction time was
chosen to produce the wild-type and the mutant recombinant
6xHis–hPAH proteins.
After IMAC purification the 6xHis hPAHwt protein
presented, for both expression vectors, 95% purity. Similar to
the results obtained with other expression systems [12,19] the
recombinant mutant forms showed lower purity grades, namely
75–80% for the I65T, R261Q and V388M (pPROLar–XPress–
His and pPROTet–Myc–His constructs). The R270KLar protein
was produced almost to homogeneity, whereas the R270KTet
mutant protein (Fig. 3) presented only 60% purity. In addition to
a main band of full-length hPAH (55 kDa), a minor band of
higher molecular mass was observed for the R270KTet mutant
form (Fig. 3). However, Western blot analysis showed that this
band did not represent immunoreactive hPAH protein (results
not shown).
The 6xHis fusion peptide was efficiently cleaved from the
recombinant enzymes (EK digestion), yielding a protein with a
MW of about 52 kDa (results not shown).
Fig. 2. Expression of wild-type and mutant 6xHis–hPAH enzymes encoded by
the recombinant vectors pPROTet–Myc–His (A) and pPROLar–XPress–His
(B), along time induction, using the optimized inducers concentrations. (•)
hPAH wt; (□) R261Q mutant form; (▽) I65T mutant form; (▴) V388M mutant
form; (◊) R270K mutant form. Each value represents the mean of two
independent experiments.
Fig. 4. Western blotting analysis of purified (1) 6xHis–hPAHwtTet (Myc
epitope); (2) 6xHis–hPAH V388MLar (Xpress epitope) and (3) co-produced
6xHis–hPAHwtTet/6xHis–hPAH V388MLar protein (Myc and Xpress epitope).
Immunodetection using the anti-Myc (A) and anti-Xpress (B) antibodies (see
text for details).
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by Western blot analysis of the purified recombinant proteins,
using the anti-Myc and the anti-Xpress antibodies. The presence
of the two subunits possessing both epitopes is illustrated in Fig.
4 for the co-produced 6xHis–hPAHwtTet/V388MLar.
In order to perform a comparative analysis, the enzymatic
activities of the homomeric forms of 6xHis hPAH proteins were
also determined (Table 2). When assayed at standard conditions
(1 mM L-Phe and 500 μM 6-MPH4), the wild-type form
revealed a catalytic activity of 5818 nmol Tyr min−1 mg−1. TheFig. 3. SDS-PAGE analysis of hPAH mutant forms expressed from recombinant
vectors pPROLar–XPress–His (A) and pPROTet–Myc–His (B). (M) Molecular
weight marker; (1–4) 6xHis–hPAH recombinant forms of R261Q (1); I65T (2);
V388M (3) R270K (4) and; wild-type (5).purified homomeric R270K protein exhibited only 2.1% (121
nmol Tyr min−1 mg−1) of residual activity, whereas mutations
I65T, R261Q and V388M presented 26.5% (1539 nmol Tyr
min−1 mg−1), 27.6% (1603 nmol Tyr min−1 mg−1) and 27%
(1569 nmol Tyr min−1 mg−1) respectively, of the activity of the
native enzyme.
The subunits of the co-produced 6xHis hPAH proteins were
expressed alternatively by each of the vectors and their
enzymatic activities were determined. The obtained values
were compared (Student's t test) in order to determine if their
difference were statistically significant (Table 2).
As shown in Table 2, the enzymatic activities of the purified
co-produced mutant proteins were always lower than the PRA.
The R270K/R261Q protein presented an experimental activity
21% lower than the PRA. For the V388M/I65T, V388M/R261Q
and I65T/R261Q we could observe a similar effect in the
decrease of the enzymatic activity (38, 35 and 28%, respective-
ly). Proteins produced by co-expressing the R270K and V388M
alleles showed the higher activity decrease (88%), while the
R270K/I65T co-produced protein presented an experimental
activity 52% lower than the PRA. The hPAHwt/V338M protein,
mimicking a heterozygous condition, also presented a residual
activity (38.5%) lower than the PRA (63.5%).
4. Discussion
Interallelic complementation is a phenomenon that occurs
when a hybrid protein is expressed from two different mutated
alleles of a gene. When compared to the predicted residual
activity the produced heteromeric protein could present a higher
(positive complementation) or lower (negative complementa-
tion) catalytic activity.
The observation that some PKU patients present a more
severe phenotype than the predicted [6] suggests that the
resulting heterotetrameric enzyme activity should be lower than
the predicted value, determined from the independent enzyme
activities of the respective homomeric mutant proteins. To give
an explanation for this phenomenon the occurrence of a negative
interallelic complementation mechanism has been evoked.
While interactions of different subunits of a hybrid hPAH
protein were already proven to occur [8,9], the enzymatic activi-
ties of such heteromeric proteins had never been determined.
In order to co-produce two different subunits of a
heteroallelic hPAH phenotype, a prokaryotic dual vector co-
Table 2
Enzymatic activities of homoallelic and heteroallelic 6xHis hPAH recombinant proteins produced by simultaneous expression of two subunits
PAH sub-unit composition Specific activity a
(nmol Tyr min−1 mg−1)
Residual enzyme
activity b (%)
PRAc
(%)
Observed
decrease (%)
hPAHwtLar/hPAHwtTet 5818±82.7 (100%) – –
I65TLar/I65TTet 1539±42.4 (26.5%) – –
R261QLar/R261QTet 1603±49.5 (27.6%) – –
R270KLar/R270KTet 121±18.4 (2.1%) – –
V388MLar/V388MTet 1569±41.0 (27.0%) – –
V388MLar/hPAHwtTet 2336 (40%) 38.5 63.5 39
V388MTet/hPAHwtLar 2200 (37%)
(P n.d.)
V388MLar/I65TTet 918±49.0 (15.8%) 16.5 26.7 38
V388MTet/I65TLar 1003±20.8 (17.2%)
(P>0.05)
V388MLar/R261QTet 1062±34.9 (18.2%) 17.6 27.3 35
V388MTet/R261QLar 987±35.5 (17.0%)
(P>0.05)
V388MLar/R270KTet 118±7.4 (2.03%) 1.77 14.4 88
V388MTet/R270KLar 88±15.6 (1.51%)
(P>0.05)
R270KLar/I65TTet 474±6.0 (8.15%) 6.91 14.3 52
R270KTet/I65TLar 330±10.5 (5.67%)
(P<0.001)
R270KLar/R261QTet 676±10.5 (11.6%) 11.8 14.8 21
R270KTet/R261QLar 691±8.3 (11.9%)
(P>0.1)
I65TLar/R261QTet 1185±15.9 (20.4%) 19.4 27.0 28
I65TTet/R261QLar 1075±20.5 (18.5%)
(P<0.01)
a Values are means ± standard deviation determined from three independent experiments, except for the V388MLar/hPAHwtTet and V388MTet/hPAHwtLar constructs
(two experiments); Statistical analysis compared subunits produced from different expression vectors; statistical significance (P value) was determined using the
Student's t test; values in parenthesis refer to % of activity relative to the wild-type form (residual activity).
b Mean of residual enzyme activity determined for both constructs.
c (PRA) Predicted enzymatic activity, calculated by averaging the experimental enzymatic activities of the corresponding homomeric proteins. (n.d.) not
determined.
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of promoter regulation allowed us to control independently the
expression of the two cloned alleles. Actually, the use of 100 ng/
ml of aTc (pPROTet–Myc–His constructs) and 0.2% arabinose/
1 mM IPTG (pPROLar–XPress–His constructs) produced
similar quantities of each different protein (Fig. 1). This fact
represents one of the greatest advantages of the dual vector
system when compared to the bicistronic system [20].
We first studied each expression vector individually in order
to confirm that they were suitable for the production of
catalytically active PAH enzyme. The use of pPROLar–
XPress–His and pPROTet–Myc–His expression vectors
allowed the purification of the full-length recombinant
6xHis–hPAH proteins (55 kDa), with purity grades ranging
from 60 to 95%. The resulting mutant homoallelic forms
presented relative enzymatic activities (Table 2) similar to those
obtained previously, using the pTrcHis prokaryotic expression
system [12,19].
The presence of different epitopes in the constructs (Myc and
Xpress) allowed us to confirm the presence of both subunits in
the coexpressing assays. As shown by Western blot analysis
(Fig. 4), cotransformation with the different pPROLar–XPress–
His and pPROTet–Myc–His constructs into the E. coli strain
DH5αPRO resulted in the production of similar levels of thetwo different subunits of the co-produced hPAHwtTet/V388MLar
protein.
In order to prove that the determined enzymatic activities of
the co-produced proteins were independent of the vector used to
express the studied allele, each hPAH subunit, comprising the
heteroallelic state, was always synthesized in the two possible
combinations (Table 2). The obtained enzymatic activities were
not significantly different (P>0.05), except for the R270K/I65T
(P<0.001) and R261Q/I65T (P<0.01) proteins. In these two
co-produced proteins the determined P value (<0.05) could not
be explained neither by the presence of a particular subunit,
namely the I65T subunit as it was not observed for the co-
produced V388M/I65T mutant protein, nor by an higher
expression level of one of the vectors. Moreover, the same
range of residual activity was calculated (Table 2) for the
R270K/I65T combinations (8.1 and 5.67%) and for the R261Q/
I65T combinations (18.5 and 20.4%). Therefore, any of the
construct combinations could be used to study the interallelic
complementation phenomenon.
We could demonstrate for the heteroallelic mutant proteins,
a decrease in the enzymatic activity when compared to the
predicted residual activity (PRA). These values, ranging from
88% (V388M/R270K) to 21% (R270K/R261Q), reflect a
negative interaction between the studied mutant subunits.
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strongly dependent on the nature of the mutant proteins
present. Among these, the R270K subunit presented a higher
negative effect, particularly over the V388M subunit. It has
been postulated that reduced stability is likely the most
important attribute for the association of the R270K mutation
with PKU in vivo [19]. Therefore, the observed drastic effect
of this mutant subunit could be related to an altered protein
oligomerisation.
Each subunit of the tetrameric hPAH comprises a N-terminal
regulatory domain (Ser2–Ser110), a catalytic domain (Ser110–
Ser411) a dimerisation motif (Ser411–Thr427) and a C-terminal
tetramerisation domain (Glu428–Lys452) [21]. The regulatory
domain from one subunit establishes contacts with the catalytic
domain of the other subunit in the dimer. The tetramers are
considered to be a dimer of dimers in which the subunits in one
dimer contact the subunits in the adjacent dimer only via the α-
helical tetramerisation motif. As none of the studied mutations
affect the hPAH tetramerisation domain (I65T and R261Q are
dimer interface mutations) [22,23] probably they will affect the
existing interactions between the subunit interfaces and not
directly the tetrameric unit assembly. As a consequence, the
enzymatic function could be directly affected as the studied
mutations could interfere with the necessary conformational
changes occurring at the dimer interface upon activation by L-
Phe [24]. We could also admit that they result in quaternary
structures relatively less stable. In this regard, the dual
expression system described herein will allow the study of the
oligomerisation pattern of the produced proteins as well as their
enzymatic properties (studies in course). It must be noted that
albeit there is now a high-resolution structure available for the
hPAH enzyme, there is still no direct proof of subunit
interaction or a clear insight into the possible structural basis
of any such interaction.
In conclusion, from our observations, it seems clear that a
phenomenon of negative interallelic complementation exists
between the studied hPAH subunits, mimicking heterozygous
and heterozygous compound patients. Furthermore, it appears
likely that this phenomenon could be a general source of
phenotypic variation in genetic diseases involving multimeric
proteins. Such interactions must be considered in any attempt to
establish genotype/phenotype correlations in patients affected
by such disorders.
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Heteroallelic proteinHybrid forms of human phenylalanine hydroxylase (hPAH) mutants have been found to present catalytic
activities lower than predicted from the individual recombinant forms, indicating that interallelic
complementation could be a major determinant of the metabolic phenotype of compound heterozygous
phenylketonuric (PKU) patients. To provide a molecular explanation for interallelic complementation we
have here developed a bicistronic expression system and a puriﬁcation strategy to obtain isolated hPAH
heteromeric forms. On co-expression of WT-hPAH (~50% tetramer; ~10% dimer) and the N- and C-terminally
truncated form ΔN102/ΔC24-hPAH (~80% dimer) no heterodimers were recovered. Moreover, by co-
expression of WT-hPAH and the N-terminally truncated form ΔN102-hPAH (~95% tetramer), heterote-
tramers, as a result of an assembly of two different homodimers, were isolated. The recovered (WT)/(ΔN102)-
hPAH heterotetramers revealed a catalytic activity deviating signiﬁcantly from that calculated by averaging
the respective recombinant homotetrameric forms. The heterotetramer assembly also results in conforma-
tional changes in the WT-hPAH protomer, as detected by trypsin limited proteolysis. The ﬁnding that the
presence of two homodimers with different kinetic parameters inﬂuences the properties of the resulting
heterotetrameric protein indicates that the dimers exhibit interactions which are transmitted across the
assembled tetramer. The bicistronic expression system developed here allowed the isolation of hybrid forms
that exhibit negative interallelic complementation, and may represent a model system for studying the
molecular pathogenic mechanisms of PAH gene mutations in compound heterozygous PKU patients,
providing the rationale to understand the observed inconsistencies both in genotype/phenotype correlations
and in the response to BH4 supplementation.rythro-5,6,7,8-tetrahydrobiop-
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WT, wild-type
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Human phenylalanine hydroxylase (hPAH, human phenylalanine
4-monooxygenase, EC 1.14.16.1), is a non-heme iron enzyme that
catalyzes the hydroxylation of L-phenylalanine (L-Phe) to L-tyrosine
(L-Tyr) in the presence of the cofactor (6R)-L-erythro-5,6,7,8-tetra-
hydrobiopterin (BH4) and dioxygen, the rate-limiting step in L-Phe
catabolism [1]. hPAH is a homotetrameric/homodimeric protein with
the protomer organized into three functional domains: a regulatory
N-terminal domain (residues 1–117) containing the phosphorylation
site (Ser16) and an autoregulatory sequence (ARS, residues 1–33); acatalytic core domain (residues 118–411); and a C-terminal region
(residues 412–452) including the dimerization and tetramerization
motifs [1,2]. The tetramer is a dimer of two conformationally different
dimers, related by a 2-fold noncrystallographic symmetry axis [3]. It is
activated 5- to 6-fold on preincubation with L-Phe, reveals a positive
kinetic cooperativity with respect to L-Phe and Michaelis–Menten
kinetics with BH4 for the non-preactivated enzyme [4] and BH4-
dependent positive cooperativity for the preactivated form [5].
Mutations in hPAH causing lost or impaired activity of the enzyme
are associated with the autosomal recessively inherited disease
phenylketonuria (PKU, OMIM 261600), the most frequent disorder
of amino acid metabolism [6], with a high genotypic heterogeneity
(more than 500 different PAH gene mutations identiﬁed to date;
http://www.pahdb.mcgill.ca [7]). If untreated, PKU patients present
neurological damages due to the increased levels of L-Phe in body
ﬂuids [8], and life-long dietary restriction of L-Phe remains the most
effective treatment for PKU [9]. Some PKU patients respond to oral
ingestion of the pterin cofactor (BH4) by a reduction in blood L-Phe
concentration (BH4-responsive) and therefore, presently BH4 is
accepted as a novel therapeutic approach. However, it has been
603J. Leandro et al. / Biochimica et Biophysica Acta 1812 (2011) 602–612shown that the full genotype determines the BH4-responsive
phenotype [10–12].
A unique property of homomeric enzymes associated with
human genetic disorders is their potential ability to exhibit
interallelic complementation (IC), a phenomenon that occurs in
heteroallelic states when particular combinations of two different
alleles, at a given locus, produce a less (positive IC) or a more
(negative IC) severe phenotype than their homoallelic counter-
parts. IC is observed in homomeric enzymes where the protomers
exhibit interactions resulting in hybrid proteins with functional or
stability properties signiﬁcantly different from the average of the
parental enzymes. The phenomenon is proposed to contribute to
the phenotypic diversity of several human diseases including
metabolic disorders such as PKU [13,14], argininosuccinic aciduria
[15–17], erythropoietic protoporphyria [18] and galactosemia
[19,20], neurodegenerative disorders such as familial amyloid
polyneuropathy [21,22] and cancer [23,24]. Interallelic comple-
mentation is assumed to be of particular importance in PKU since
~75% of PKU patients are compound heterozygous, encoding two
different mutant hPAH protomers [25]. Experimental evidence
lending support to a negative IC in some compound heterozygous
PKU patients has been obtained by the observations that the
patients present: (i) a more severe metabolic phenotype than that
anticipated by the predicted residual activity (PRA) based on in
vitro assays of recombinant proteins [26–28], and (ii) an absence
or only a partial response to BH4, although carrying two BH4-
responsive alleles [29]. Interactions between different hPAH
protomers have been demonstrated by three different experimen-
tal strategies, i.e. in vitro formation of heterotetramers from
different dimers [30], the yeast two-hybrid system [31] and a
dual vector prokaryotic expression system producing two different
hPAH subunits mimicking the natural heteroallelic state in
heterozygous or in compound heterozygous patients [14]. Howev-
er, the molecular mechanism of negative IC and its role in PKU
pathogenesis is far from being solved since heterotetrameric forms
of hPAH have only been demonstrated in vitro [30], but never
isolated and characterized biochemically.
In order to provide some insight into the assembly process of
heteroallelic hPAH proteins and their non-additive gene dosage
effect, truncated forms of the protein (ΔN102-hPAH and ΔN102/
ΔC24-hPAH) were co-expressed with WT-hPAH, and the hetero-
meric forms characterized biochemically. To isolate the recombinant
heteromeric proteins in high yield and purity a bicistronic
expression system was developed, presenting the different proto-
mers as fusion proteins with the chaperone maltose binding protein
(MBP) [30,32] and different afﬁnity puriﬁcation tags (calmodulin
binding peptide (CBP), hexahistidyl peptide (6His) and StrepII
peptide). The afﬁnity isolated heteromeric species were character-
ized by their steady-state kinetic properties and susceptibility to
limited proteolysis.
2. Materials and methods
2.1. Materials
The DNA primers used for mutagenesis were provided by
Eurogentec (Seraing, Belgium) and the restriction endonucleases
were fromNew England Biolabs (USA). Escherichia coli BL21(DE3) and
the prokaryotic expression vector pETDuet-1 were obtained from
Novagen (Merck KGaA, Darmstadt, Germany). The restriction prote-
ase factor Xa was obtained from Protein Engineering Technology ApS
(Aarhus, Denmark). SDS molecular mass standard was delivered by
Bio-Rad and the pterin cofactor (6R)-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4) was obtained from Schircks Laboratories (Jona,
Switzerland). Trypsin and trypsin inhibitor were delivered by
Sigma-Aldrich (St. Louis, MO, USA).2.2. Construction of the bicistronic expression vectors
The calmodulin binding peptide (later replaced by the StrepII
sequence) and the hexahistidyl peptide (6His; HHHHHH) were ﬁrstly
selected to produce different N-terminal tagged recombinant proteins
using the bicistronic expression vector pETDuet-1. This vector
contains two multiple cloning sites (MCS1 and MCS2), each preceded
by a T7 promoter/lac operator and a ribosome binding site. A T7
terminator sequence is located at 3′ of the MCS2.
The strategy to construct the bicistronic expression vector is
depicted in Supplementary Fig. S1. The sequence coding for the
calmodulin binding peptide (CBP; KRRWKKNFIAVSAANRFKKISSS-
GAL) together with a PmeI restriction sequence were introduced 5′
to the MBP coding sequence by three steps of site-directed
mutagenesis using the pMAL-hPAH vector as a template [33] and
primers CBP1st-F/CBP1st-R, CBP2nd-F/CBP2nd-R and CBP3rd-F/
CBP3rd-R (Table 1). The resulting vector pMAL-CBP-MBP-pep(Xa)-
WT-hPAH was double digested with PmeI/SbfI. The isolated expres-
sion cassette was blunted with T4 DNA polymerase, according to
standard procedures, and cloned into the MCS1 of pETDuet-1 vector
which had been previously digested with NcoI, blunted and depho-
sphorylated with calf intestinal alkaline phosphatase (CIP), thus
generating the expression vector pETDuet-1-CBP-MBP-pep(Xa)-WT-
hPAH.
In order to replace the CBP tag by the StrepII tag (WSHPQFEK), two
steps of site-directed mutagenesis were performed using the
pETDuet-1-CBP-MBP-pep(Xa)-WT-hPAH as template and primers
STRII-F/STRII-R and CBPDel-F/CBPDel-R (Table 1). In the obtained
construct (pETDuet-1-StrepII-MBP-pep(Xa)-WT-hPAH) a new T7
terminator was introduced 3′ to MCS1, by site-directed mutagenesis,
using primers CRET7-F/CRET7-R (Table 1).
To create the bicistronic expression construct the sequence coding
for the 6His tag and the PmeI restriction sequence were previously
introduced 5′ to theMBP coding sequence by site-directedmutagenesis,
using pMAL-MBP-pep(Xa)-ΔN102-hPAH or pMAL-MBP-pep(Xa)-ΔN102/
ΔC24-hPAH constructs as templates [34] and primers HisF/HisR
(Table 1). The expression cassette was isolated, after PmeI/SbfI double
digestion, blunt-ended and cloned into the MCS2 of pETDuet-1-StrepII-
MBP-pep(Xa)-WT-hPAH vector which had been previously digested
with EcoRV (MCS2), blunt-ended and dephosphorylated. The pETDuet-
1-[StrepII-MBP-pep(Xa)-WT-hPAH/6His-MBP-pep(Xa)-ΔN102-hPAH]
and pETDuet-1-[StrepII-MBP-pep(Xa)-WT-hPAH/6His-MBP-pep(Xa)-
ΔN102/ΔC24-hPAH] bicistronic constructs were obtained (Fig. 1).
Site-directed mutagenesis reactions were always performed using the
Quikchange® II XL system (Stratagene, La Jolla, CA, USA) and the
authenticity of mutagenesis reactions and cloning was always veriﬁed
by DNA sequencing using the BigDye® Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) in an ABI 3730xl DNA Analyzer
(Applied Biosystems). All the expression constructs present a cleavage
site for factor Xa (IEGR) between the N-terminal fusion protein and the
hPAH sequence.
2.3. Expression and puriﬁcation of recombinant hPAH
E. coli BL21(DE3) competent cells were transformed with the
pETDuet-1-[StrepII-MBP-pep(Xa)-hPAH1/6His-MBP-pep(Xa)-hPAH2]
(hPAH1: WT-hPAH; hPAH2: ΔN102-hPAH or ΔN102/ΔC24-hPAH)
expression vectors and grown in LB medium, supplemented with
50 μg⋅mL−1 ampicillin and 0.2% glucose, at 37 °C. Protein expression
was induced with 1 mM isopropyl thio-β-D-galactoside (IPTG),
when the A600 was about 0.8. Ferrous ammonium sulfate, at
0.2 mM, was added simultaneously with IPTG and 3 h after
induction. After 8 h incubation, at 28 °C, bacteria were harvested
and the pellets stored at −20 °C until use. To rule out homologous
recombination, plasmid integrity was checked. To purify the
recombinant enzymes, cells were resuspended in lysis buffer
Table 1
Oligonucleotides used for site-directed mutagenesis.
Template Primersa Sequence (5′→3′)b
pMAL-hPAHwt CBP1st F CCAACAAGGACCATAGATTATGGTTTAAACTTAAGCGACGATGGAAAAAGAAAAATCGAAGAAGGTAAACTGG
CBP1st R CCAGTTTACCTTCTTCGATTTTTCTTTTTCCATCGTCGCTTAAGTTTAAACCATAATCTATGGTCCTTGTTGG
pMAL-CBP1-hPAHwt CBP2nd F CTTAAGCGACGATGGAAAAAGAATTTCATAGCCGTCTCAGCAGCCAACCGCAAAATCGAAGAAGGTAAACTGG
CBP2nd R CCAGTTTACCTTCTTCGATTTTGCGGTTGGCTGCTGAGACGGCTATGAAATTCTTTTTCCATCGTCGCTTAAG
pMAL-CBP2-hPAHwt CBP3rd F GCCGTCTCAGCAGCCAACCGCTTTAAGAAAATCTCATCCTCCGGGGCACTTAAAATCGAAGAAGGTAAACTGG
CBP3rd R CCAGTTTACCTTCTTCGATTTTAAGTGCCCCGGAGGATGAGATTTTCTTAAAGCGGTTGGCTGCTGAGACGGC
pETDuet-1-CBP-hPAHwt STRII F GAAAATCTCATCCTCCGGGGCACTTGCTAGCTGGAGCCACCCGCAGTTCGAAAAAGGCAGCAAAATCGAAGAAGGTAAACTGG
STRII R CCAGTTTACCTTCTTCGATTTTGCTGCCTTTTTCGAACTGCGGGTGGCTCCAGCTAGCAAGTGCCCCGGAGGATGAGATTTTC
pETDuet-1-CBP-STRII-hPAHwt CBPDel F CAATTCCCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACCATGGCTAGCTGGAGCCACCCGCAGTTCGAAAAA
GGCAGCAAAATCGAAGAAGG
CBPDel R CCTTCTTCGATTTTGCTGCCTTTTTCGAACTGCGGGTGGCTCCAGCTAGCCATGGTATATCTCCTTCTTAAAGTTAAACAAAAT
TATTTCTAGAGGGGAATTG
pETDuet-1-STRII-hPAHwt CRET7T F GCAGGTCGACAAGCTTGCGGCCGCATAATGCTTCTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG
AAGTCGAACAGAAAGTAATCGTATTGTACACG
CRET7T R CGTGTACAATACGATTACTTTCTGTTCGACTTCAAAAAACCCCTCAAGACCCGTTTAGAGGCCCCAAGGGGTTATGCTAG
AAGCATTATGCGGCCGCAAGCTTGTCGACCTGC
pMAL-hPAHΔN102 and
pMAL-hPAHΔN102/ΔC24
HIS F CCAACAAGGACCATAGATTATGGTTTAAACCATCACCATCACCATCACAAAATCGAAGAAGGTAAACTGG
HIS R CCAGTTTACCTTCTTCGATTTTGTGATGGTGATGGTGATGGTTTAAACCATAATCTATGGTCCTTGTTGG
a F—forward, R—reverse.
b Mismatch nucleotides are shown in boldface; nucleotides used to create new restrictions sites are underlined.
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supplemented with 1× Complete Protease Inhibitor Cocktail (Roche
Applied Science) and disrupted by passage through a French Press.
The presence of the MBP tag, in both hPAH subunits, allowed the
puriﬁcation of the fusion proteins using an amylose resin (New
England Biolabs), previously equilibrated with 15 mM Na–Hepes,
200 mM NaCl, and 1 mM EDTA, pH 7.4. Recombinant proteins were
eluted with 10 mM maltose [33].
The tetramers and dimers were isolated by size-exclusion
chromatography (SEC), using a HiLoad Superdex 200 HR columnA
B
WT-hPAH
1 117 411 452
RD CD OD
ΔN102-hPAH
ΔN102/ΔC24-hPAH
T7lac-1
T7lac-2
LacI
AmpR
pBR322
origin
T7 T
T7 T
StrepIIMBP
MBP
pep(Xa)
(Xa)pep
hPAH1
hPAH2
6His12.3 kb
pETDuet-1-
-StrepII-hPAH1-
-6His-hPAH2
Fig. 1. Schematic representation of the bicistronic expression construct and the hPAH
polypeptide chains used to study interallelic complementation. (A) pETDuet-1
expression construct carrying two expression cassettes each under the control of a
T7 lac promoter (T7lac-1 and T7lac-2) and presenting a T7 polymerase termination site
(T7T); the hPAH1 polypeptide chain is expressed as a fusion protein with the StrepII tag
(StrepII) and the maltose binding protein (MBP) and the hPAH2 polypeptide chain is
expressed as a fusion protein with the hexahistidyl tag (6His) and MBP; pep(Xa)
represents the sequence encoding the factor Xa protease cleavage site. (B) Schematic
illustration of the structure of wild-type (WT-hPAH) and truncated forms (ΔN102-
hPAH and ΔN102/ΔC24-hPAH) of hPAH with the regulatory (RD), catalytic (CD) and
oligomerization (OD) domains represented; the residue number of the last amino acid
in each domain is indicated.(1.6 cm×60 cm, Amersham Biosciences) and a mobile phase contain-
ing 20 mM Na–Hepes, 200 mM NaCl, pH 7.0 (SEC buffer) pumped at a
ﬂow rate of 0.38 mL⋅min−1. The relative molecular mass of the
different oligomeric forms was estimated from a calibration curve
obtained with the following standard proteins: aprotinin (6.5 kDa),
ribonuclease A (13.7 kDa), carbonic anhydrase (29 kDa), ovalbumin
(43 kDa), BSA (66 and 132 kDa), conalbumin (75 kDa), aldolase
(158 kDa), ferritin (440 kDa) and thyroglobulin (669 kDa). Blue
Dextran 2000 and AMP were used to determine the void volume
(V0=45.2 mL) and the total exclusion volume (VT=115.5 mL) of the
column, respectively. All puriﬁcation steps were carried out at 4 °C.
The relative amounts of the different oligomeric states were
calculated by deconvolution of the obtained chromatograms using
the PeakFit software (Systat Software Inc). Protein concentration was
estimated by the Bradford method [35] using bovine serum albumin
(BSA) as the standard.2.4. Isolation of hybrid proteins
The tetrameric or dimeric fractions obtained from SEC were
applied to a Ni-chelating resin (Ni–NTA, Qiagen, Valencia, CA), pre-
equilibrated in SEC buffer containing 10 mM imidazole, and stirred for
1 h at 4 °C. The ﬂow-through was collected (Fraction 1: StrepII-MBP-
hPAH1 homomeric proteins) and the resin was washed with SEC
buffer containing 20 mM imidazole, followed by a SEC buffer washing
step containing 50 mM imidazole. The fusion proteins were eluted
with SEC buffer containing 150 mM imidazole (Fraction 2: 6His-MBP-
hPAH2 homomeric and StrepII-MBP-hPAH1/6His-MBP-hPAH2 hetero-
meric proteins).
Fraction 2 was then applied to a Strep-Tactin resin (Strep-Tactin
Superﬂow high capacity, IBA, Göttingen, Germany) and stirred for 1 h
at 4 °C. The ﬂow-through was collected (Fraction 3: 6His-MBP-hPAH2
homomeric proteins) and the resin was washed with SEC buffer. The
hybrid proteins were eluted with SEC buffer containing 2.5 mM
desthiobiotin (Fraction 4: StrepII-MBP-hPAH1/6His-MBP-hPAH2 het-
eromeric proteins).
The fusion proteins obtained in Fractions 1, 3 and 4 were cleaved
for 4 h at 4 °C by factor Xa (Protein Engineering Technology ApS),
using a protease to substrate ratio of 1:30 (by mass), and applied to a
second column of amylose resin, to removeMBP, followed by removal
of factor Xa protease using the Xa Removal Resin (QIAGEN). The
homomeric hPAH1 and hPAH2 and the heteromeric hPAH1/hPAH2
forms were then obtained.
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acrylamide gels. The gels were stained by 0.1% (w/v) Coomassie
Brilliant Blue R250 (Bio-Rad) in 50% (v/v) methanol and 10% (v/v)
acetic acid. Stained gels were scanned using VersaDoc 4000 (Bio-Rad)
and the protein bands were quantiﬁed using the Quantity One 1-D
Analysis Software (Bio-Rad).
2.5. Assay of enzymatic activity
The hPAH activity was assayed essentially as described [33], using
0.1 mg⋅mL−1 of catalase and an enzyme activation step by prior
incubation (5 min) with L-Phe. BSA, at 0.5% (w/v), was included in the
reaction mixture to stabilize the diluted puriﬁed hPAH preparations.
The amount of L-Tyr formed after 1 min was measured by HPLC and
ﬂuorimetric detection [36]. The steady-state kinetic data were
analyzed by nonlinear regression analysis using the SigmaPlot®
Technical Graphing Software and the modiﬁed Hill equation of LiCata
and Allewel [37] for cooperative substrate binding as well as substrate
inhibition [38]. In order to study the effect of preincubationwith L-Phe
on the speciﬁc activity, 1 mM L-Phe was added together with 75 μM
BH4 at the initiation of the hydroxylation reaction. In this case a 3 min
time course was then followed.
2.6. Limited proteolysis with trypsin
Limited proteolysis of WT, ΔN102 and (WT)/(DN102)-hPAH
tetrameric forms was performed at 25 °C in 20 mM Na–Hepes,
200 mM NaCl, pH 7.0 and a protease to hPAH ratio of 1:200 (byStrepII MBP pep(Xa) hPAH1
6His MBP pep(Xa) hPAH2
Amylose affinity
purification
Size Exclusion
Chromatography
or
6His 
Purification
(Ni-NTA)
FT
Homotetramers
hPAH1
Tetrameric Fraction Dimeric Fraction
or
Ho
    
or
Fig. 2. Flow-chart of the puriﬁcation procedure of recombinantly co-expressed hPAH polype
different hPAH proteins was applied to an amylose resin in the ﬁrst puriﬁcation step. TheMBP
The tetrameric (or dimeric) fraction recovered was applied to a Ni–NTA resin. The StrepII tag
6His tagged homotetramers (or homodimers) and StrepII/6His tagged heterotetramers (or h
fraction was applied to a Strep-Tactin resin. The 6His tagged homotetramers (or homo
heterodimers) were eluted with desthiobiotin. This procedure resulted in the separation of t
and heteromeric StrepII/6His tagged.mass) in the absence or presence of 1 mM L-Phe. The ﬁnal protein
concentration was 0.3 mg⋅mL−1. At timed intervals (0–60 min)
aliquots of the reaction were mixed with soybean trypsin inhibitor
(at 1:1.5 (by mass) protease to inhibitor ratio) and subjected to SDS-
PAGE analysis. Gels were stained by Coomassie brilliant blue and the
band corresponding to the full-length protein was quantiﬁed by
densitometry.
3. Results
3.1. Co-expression of hybrid hPAH proteins using a bicistronic expression
system
Using a dual vector expression system encoding two different
epitopes (Myc and Xpress) we have previously shown the presence of
assembled hybrid hPAH proteins presenting a catalytic activity lower
than the PRA [14]. In theory ﬁve different tetrameric species would be
formed, from the combination of two different co-expressed hPAH
subunits (hPAH1:hPAH2), in the following ratios: 0:4, 1:3, 2:2, 3:1 and
4:0. However, by performing a cross-linking reaction of the co-
expressed Myc-WT-hPAH and Xpress-WT-hPAH prior to the co-
immunoprecipitation step, heterotetramers but not heterodimers
were detected in the immunoblots (R. Almeida, J. Leandro et al.,
personal communication). The absence of heterodimers indicates that
the heterotetrameric species 1:3 and 3:1 (hPAH1:hPAH2) would not
be formed and only the heterotetrameric 2hPAH1:2hPAH2 will be
expected, as represented in Fig. 2. Nevertheless, using the described
dual expression system [14], the low yields of obtained hybridImidazole
elution
StrepII 
Purification
(StrepTactin)
Desthiobiotin
elution
Heterotetramers 
  hPAH1/hPAH2
FT
modimers
  hPAH1 
or
Homotetramers
        hPAH2
or
Homodimers
      hPAH2 
or
  Heterodimers
  hPAH1/hPAH2
ptide chains (hPAH1 and hPAH2). The supernatant of lysed bacteria co-expressing two
fusion proteins were elutedwithmaltose and applied to a size-exclusion column (SEC).
ged homotetramers (or homodimers) were collected in the ﬂow-through (FT) and the
eterodimers) bound to the resin were eluted with imidazole. In the last step, the eluted
dimers) were obtained in the FT and the StrepII/6His tagged heterotetramers (or
hree different hPAH protein species: homomeric StrepII tagged, homomeric 6His tagged
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for further biochemical and structural characterization. To overcome
this problem, we developed here a bicistronic expression strategy,
where in addition to two different puriﬁcation tags (CBP or StrepII,
and 6His), the putative molecular chaperone maltose binding protein
was used as fusion partner, N-terminally to the hPAH protein, as
outlined in Fig. 1A. The presence of two different puriﬁcation tags
offers the possibility to obtain pure hetero-oligomeric fractions by
performing two afﬁnity-chromatographic steps (Fig. 2). MBP was
chosen as fusion partner (common to both polypeptides), as MBP has
been shown to have a chaperone like effect [32,39], improving the
yield of recombinant hPAH [30,33]. Using this strategy the WT-hPAH
(~50 kDa subunit) was co-expressed with truncated forms of hPAH
(Fig. 1B), namely the ΔN102-hPAH (~38.8 kDa subunit) which lacks
the ﬁrst 102 residues (corresponding to the N-regulatory domain)
and is mainly expressed as a tetramer (96%) (Table 2); and the double
truncated form ΔN102/ΔC24-hPAH (~36.2 kDa subunit) which also
lacks the 24 C-terminal residues (corresponding to the tetrameriza-
tion motif) and is mainly expressed as a dimer (81%) (Table 2). The
rationale for co-expressing the WT-hPAH with the truncated forms
was fourfold. First, co-expressing the WT-hPAH with the double
truncated form (which is isolated mainly as dimer), will expectedly
favor the assembly of a heterodimer and thus the presence/absence of
these species will allow us to refute/validate our previous observa-
tions concerning the assembly of heterodimers (R. Almeida, J. Leandro
et al., personal communication). Secondly, co-expressing the WT-
hPAH with the N-terminally truncated form (which is isolated mainly
as tetramer) will favor the assembly of a heterotetramer. Thirdly, due
to the different catalytic properties of the wild-type and truncated
forms [2,34] the impact of protomer interactions on the kinetic
properties of the assembled heteromeric forms will be proﬁciently
assessed. Fourthly, using SDS-PAGE analysis a clear distinction and
quantiﬁcation of the ratio of the different subunits will be possible
since the truncated forms present molecular masses lower than the
wild-type.
Small tags characterized by a high speciﬁcity and mild elution
conditions (Supplementary Table S1) were selected. The polyhistidine
tag was our ﬁrst choice since we had already used it to express and
purify recombinant hPAHs [40]. The choice of the second afﬁnity tag
was more challenging given the large number of alternatives [41,42].Table 2
Subunit molecular mass, major oligomeric forms, apparent molecular mass and relative
amounts of the hPAH fusion protein forms used in this study.
Expressed or
co-expressed
fusion proteins
Subunit molecular
mass (fusion
protein)a (kDa)
Oligomeric
state
Apparent
molecular
massb
Relative
amountsb,c
WT-hPAH 95.6 Aggregated − (40%)
Tetramer 371 kDa (52%)
Dimer 205 kDa (8%)
ΔN102-hPAH 84.4 Tetramer 310 kDa (96%)d
ΔN102/
ΔC24-hPAH
81.8 Aggregated − (17%)d
Dimer 156 kDa (81%)d
(WT)/
(ΔN102)-hPAH
95.6/84.4 Aggregated − (9%)
Tetramers −e (62%)
Dimer 219 kDa (12%)
(WT)/(ΔN102/
ΔC24)-hPAH
95.6/81.8 Aggregated − (20%)
Tetramer 412 kDa (14%)
Dimers −e (55%)
a Subunit molecular mass calculated from the amino acid sequence.
b The apparent molecular mass of the oligomeric forms and their relative amounts
were calculated by deconvolution analysis of the size-exclusion chromatograms using
the PeakFit software (Systat Software Inc) of the MBP-fusions proteins before Ni–NTA
and Strep-Tactin puriﬁcation.
c Degradation products not included.
d Data from [34].
e Apparent molecular mass not determined, as the broad peak correspondent to 2 or
more different species.As a ﬁrst candidate we tested the CBP peptide. However, during the
puriﬁcation process the hPAH polypeptide, preceded by the CBP tag
(CBP-MBP-pep(Xa)-hPAH1), suffered extensive aggregation as the
result of the effect of a highly hydrophobic patch, present in the
middle of the CBP tag (Supplementary Fig. S2). This aggregation was
not overcome by the use of glycerol (10%), or by the mild non-ionic
detergent n-octylglucoside (15 mM) nor by the use of the improved E.
coli C41(DE3) strain [43,44] (data not shown). Hence, the CBP tag was
replaced by the StrepII tag which allowed the recovery of soluble
hPAH in high yields. Since the original pETDuet-1 vector presents only
one T7 terminator after MCS2, a new T7 terminator was introduced
after MCS1 (Fig. 1A), in order to guarantee the existence of just two
mRNAs, each one corresponding to the transcribed sequence of the
two different hPAH cDNAs.
The expression conditions (28 °C, 1 mM IPTG, 8 h) were chosen in
a compromise between the maximum total recombinant protein
produced, its amount in the soluble fraction and the minimization of
hPAH deamidation that occurs with long induction times [45]. The
expression of the recombinant hPAHs asMBP-fusion proteins resulted
in high yields (~12 mg/L culture) when compared with the values
obtainedwith the dual expression system used in our previous studies
(~0.3 mg of fusion protein/L culture [14]). After the introduction of
the new T7 terminator similar levels of the translated proteins were
produced, as shown by SDS-PAGE analysis of the co-expressed
proteins after amylose afﬁnity puriﬁcation (Supplementary Fig. S3).
The double truncated dimer ΔN102/ΔC24-hPAH was an exception
since it was recovered in the soluble (Supplementary Fig. S3B, lane 3)
and dimeric fractions at higher levels due to its higher solubility. As
expected, on size-exclusion chromatography the separately expressed
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH were recovered
mainly in the tetrameric form whereas the double truncated 6His-
MBP-ΔN102/ΔC24-hPAH was recovered as a dimer (Table 2). Ac-
cordingly, for the co-expressed StrepII-MBP-WT-hPAH and 6His-
MBP-ΔN102/ΔC24-hPAH the dimer represented the major oligomeric
form (Fig. 3A). SDS-PAGE of this fraction (peak 3) revealed one
distinct band at ~96 kDa (StrepII-MBP-WT-hPAH) and another at
~82 kDa (6His-MBP-ΔN102/ΔC24-hPAH) of different intensities, as
the double truncated form assembles as dimers with a higher
solubility (Fig. 3A, inset, lane 3). SDS-PAGE of the tetrameric fraction
(peak 2) gave a single band of ~96 kDa (Fig. 3A, inset, lane 2)
corresponding to the StrepII-MBP-WT-hPAH protein. For the co-
expressed StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH, the
tetramers were the predominant species (Fig. 4A) with 96 and 84 kDa
bands on SDS-PAGE (Fig. 4A, inset, lane 2), corresponding to the
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH, respectively.
The dimeric fraction corresponding to the WT-hPAH (Fig. 4A, inset,
lane 3), revealed a band corresponding to the truncated form, since
the dimeric fraction (peak 3) was not completely resolved from the
ΔN102-hPAH tetramer.
3.2. Study of the heterodimer and heterotetramer formation using WT
and truncated forms of hPAH
3.2.1. (WT)/(ΔN102/ΔC24)-hPAH heterodimer is not formed
When the dimeric fraction of the co-expressed StrepII-MBP-WT-
hPAH and 6His-MBP-ΔN102/ΔC24-hPAH was applied to the Ni–NTA
resin, a protein with an apparent molecular mass of ~96 kDa,
corresponding to the StrepII-MBP-WT-hPAH subunit, was recovered
in the ﬂow-through (Fig. 3B, lane 2). Only a trace amount of a ~82 kDa
protein was observed, corresponding to the 6His-MBP-ΔN102/ΔC24-
hPAH, indicating that homodimeric StrepII-MBP-WT-hPAH was
mainly obtained in the ﬂow-through. Elution of bound proteins
with imidazole gave essentially one band at 82 kDa (Fig. 3B, lane 3),
suggesting that only the 6His-MBP-ΔN102/ΔC24-hPAH species was
recovered. In fact, when this fraction was applied to the Strep-Tactin
resin (Fig. 3C) a band corresponding to the 6His-MBP-ΔN102/ΔC24-
Fig. 3. Isolation and SDS-PAGE analysis of heterodimeric StrepII-MBP-WT-hPAH/6His-MBP-ΔN102/ΔC24-hPAH proteins. (A) Size-exclusion chromatography of the co-expressed
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102/ΔC24-hPAH with three main peaks: (1) aggregated forms; (2) tetramers; and (3) dimers. The inset panel represents the SDS-PAGE
analysis demonstrating the purity of the proteins eluted as tetramers (lane 2) and dimers (lane 3). The fraction with the double arrow between the two dashed lines indicates the
collected dimers used in the further puriﬁcation steps. (B) SDS-PAGE analysis of Ni–NTA puriﬁcation. Lane 1, dimeric fraction from (A) applied on the Ni–NTA chelating resin; lane 2,
ﬂow-through containing StrepII-MBP-WT-hPAH homodimers (subunit Mr of ~96 kDa); lane 3, 150 mM imidazole eluted fraction containing 6His-MBP-ΔN102/ΔC24-hPAH
homodimers (subunit Mr of ~82 kDa) and the potential StrepII-MBP-WT-hPAH/6His-MBP-ΔN102/ΔC24-hPAH heterodimers (subunits Mr of ~96 and ~82 kDa, respectively). (C)
SDS-PAGE analysis of the Strep-Tactin puriﬁcation. Lane 1, ﬂow-through containing 6His-MBP-ΔN102/ΔC24-hPAH homodimers; lane 2, desthiobiotin eluted fraction after acetone-
precipitation (see main text for further explanation — Results section). Lane M, low-molecular-mass marker (104.4, 83.2, 49.3, 36.9 and 28.9 kDa). At the bottom of each lane is
indicated the expected hPAH forms as depicted in Fig. 2, with the StrepII-MBP-WT-hPAH polypeptide chain (□) and the 6His-MBP-ΔN102/ΔC24-hPAH polypeptide chain (○).
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ﬂow-through (Fig. 3C, lane 1), and only negligible amounts of
recombinant 82 kDa and 96 kDa fusion proteins were eluted with
desthiobiotin (Fig. 3B, lane 2). This fraction was acetone-precipitated,
and the recovered proteins, representing less than 1% of the
homodimeric proteins, may correspond to proteins that remained
bound to the column from the previous steps of puriﬁcation. The
results indicate that only StrepII-MBP-WT-hPAH and 6His-MBP-
ΔN102/ΔC24-hPAH homodimers, but no StrepII-MBP-WT-hPAH/
6His-MBP-ΔN102/ΔC24-hPAH heterodimers, were formed.3.2.2. The (WT)/(ΔN102)-hPAH heterotetramer
The His-tag afﬁnity puriﬁcation of the co-expressed StrepII-MBP-
WT-hPAH and 6His-MBP-ΔN102-hPAH proteins resulted in the
recovery of the StrepII-MBP-WT-hPAH homotetramer (~96 kDa
subunit) in the ﬂow-through when applied to the Ni-chelating resin
(Fig. 4B, lane 2), and the imidazole elution recovered the StrepII-MBP-
WT-hPAH (~96 kDa) and 6His-MBP-ΔN102-hPAH (~84 kDa), in a
~1:3 ratio (Fig. 4B, lane 3). Subsequent StrepII-tag afﬁnity puriﬁcation
of this fraction resulted in the recovery of the 6His-MBP-ΔN102-hPAH
homotetramer (~84 kDa subunit) in the ﬂow-through (Fig. 4C, lane
1), and the desthiobiotin elution recovered the heterotetramerStrepII-MBP-WT-hPAH/6His-MBP-ΔN102-hPAH, with two bands
(~96 and ~84 kDa subunit ) in a 1:1 ratio (Fig. 4C, lane 2).
3.3. Steady-state kinetic analysis of the (WT)/(ΔN102)-hPAH
heterotetramers
After cleavage of the fusion tags the steady-state kinetic parameters
of the tetrameric forms of WT-hPAH, ΔN102-hPAH and the (WT)/
(ΔN102)-hPAH heterotetramer were determined (Tables 3 and 4). The
factor Xa cleavage of the fusion proteins resulted in some unspeciﬁc
cleavage that generated a mixture of WT-hPAH full-length and ΔΝ13-
hPAH for the WT fusion protein [33]; and the cleavage of the ΔΝ102-
hPAH fusion protein generated the truncated form ΔN112-hPAH [34].
However, the kinetic properties of themixture of the full-lengthWT and
ΔΝ13-hPAH enzymes were similar to those of the full-length enzyme
in terms of cooperativity and substrate activation, with only the
phosphorylation of S16 by cAMP-dependent protein kinase being
affected [33]. The kinetic properties obtained for WT and ΔN102-
hPAH are in line with the reported values in the literature [2,33,34].
Whereas relatively small differences in the Km value for the cofactor
were observed between the three species (Table 4), marked differences
were observed for L-Phe in terms of concentration at half-maximal
activity ([S]0.5), catalytic efﬁciency, catalytic activationand cooperativity
Fig. 4. Isolation and SDS-PAGE analysis of heterotetrameric StrepII-MBP-WT-hPAH/6His-MBP-ΔN102-hPAH proteins. (A) Size-exclusion chromatography of the co-expressed
StrepII-MBP-WT-hPAH and 6His-MBP-ΔN102-hPAH with four main peaks: (1) aggregated forms, (2) tetramers, (3) dimers; and (4) low-molecular protein degradation products
from the amylose puriﬁcation (see Fig. 2). The inset panel represents the SDS-PAGE analysis of isolated protein from each peak in the elution proﬁle, tetramers (lane 2), dimers (lane
3) and degradation products (lane 4). The fraction with the double arrow between the two dashed lines indicates the collected tetramers used in the further puriﬁcation steps.
(B) SDS-PAGE analysis of the Ni–NTA resin puriﬁcation. Lane 1, tetrameric fraction from SEC applied on the Ni–NTA resin; lane 2, ﬂow-through containing StrepII-MBP-WT-hPAH
homotetramers (subunit Mr of ~96 kDa) (3); lane 3, 150 mM imidazole eluted fraction containing 6His-MBP-ΔN102-hPAH homotetramers (subunit Mr of ~84 kDa) and StrepII-
MBP-WT-hPAH/6His-MBP-ΔN102-hPAH heterotetramers (subunits Mr of ~96 and ~84 kDa, respectively). (C) SDS-PAGE analysis of Strep-Tactin puriﬁcation. Lane 1, ﬂow-through
containing 6His-MBP-ΔN102-hPAH homotetramers; lane 2, desthiobiotin eluted fraction containing StrepII-MBP-WT-hPAH/6His-MBP-ΔN102-hPAH heterotetramers. Lane M, low-
molecular-mass marker (104.4, 83.2, 49.3, 36.9 and 28.9 kDa). At the bottom of each lane is indicated the expected hPAH forms as depicted in Fig. 2, with the StrepII-MBP-WT-hPAH
polypeptide chain (□) and the 6His-MBP-ΔN102-hPAH polypeptide chain (○).
608 J. Leandro et al. / Biochimica et Biophysica Acta 1812 (2011) 602–612(Fig. 5 and Table 3). The (WT)/(ΔN102)-hPAH heterotetramer revealed
a lower [S]0.5 (L-Phe) value (76±17 μM) than the WT-hPAH homo-
tetramer ([S]0.5=151±6 μM), but only slightly higher than the
truncated homotetramer ΔN102-hPAH ([S]0.5=55±3 μM) (Table 3).
The heterotetramer is also characterized by a marked decrease in the
kcat (0.34±0.03×103 nmol Tyr⋅min−1⋅nmol tetramer−1), a value
lower than that predicted by averaging the kcat of the homotetramericTable 3
Steady-state kinetic constants for the substrate (L-Phe) of WT-hPAH homotetramer, ΔN102
hPAH Vmax kcat kcat (PRA) Vi
103 nmol
Tyr⋅min−1⋅mg−1
103 nmol
Tyr⋅min−1⋅nmol−1
103 nmol
Tyr⋅min−1⋅mg−
WT 2.79±0.07 0.56±0.01 − 1.55±0.14
ΔN102 10.4±0.27 1.68±0.04 − 4.53±0.27
(WT)/(ΔN102) 1.85±0.18 0.34±0.03 1.12 1.03±0.05
The catalytic activity was measured as described in the Materials and methods section at 25 °
activity and kcat/[S]0.5 the catalytic efﬁciency which was calculated on the basis of the tetram
(ΔN102)-hPAH, respectively. PRA, predicted residual activity of the heterotetramer, is the mcounterparts (kcat,PRA=1.12×103nmol Tyr⋅min−1⋅nmol tetramer−1)
(Table 3).Moreover, the (WT)/(ΔN102)-hPAHheterotetramer revealed
no kinetic cooperativity (nH=1.0±0.1)with respect to L-Phe and is not
activated by L-Phe preincubation (1.1-fold), properties also observed for
the truncated homotetramerΔN102-hPAH (nH=1.2±0.1 and 1.0-fold,
respectively). By contrast the WT-hPAH homotetramer revealed a
kinetic positive cooperativity (nH=2.1±0.1) and a 3.6-fold activation-hPAH homotetramer and (WT)/(ΔN102)-hPAH heterotetramer.
[S]0.5 Ki kcat/[S]0.5 nH Fold activation
R(ν+L-Phe/ν− L-Phe)
1
μM mM μM−1⋅min-1
151±6 2.20±0.44 4 2.1±0.1 3.6
55±3 1.56±0.17 30 1.2±0.1 1.0
76±17 0.86±0.23 4 1.0±0.1 1.1
C, 75 μM BH4 (L-Phe variable). [S]0.5 represents the L-Phe concentration at half-maximal
er molecular mass of 200, 161.2 and 180.6 kDa for WT-hPAH, ΔN102-hPAH and (WT)/
ean of the kcat of the corresponding homotetramers.
Table 4
Steady-state kinetic constants for the cofactor (BH4) of WT-hPAH homotetramer,
ΔN102-hPAH homotetramer and (WT)/(ΔN102)-hPAH heterotetramer.
hPAH Vmax kcat kcat (PRA) Km
103 nmol
Tyr⋅min−1⋅mg−1
103 nmol
Tyr⋅min−1⋅nmol−1
μM
WT 2.83±0.08 0.57±0.02 − 27±3
ΔN102 10.1±0.44 1.63±0.07 − 39±5
(WT)/(ΔN102) 1.44±0.05 0.26±0.01 1.10 24±3
The catalytic activity was measured as described in the Materials and methods section
at 25 °C, 1 mM L-Phe (BH4 variable). PRA, predicted residual activity.
Fig. 5. The effect of substrate (L-Phe) concentration on the catalytic activity of the
heterotetrameric (WT)/(ΔN102)-hPAH protein and homotetrameric counterparts. The
hPAH activity was assayed at standard conditions (0–4 mM L-Phe, 75 μM BH4 and
25 °C) for the isolated homotetrameric WT-hPAH (A), homotetrameric ΔN102-hPAH
(B) and heterotetrameric (WT)/(ΔN102)-hPAH (C). The insets represent the data
obtained in the concentration range 0–500 μM L-Phe. The kinetic constants are
summarized in Table 3.
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was 4 μM−1⋅min−1 for both the heterotetrameric form andWT-hPAH.
3.4. Limited proteolysis of (WT)/(ΔN102)-hPAH heterotetramer with
trypsin
On limited proteolysis by trypsin, the WT-hPAH homotetramer
(Fig. 6A) was found to be more resistant than the homotetrameric N-
terminal truncated form both in the absence and presence of L-Phe
(Fig. 6B). A small proteolytic fragment is rapidly cleaved off in the
ΔN102-hPAH homotetramer, during the ﬁrst 10 min of incubation,
generating a core fragment of ~35 kDa resistant to further trypsin
proteolysis. A core fragment of similar molecular mass was also
obtained from the WT-hPAH trypsin proteolysis (data not shown).
Whereas the WT-hPAH became markedly more susceptible to limited
proteolysis in the presence of L-Phe, only a slight increase in the rate of
proteolysis was observed for the truncated form (Fig. 6A and B).While
the heterotetrameric (WT)/(ΔN102)-hPAH revealed no signiﬁcant
difference in the rate of proteolysis for the ΔN102-hPAH protomer
(Fig. 6D), the WT protomer is more rapidly degraded (Fig. 6C).
4. Discussion
4.1. The developed bicistronic expression system is a valuable tool to
produce and isolate heteromeric forms of hPAH
Co-expression of different proteins in E. coli can be achieved using
three different strategies: (i) a multi-vector expression system (e.g.
dual vector system with plasmids with different replication origins
and selection markers and with identical or different promoters), (ii)
a single polycistronic plasmid with a single promoter, encoding a long
polycistronic mRNA, and (iii) a single polycistronic plasmid with
individual promoters [46]. In our previous work [14] we followed the
ﬁrst strategy but the low yield preclude the isolation of the hybrid
species. Since the use of the second strategy (one polycistronic vector
with a single promoter) has been reported to lead to a lower
expression of themore downstream encoded protein [47], we decided
to follow the third strategy. Using a bicistronic vector with individual
but identical promoters (T7 promoter) and two terminators, we
obtained similar and high expression levels of both proteins. By using
a single plasmid we also assured that the two proteins should localize
within the same region of the cell, in contrast to replication from
different plasmids which could have a different subcellular localiza-
tion within the bacterium [48]. Additionally, due to expression from
two similar sequences, veriﬁcation of plasmid integrity is necessary to
rule out homologous recombination, as E. coli BL21(DE3) (recA+
strain) is one of the most commonly used expression strains.
Alternatively, a recA− derivative of BL21 should be used (e.g. BLR
(DE3) [49]).
In the present work the hPAH variants (WT and truncated forms)
were recognized by their different molecular mass. In studies on
missense mutations, the detection and quantiﬁcation can readily be
achieved by immuno-detection with monoclonal antibodies speciﬁcfor the epitope tags (hexahistidyl peptide and StrepII peptide) andMS
peptide analyses. Moreover, the depicted vector can be easily adapted
to an in vitro transcription-translation system (the large tags can be
removed and a consensus Kozak sequence introduced at theMCS2), as
a potential tool to study the observed inconsistencies in BH4
supplementation (see below).
4.2. The formation of hPAH heteromers occurs by a non-random
assembly process
The C-terminal oligomerization domain of WT-hPAH (residues
412–452) consists of two short β-strands (Ser411-Tyr414 and Ile421-
Leu424), connected by a loop (residues 415–420), and a 40 Å long α-
helix (Gln428-Lys452). Dimerization is mediated by several van der
Fig. 6. Time-course for the limited proteolysis of the heterotetrameric (WT)/(ΔN102)-hPAH protein and homotetrameric counterparts by trypsin. The susceptibility to trypsin
proteolysis ofWT-hPAH homotetramer (● and○) and ΔN102-hPAH homotetramer (▲ and△) is shown in panels A and B, respectively. In C and D, the proteolysis patterns of theWT
(● and○) andΔN102 (▲ and△) protomers of the heterotetrameric (WT)/(ΔN102)-hPAH are shown, respectively. Limited proteolysis was performed in the absence (ﬁlled symbols,
● and▲) or presence (open symbols, ○ and△) of 1 mM L-Phe at a protease/hPAH ratio of 1:200 (by mass). At time interval aliquots were mixed with soybean trypsin inhibitor and
subjected to SDS-PAGE, and the band corresponding to the remaining full-length protein was quantiﬁed (WT subunit: ~50 kDa and ΔN102 subunit: ~38.8 kDa). The data were ﬁtted
to a single exponential decay curve. The recovery of the full-length WT-hPAH protomer in the heterotetramer at t~20 min, in the absence of L-Phe, is practically the same as in the
WT-hPAH homotetramer in the presence of L-Phe.
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loops (residues 415–420), one of each protomer [1,50], and through a
relatively polar interface contributed by the regulatory domain in one
protomer and the catalytic domain in the other protomer [51].
In the present study, the co-expression of WT-hPAH and truncated
forms of the protein allowed the isolation of heterotetramers,
resulting from the assembly of different homodimers (2hPAH1/
2hPAH2), but no heterodimers were recovered. Thus, the absence of
a random assortment of hPAH protomers suggests that hPAH
dimerization, via the Asp415-Arg420 loop of the dimerization motif,
is a co-translational process and that tetramer formation (dimer of
dimers) occurs post-translationally. Tetramerization occurs from
preformed dimers through domain swapping of the C-terminal α-
helices (Gln428-Lys452) [1], and our data indicate that these
interactions will not be affected by the presence of two different
stable dimers with a WT like C-terminal α-helix structure. A co-
translational assembly of dimers could explain why hPAH monomers
were never found for WT-hPAH [34] or in mutant forms, except for
Y417Hmapped to the dimerization motif preventing the formation of
dimers [52].
4.3. The WT protomer within the heterotetramer reveal conformational
changes
Binding of L-Phe at the active site triggers reversible conforma-
tional changes in the catalytic domain [53], which are transmitted
globally (dimer and tetramer) through several hinge-bending regions[53–56] resulting in a more open structure [54]. This conformational
change results in an increased susceptibility to limited proteolysis by
trypsin (Fig. 6A). The WT protomer revealed a higher susceptibility to
limited proteolysis when present in the heterotetrameric (WT)/
(ΔN102)-hPAH than in the homomeric form, both in the absence and
presence of L-Phe, indicating that the WT protomer adopts a more
open conformation. These results suggest that the assembly of the two
different dimers (WT and ΔN102) induces a conformational change in
the WT protomers mediated by the C-terminal 40-Å long α-helix
(Gln428-Lys452), as the only contact between the two dimers in the
assembled tetramer occurs by domain swapping of the four C-
terminal helices (two from each dimer) [1].
4.4. Functional implications of the assembly of hPAH heterotetramers
A comparison of the steady-state kinetic parameters of the (WT)/
(ΔN102)-hPAH heterotetramer with the homotetrameric counter-
parts (Table 3) revealed that the heterotetramer has acquired a
catalytic efﬁciency similar to that of WT-hPAH. However, it has lost
the cooperativity with respect to L-Phe and the ability to be activated
by the substrate, which are characteristic properties of the ΔN102-
hPAH tetramer. Moreover, the Vmax-value was only ~30% of the
predicted residual activity (PRA), thus demonstrating a negative
interallelic complementation. However, it should be noted that the
isolatedWT-hPAH dimeric form revealed no kinetic cooperativity and
only aminor fold activation by L-Phewhen compared to theWT-hPAH
tetramer [4], and the kinetic properties of the isolated ΔN102-hPAH
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tetramers (Table 2). If the two dimers in the heterotetramer were
acting isolated, the lack of cooperativity and substrate activation in
the hybrid could be explained. However, the L-Phe concentration at
half-maximal activity ([S]0.5) of the WT-hPAH dimeric form is much
higher than the WT-hPAH tetramer [4], whereas the hybrid tetramer
displays a [S]0.5 (L-Phe) lower than the WT-hPAH tetramer. Taking
these results into consideration and the ones obtained from the
trypsin limited proteolysis, indicating that the WT dimer in the
heterotetramer underwent a conformational change, it was not
unexpected to ﬁnd that the catalytic properties of the heterotetramer
were consistently different from those obtained theoretically by
averaging the homomeric counterparts. The fact that the presence of
two homodimers with different kinetic parameters can alter the
properties of resulting hybrid protein indicates that interactions are
transmitted across the overall assembled protein and that the dimers
are not acting isolated.
4.5. Implications of heterotetrameric assembly in PKU
Although the mutant partner used in the present study is a
truncated protein and not a PKU-mutant enzyme, the results obtained
in this work can give some insight into the mechanisms involved in
PKU, as we report here the ﬁrst isolation of a heterotetrameric form of
hPAH with properties deviating signiﬁcantly from the average of
those of the parental enzymes. The developed expression/puriﬁcation
strategy provides the necessary experimental tools for studies on
disease-associated hPAH mutations, notably those demonstrating
inconsistencies both in genotype/phenotype correlations and in the
response to BH4 supplementation. The mechanisms underlying BH4-
responsiveness are multifactorial, including correction of catalytic
defect (decreased afﬁnity for BH4) and stabilization of the mutant
protein against degradation/inactivation in vivo and in vitro [57–59].
Until now, in vitro studies to unravel the mechanism of BH4-
responsiveness (e.g. steady-state kinetic analysis, isothermal titration
calorimetry and thermostability followed by circular dichroism
spectroscopy) have been limited to the study of homotetrameric
proteins. However, they do not represent the hPAH protein
population of a compound heterozygous patient. The isolation of the
heterotetramers will allow the in vitro characterization of these
species in terms of the cofactor effect. However, one limitation of the
prokaryotic expression system is that it is not amenable to test the
effect of precise BH4 concentrations when the protein assembles in
vivo. One alternative is to use the described system (with minor
modiﬁcations) in an in vitro transcription–translation expression
system. It will be important to understand how the mutations alter
the observed 2hPAH1:2hPAH2 association of hPAH dimers and if they
also exert a dominant negative impact on the function of the
heteromeric species. As a large fraction of PKU mutations affects
stability and/or folding efﬁciency, this system will also be a valuable
tool to understand how an aggregation-prone mutant (e.g. G46S
[30,60]) affects the other mutant partner within the heteromeric
protein.
The characterization of the interactions between wild-type and
mutant dimers and between different mutant dimers (compound
heterozygous) is clinically relevant, as they will contribute to a better
understanding of the metabolic phenotype in the HPA/PKU patients
and BH4-responsiveness. It will also be essential in the development
of new emerging therapies (e.g. pharmacological chaperones), as the
hybrid proteins could respond differently from the parental enzymes.
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Supplementary Fig. S1. Schematic representation of the development of the bicistronic 
expression constructs to isolate recombinant heteromeric hPAH proteins. MBP, maltose binding 
protein; CBP, calmodulin binding peptide; StrepII, StrepII tag; 6His, hexa-histidyl tag; LacI, lac 
repressor; Ampr, ampicillin resistance; T7 lac, T7 lac promoter; pep(Xa), sequence encoding the 
Factor Xa protease cleavage site; T7T, T7 terminator; MCS, multiple cloning site; hPAH1, hPAH 
WT or mutant1; hPAH2, hPAH mutant2. 
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Supplementary Fig. S2. Effect of the calmodulin binding peptide on the co-expression of 
(WT)/(∆N102)-hPAH fusion proteins. 10 % SDS-PAGE analysis of the purification of 
recombinant (WT)/(∆N102)-hPAH. Lane 1, total cell lysate after 8h induction of recombinant 
hPAH by 1 mM IPTG at 28 ºC; lane 2, soluble fraction; lane 3, insoluble fraction, lane 4, flow-
through from the amylose column; lanes 5−7, washing of amylose column; lane 8, elution of the 
isolated CBP-MBP-WT-hPAH/6His-MBP-∆N102-hPAH fusion proteins from the amylose 
column; lane 9, isolated fusion proteins after concentration; lane 10, isolated tetrameric fusion 
proteins after size-exclusion chromatography; lane 11, low-molecular-mass marker. Co-
expression using the construct pETDuet-1-[CBP-MBP-pep(Xa)-WT-hPAH/6His-MBP-pep(Xa)-
∆N102-hPAH]. 
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Supplementary Fig. S3. SDS-PAGE analysis of the amylose affinity purification of the 
recombinant (WT)/(∆N102)-hPAH (A) and (WT)/(∆N102/∆C24)-hPAH (B) proteins. Lane 1, 
low-molecular-mass marker; lane 2, total cell lysate after 8h induction of recombinant hPAH by 
1 mM IPTG at 28 ºC; lane 3, soluble fraction; lane 4, insoluble fraction, lane 5, flow-through 
from the amylose column; lanes 6 and 7, washing of amylose column; lane 8, elution of the 
isolated recombinant hPAH fusion proteins from the amylose column. Co-expressions using the 
constructs pETDuet-1-[StrepII-MBP-pep(Xa)-WT-hPAH/6His-MBP-pep(Xa)-∆N102-hPAH] (A) 
and pETDuet-1-[StrepII-MBP-pep(Xa)-WT-hPAH/6His-MBP-pep(Xa)-∆N102/∆C24-hPAH] (B), 
respectively. 
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Supplementary Table S1 
Properties of the affinity tags used in this study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Affinity 
tag 
Sequence Residues Size 
(kDa) 
Resin Elution Conditions 
MBP Protein 396 40.0 Amylose 10 mM maltose 
 
CBP KRRWKKNFIAVSAANRFKKISSSGAL 26 3.0 Calmodulin 2 mM EGTA 
 
6His HHHHHH 6 0.8 Ni2+-NTA 150 mM imidazole 
 
StrepII WSHPQFEK 8 1.1 Strep-Tactin 2.5 mM desthiobiotin 
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ChaperoneThe missense mutation pG46S in the regulatory (R) domain of human phenylalanine hydroxylase (hPAH),
associated with a severe form of phenylketonuria, generates a misfolded protein which is rapidly degraded on
expression in HEK293 cells. When overexpressed as a MBP-G46S fusion protein, soluble and fully active
tetrameric/dimeric forms are assembled and recovered in a metastable conformational state. When MBP is
cleaved off, G46S undergoes a conformational change and self-associates with a lag phase and an autocatalytic
growth phase (tetramers≫dimers), as determined by light scattering. The self-association is controlled by
pH, ionic strength, temperature, protein concentration and the phosphorylation state of Ser16; the net charge
of the protein being a main modulator of the process. A superstoichiometric amount of WT dimers revealed a
2-fold enhancement of the rate of G46S dimer self-association. Electron microscopy demonstrates the
formation of higher-order oligomers and linear polymers of variable length, partly as a branching network,
and partly as individual long and twisted ﬁbrils (diameter ~145–300 Å). The heat-shock proteins Hsp70/
Hsp40, Hsp90 and a proposed pharmacological PAH chaperone (3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-
1,2-dihydroisoquinolin-1-one) partly inhibit the self-association process. Our data indicate that the G46S
mutation results in a N-terminal extension of α-helix 1 which perturbs the wild-type α–β sandwich motif in
the R-domain and promotes new intermolecular contacts, self-association and non-amyloid ﬁbril formation.
Themetastable conformational state of G46S as aMBP fusion protein, and its self-association propensity when
released from MBP, may represent a model system for the study of other hPAH missense mutations
characterized by misfolded proteins.ylase; rPAH, rat phenylalanine
ine; BH4, (6R)-L-erythro-5,6,7,8-
; MBP, maltose binding protein;
, tetramer; DM, dimer; ANS, 8-
xide; EM, electron microscopy
47 55586360.
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The human inborn error of metabolism phenylketonuria (PKU;
OMIM# 261600) is caused by a dysfunction of the liver enzyme
phenylalanine hydroxylase (hPAH; EC 1.14.16.1), inherited in an
autosomal recessive fashion. At presentN500 disease causingmutations
havebeen identiﬁed in thehuman PAHgene (seePAHMutationAnalysis
Consortium database: http://www.pahdb.mcgill.ca/) [1]. Most of them
are associated with PKU, and a smaller number has been identiﬁed
among non-PKU hyperphenylalaninemia (HPA) patients. The current
spectrum of alleged PKU/HPA mutations consists of ~60% missense
substitutions, ~13% splice variants, ~13% deletions, ~6% nonsense
(termination) mutations, and a few insertions, representing a broadspectrum of clinical, metabolic and enzymatic phenotypes [2]. Expres-
sion analyses of ~100 missense mutations in complementary in vitro
systems (for review, see the PAH Mutation Analysis Consortium
database) [1] have identiﬁed at least three main groups of enzymatic
phenotypes which differ in their kinetic behavior and/or stability [3,4],
i.e. (i) structurally stable mutations with altered kinetic properties, e.g.
mutations at residues involved in substrate (L-phenylalanine, L-Phe) or
the pterin cofactor ((6R)-L-erythro-5,6,7,8-tetrahydrobiopterin, BH4)
binding; (ii)mutationswithnormal or almostnormalkinetic properties,
but reduced stability both in vitro and in vivo; and (iii) mutations
affecting both kinetic and stability properties of the enzyme.
Since a majority of the mutations results in enzyme forms with a
propensity to self-associate when expressed as recombinant proteins in
E. coli or in an in vitro transcription–translation system, PKU is often
considered as a protein misfolding disease [5]. These mutations are
located in different regions of the three-domain structure [4,6–9], and
the mechanism of self-association may therefore have a variable
structural basis. When overexpressed in E. coli several misfolding
mutations result in both soluble and insoluble “aggregates”, even when
expressed and puriﬁed as MBP fusion proteins. Although MBP has been
shown to have a chaperone like effect [10,11], the soluble mutant
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However, in some mutations, e.g. the missense mutation pG46S in the
regulatory (R) domain, the expressed protein is assembled and
recovered as stable tetrameric/dimeric forms, in addition to some
soluble higher-order oligomers [12]. The MBP-G46S-hPAH tetramer is
characterized by a near normal catalytic efﬁciency, but when the
tetramer is cleaved by the restriction protease factor Xa, the G46S
tetramer is destabilized and self-associates [12]. When expressed in
eukaryotic cells as a non-fusion protein the enzyme is unstable and is
rapidly degraded [12], thus explaining the severe PKU phenotype.
However, the molecular mechanism of the self-association and the
structural properties of the higher-order oligomers remain to be
determined.
In the present study, the pG46S mutation was carefully analyzed.
This mutation belongs to the second group of enzymatic phenotypes
previously deﬁned, with reduced stability both in vitro and in vivo that
results in a severe form of PKU [12]. This group represents a large
proportion of the PKU mutations, with a loss-of-function pathogenesis
due to reduce stability [13]. The mutation pG46S is also located in the
regulatory domain of hPAH, and there is growing evidence that the R-
domain of hPAH is largely involved in the instability of hPAH mutant
proteins [9]. Therefore, the recombinantWT-hPAH and the G46S-hPAH
mutant form were isolated as MBP-(pep)Xa-PAH fusion proteins with
the goal to: (i) characterize the self-association process of G46S-hPAH
induced in vitro by factor Xa cleavage and how the solvent conditions
affect its propensity to self-associate; (ii) examine the effect of
substrates (L-Phe andBH4), phosphorylation of Ser16 (Ser16 is, together
with substrate and cofactor, one of the main regulators of hPAH
function, involved in the activation of the enzyme [14] and causing
conformational changes in the regulatory domain [15,16]) and
molecular/pharmacological/chemical chaperones on the propensity to
self-associate; (iii) investigate if the self-association results in the
formation of any stable polymeric structures such asﬁbrils, and (iv) gain
some insight into the molecular mechanism by which such structures
are formed. To answer these questions,weused a combined approachof
real-time light-scattering, thioﬂavin-T and ANS ﬂuorescence and
structural analyses by electron microscopy (EM). Additionally, comple-
mentary studies on a MBP fusion protein with the regulatory domain,
comprising residues 2–120, were performed on the WT and G46S
mutant form.
2. Material and methods
2.1. Materials
TB1 cells, the prokaryotic expression vector pMAL-c2/pMAL-hPAH
and the amylose resin were obtained from New England Biolabs (USA).
The restriction protease factor Xa was obtained from Protein Engineer-
ing Technology ApS (Aarhus, Denmark). The catalytic C-subunit of
cAMP-dependent protein kinase (PKA)was from Biafﬁn GmBH& Co KG
(Kassel, Germany). SDS molecular mass standard (low Mr range) was
delivered byBio-Rad. Thepterin cofactor tetrahydrobiopterin (BH4)was
obtained from Schircks Laboratories (Jona, Switzerland) and glycerol,
trimethylamine N-oxide (TMAO) and (−)-epigallocatechin gallate
(EGCG) were from Sigma-Aldrich (St. Louis, MO, USA). 3-amino-2-
benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-1-one was pur-
chased from Maybridge (Tintagel, Cornwall, UK). The recombinant
humanmolecular chaperones Hsp40 (catalog number SPP-400), Hsp70
(catalog number ESP-555) and Hsp90 (catalog number SPP-776) were
provided by Assay Designs (Ann Arbor, MI, USA).
2.2. Site-speciﬁc mutagenesis
The WT regulatory domain (WT-hPAH (2–120)) and the mutant
G46S regulatory domain (G46S-hPAH (2–120)) were obtained by
introducing a stop signal in codon 121 of hPAH, by site-directedmutagenesis (QuikChangeR II, Stratagene), using the pMAL-WT-hPAH
vector [17] and pMAL-G46S-hPAH vector [12] as template, respectively.
Primers 5′-GACACAGTGCCCTGGTAACCAAGAACCATTCAAGAGC-3′ (for-
ward) and 5′-GCTCTTGAATGGTTCTTGGTTACCAGGGCACTGTGTC-3′
(reverse) used for mutagenesis were provided by Eurogentec, Seraing,
Belgium (the mismatch nucleotides are shown in bold type). The
authenticity of the mutagenesis was veriﬁed by DNA sequencing as
described previously [12].
2.3. Expression and isolation of fusion proteins
Expression of both the WT and the mutated form G46S of hPAH
and the R-domain of hPAH (residues 2–120) was performed in E. coli
as fusion proteins (MBP-(pep)Xa-hPAH) [17]. The bacteria were
grown at 37 °C and the induction of hPAH by 1 mM isopropyl-thio-
β-D-galactoside (IPTG) was performed for 24 h at 28 °C. The fusion
proteins were puriﬁed by afﬁnity chromatography (amylose resin) and
centrifuged in a TL-100 Ultracentrifuge (Beckman, USA) for 20 min at
50,000 g before size-exclusion chromatography (SEC) as described [17].
SEC was performed at 4 °C using a HiLoad Superdex 200 HR column
(1.6 cm×60 cm) prepacked from Amersham Biosciences (GE Health-
care, Uppsala, Sweden). Themobile phase consisted of 20 mMNa-Hepes
and 0.2 M NaCl, pH 7.0 and the ﬂow rate was 0.38 ml min−1. The
tetrameric/dimeric hPAHfusionproteins and theR-domain of hPAHalso
as a fusion protein were collected and concentrated by Centriplus 30
ﬁlter (Amicon, MA, USA). The concentration of puriﬁed fusion proteins
was measured by the absorption coefﬁcient A280 (1 mgml−1 cm−1)=
1.63 [17] for the full-length enzymes andA280 (1 mgml−1 cm−1)=1.34
for the truncated form hPAH (2–120). A colorimetric method [18] was
also used in some cases tomeasure enzyme concentrations, with bovine
serum albumin as the standard.
T427P-hPAH [19] and ΔC24-hPAH [20] were expressed as fusion
proteins with MBP in E. coli and isolated essentially as the G46S
mutant protein, except that before SEC the proteins were cleaved for
4 h at 4 °C by factor Xa protease, using a protease to substrate ratio of
1:200 (by mass) to remove the MBP partner.
2.4. Phosphorylation of hPAH fusion protein
The phosphorylation of the fusion protein (tetrameric form) was
performed in a reactionmixture containing 0.1 mMethylene glycol bis-
(α-amino ether)-N,N,N′N′-tetraacetic acid, 0.03 mM EDTA, 1 mM DTT,
10 mM MgAc, 60 μM ATP in 15 mM Na-Hepes, pH 7.0, at 30 °C for 1 h
[21]. The enzyme concentrations were 20 μM (hPAH) and 100 nM
(catalytic subunit) of PKA. The degree of phosphorylationwasmeasured
by the electrophoreticmobility shift [6]. The non-phosphorylated fusion
protein controlwasobtainedby incubating theenzyme in theabsenceof
added PKA catalytic subunit, under otherwise identical conditions.
2.5. Cleavage of MBP-hPAH fusion proteins and assay of self-association
by light scattering
In order to study the time-course for the cleavage of the tetrameric
and dimeric MBP-hPAH fusion proteins and the self-association of the
released enzyme, the fusion proteins were incubated in a medium
containing 20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 at 25 °C, except when
stated otherwise. Before assay the tetrameric or dimeric fusion proteins
were subjected to high-speed ultracentrifugation at 210,000 g for
15 min at 4 °C. In the standard assay the concentration of the fusion
protein was 0.74 mgml−1 and the concentration of factor Xa was
adjusted to give a ﬁnal ratio (by weight) of 1:150 relative to the fusion
protein. Parameters as pH, neutral salt concentration, temperature,
protein concentration and the presence of substrates (L-Phe and BH4)
varied in different experiments as described in the Results section. Self-
association of the factor Xa released enzyme was followed in real-time
by light scattering, as measured by the increase in apparent absorbance
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Spectrophotometer with a Peltier temperature control unit. The change
in light scattering was expressed as ΔA′350 by subtracting the
background absorbance in the absence of added factor Xa. ΔA′350/Δt is
the rate of formationof higher-order oligomers/polymers obtained from
the slope of the linear growth phase of each light scattering curve. For
every self-association experiment a parallel time-course cleavage
analysis was conducted to rule out any change in the cleavage rate of
the fusion protein.
2.6. SDS-PAGE analyses
SDS-PAGE analyses were performed in a 10% (w/v) polyacryl-
amide gel [22]. The gels were stained by Coomassie Brilliant Blue R-
250, scanned using VersaDoc 4000 (Bio-Rad) and quantiﬁcation of the
protein bands was obtained by using the Quantity One 1-D Analysis
Software (Bio-Rad Laboratories, Hercules, CA, USA).
2.7. Cleavage of G46S-hPAH fusion protein in the presence of chaperones
In order to study the inﬂuence of chaperones on the self-association
process following cleavage of the mutant enzyme, tetrameric MBP-
G46S-hPAH and chaperone were added (together with the factor Xa
protease) at a variable molar ratio as described in Results. The
experimental conditions were the same as in the cleavage experiments
without chaperone, except in the caseof thepharmacological chaperone
thatwas dissolved in DMSO and used at a ﬁnal concentration of 100 μM
and 0.83% DMSO. In this case controls were included with 0.83% DMSO.
2.8. Negative staining electron microscopy
For negative staining EM of unpolymerized and polymerized G46S-
hPAH Formvar-coated 200 mesh nickel grids (Electron Microscopy
Sciences, Fort Washington, USA) were used. The grids were further
coated with carbon, stored dust-free in Petri dishes kept at low
humidity, and glow-discharged for 15 s prior to use. Negative staining
was carried out by ﬁrst applying 5 μl of a protein solution on the
specimen grid. Following absorption for 60 s, the sample drop was
removed by blotting with ﬁlter paper and the grid was stained twice
with 2% aqueous uranyl acetate. After application, the ﬁrst drop (10 μl)
was blotted off immediately, whereafter a fresh drop of the stain was
added to the grid for 15 s. After ﬁnal blotting and drying, the specimens
were observed in a Jeol 1230 Electron Microscope operated at 80 kV.
2.9. Thioﬂavin-T ﬂuorescence assay
The assay was performed according to a standard protocol [23].
Brieﬂy, the thioﬂavin-T (ThT, Sigma-Aldrich)measurementsweremade
by taking reaction aliquots and diluting them to 1.3 μMhPAH in 20 mM
Na-Hepes, 0.1 M NaCl, pH 7.0 containing 20 μM ThT. Immediately
following sample preparation the ﬂuorescence was measured in a
Perkin-Elmer LS-50B instrument (Perkin-Elmer, Waltham, MA, USA) at
25 °C (constant temperature cell holder) using an excitation of 440 nm
andemission of 482 nm,with slitwidths for excitation and emissionof 3
and 7 nm, respectively, andby averaging four scans. The reportedvalues
were correctedby subtracting thebackgroundﬂuorescence of ThT in the
absence of protein oligomers and controls with the protein oligomers in
the absence of ThT (light scattering).
2.10. ANS ﬂuorescence assay
Binding of 8-anilino-1-naphthalenesulfonic acid (ANS, Sigma-
Aldrich) was performed as described by Aukrust et al. [24]. Brieﬂy,
1.3 μMhPAHwas incubatedwith 60 μMANS in 20 mMNa-Hepes, 0.1 M
NaCl, pH7.0 at roomtemperature for 5 min in thedark. Theﬂuorescence
emission spectra were recorded between 400 and 600 nm (6 nm slitwidth) at 25 °C using an excitation wavelength of 385 nm (6 nm slit
width) on a Perkin-Elmer LS-50B luminescence spectrometer and by
averaging four scans.
2.11. Assay of hPAH activity
The hPAH activity was assayed at 25 °C in a standard reaction
mixture containing a 0.4 μM subunit (unless otherwise stated)
of tetrameric WT or G46S mutant fusion protein forms of hPAH, 1 mM
L-Phe, 0.5 mg ml−1 bovine serum albumin, 5 mM dithiothreitol,
0.1 mgml−1 catalase, 100 μM ferrous ammonium sulfate in 100 mM
Na-Hepes, pH 7.0 [17]. After preincubation (5 min) with L-Phe the
reaction was started by adding 75 μM (unless stated otherwise) BH4 to
the reaction mixture. The amount of L-Tyr formed after 1 min was
measured by high pressure liquid chromatography and ﬂuorimetric
detection [25]. The steady-state kinetic datawere analyzed by nonlinear
regression analysis using the SigmaPlot® Technical Graphing Software
and themodiﬁedHill equationof LiCata andAllewel [26] for cooperative
substrate binding as well as substrate inhibition [27]. In some
experiments, 1 mM L-Phe was added either at the start of the
preincubation period or together with 75 μM BH4 at the initiation of
the hydroxylation reaction. In this case a 3 min time-course was then
followed in order to study the effect of preincubation with L-Phe on the
speciﬁc activity.
2.12. Computational analysis
An estimation of the free energy of unfolding of the mutant protein
was predicted using the CUPSAT server (http://cupsat.tu-bs.de/) [28]
and the free energy of folding was predicted using the Concoord/PBSA
server (http://ccpbsa.bioinformatik.uni-saarland.de/ccpbsa/) [29]. In
order to evaluate the effect on G46S mutation on the secondary
structure of the hPAH protein an algorithm based on helix–coil
transition theory, AGADIR, was used to predict helical propensity
(http://agadir.crg.es/) [30]. To identify the location of hinges in PAH we
subjected the apo-rPAH crystal structure (PDB ID: 2PHM) to further
analysis using the HingeMaster software program that predicts the
hinge location in a protein by integrating existing hinge predictors
(TLSMD, StoneHinge, FlexOracle and HingeSeq) with a family of novel
hinge predictors based on grouping residues with correlated normal
mode motions (http://molmovdb.org/cgi-bin/submit-ﬂexoracle.cgi)
[31].
2.13. Statistical analyses
Data obtained from independent measurements are presented as
mean±SD and Student's t-test was conducted for statistic analysis of
quantitative data (Pb0.01 was considered signiﬁcant).
3. Results
3.1. Structural effects of the G46S mutation
The~50 kDamonomer ofWTmammalianPAHassembles in vivoand
on overexpression in bacteria to form tetramers (TMs) and dimers
(DMs). Atomic resolution structures of hPAH and rPAH have revealed
that the monomer consists of three structural and functional domains,
i.e. a regulatory (R), a catalytic (C) and a tetramerization (T) domain
[32–34]. On the basis of the 3D structures of the C–T domains of hPAH
and the R–C domains of rPAH a composite full-length model has been
assembled for the PAH tetramer [8] (Fig. 1A and B). It is organized as an
asymmetric dimer of dimers, and the model has the approximate
dimensions of 85 Å×100 Å×75 Å. The R-domain has an α–β sandwich
(βαββαβ) motif composed of a four-stranded antiparallel β-sheet
ﬂanked on one side by two short α-helices and the other side by the C-
domain (Fig. 1C). Using the HingeMaster software program [31] (see
Fig. 1. 3D structure of PAH and the localization/interactions of the G46 residue in the N-terminal regulatory domain. (A) Structure of a composite model of full-length tetrameric
hPAH. Cα-trace ribbon of the model created by combining the regulatory/catalytic domain crystal structure of rPAH (PDB ID: 1PHZ) and the catalytic/tetramerization domain
structure of hPAH (PDB ID: 2PAH). Each monomer is colored separately, with the lightest color representing the regulatory domain (R) and the darkest color representing the
tetramerization domain. (B) Side view 90° rotation from the view in A, with the position of the four regulatory domains indicated by a R. (C) Ribbon representation of the regulatory/
catalytic domain crystal structure of rPAH in the monomeric form with the regulatory domain shown in green, the catalytic domain in red and G46 in stick model (pointed arrow).
(D) Close-up of the location of G46 in the regulatory domain of rPAH, at the end of the loop between β-strand 1 and α-helix 1, where it H-bonds to K50. The Cα-atom trace is shown
in green ribbon, with the relevant residues in stick model and water molecules as red spheres. The ﬁgures were created using MOLSCRIPT [76] (A and B) and PyMOL, version 1.1
(DeLano Scientiﬁc) [77] (C and D).
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domain structurearound the interdomain residues 118–119andaround
the intradomain residues 26–27 (Fig. 2A).
The residue G46 is positioned at the entry of α-helix 1 (A47–E57)
in a ﬁve residue (L41–G46) loop structure (loop 1), with a relatively
low crystallographic B-factor (Fig. 2B), linking β-strand 1 and α-helix
1 (Fig. 1D), and is stabilized by H-bonds and a salt-bridge (K42–E44)
(Fig. 1D). The α-helix 1 is stabilized at the C-terminal end by forming a
hydrophobic interphase with α-helix 2 (not shown). Using the
coordinates of the R–C domains (PDB ID: 1PHZ) and two structure-
based methods for the estimation of the free energy of unfolding [28]
and folding [29] of mutant proteins, substitutions of G46 with any
amino acid were found to be destabilizing, and for the G46S mutation
the folding free energy was calculated to ΔΔG=4.1 kcal mol−1 with a
major electrostatic contribution (ΔΔGes=4.7 kcal mol−1). Since Gly
is known to have a large destabilizing effect on α-helices [35],
whereas a substituted Ser and the preceding residues (V45, E44, E43,
K42 and L41) in loop 1 have all a relatively high α-helix-forming
propensity [35], the G46 substitution is predicted to promote a N-terminal extension of α-helix 1 by four residues or one turn using the
AGADIR algorithm [30] (Fig. 2C).
3.2. Expression and isolation of the MBP fusion proteins
On expression of WT and the mutant form G46S as fusion proteins
(MBP-(pep)Xa-hPAH) the proteins were obtained in high yields and
separated into their oligomeric forms by SEC (Fig. 3A and B). The
chromatogram of both forms revealed a comparable elution pattern in
which peak 1 represented higher-order oligomeric forms (eluted at or
near the void volume), and peak 3 and peak 4 represented the TM and
DM forms, respectively [12,17].
3.3. Catalytic properties of MBP-WT-hPAH and MBP-G46S-hPAH fusion
proteins
Determination of the steady-state catalytic properties of the
tetrameric MBP-G46S-hPAH fusion protein revealed that it has a
higher speciﬁc activity than the WT protein, and a slightly higher
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Fig. 2. Structural properties of the regulatory domain. (A) Combined hinge prediction
scores of the R–C domain structure in the non-phosphorylated form of rPAH (PDB ID:
2PHM) using the HingeMaster server [31] as a function of amino acid residue number. A
similar score proﬁle was obtained for the phosphorylated form (PDB ID: 1PHZ). (B) The
crystallographic B-factor values vs. residue numbers in the regulatory domain (PDB ID:
1PHZ). (C) Prediction of the effect of the G46→S substitution on the propensity to form
an α-helix in the sequence comprising residues 30 to 58 using the AGADIR algorithm
[30]. The black bars represent the propensity to form an α-helix in the WT-PAH protein
and the gray bars correspond to the α-helix propensity in the mutant G46S-hPAH.
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[S]0.5=106±2 μM for MBP-WT-hPAH) (Table 1). The afﬁnity for the
cofactor BH4 was unaffected. The mutant fusion protein revealed a
low kinetic cooperativity with respect to L-Phe (nH=1.2±0.1) and
was already in an activated conformational state. Both proteins
showed an inhibition at higher substrate concentrations.3.4. Cleavage of the MBP fusion proteins
In the standard assay conditions the cleavage reaction was similar
for the tetrameric WT (not shown) and the mutant fusion protein
(Fig. 4A), with t1/2 (time at 50% cleavage) of ~11 min. The half-time
and the end point of the cleavage reaction varied to some extent with
the solvent conditions, notably with the ionic strength (Supplemen-
tary Fig. S1A) and the temperature (Supplementary Fig. S1B).
3.5. Self-association of tetrameric and dimeric forms of G46S-hPAH
At the selected standard assay conditions (pH 7.0, 0.1 M NaCl and
25 °C) the cleavage of the MBP-WT-hPAH tetramer (0.74 mg ml−1)
did not result in any change in light scattering (Fig. 4B). By contrast,
the G46S-hPAH mutant form revealed a propensity to self-associate
(Fig. 4B). A sigmoidal time-course was observed for the increase in
light scattering with three relatively distinct phases, i.e. a delay period
(lag phase), a growth phase of increasing light scattering (ΔA′350/Δt
(AU min−1)=0.026±0.003) and a ﬁnal phase with a decrease in
light scattering. In the absence of added factor Xa no change in light
scattering of theMBP-G46S-hPAH fusion protein was observedwithin
the time-scale of 3 h. A comparison of the TM and DM mutant fusion
proteins (Fig. 7A) revealed that the DM displayed a similar lag phase
but a 2-fold lower ΔA′350/Δt value than the TM (at equal protein
concentration) at pH 7.0.
3.6. Effects of pH and ionic strength
WT-hPAH and the R-domain (residues 1–120) have theoretical pIs
of ~pH 6.2 and ~pH 6.1, respectively. Whereas no signiﬁcant
difference was observed in the cleavage rate of the fusion protein in
the pH interval of 6.4 to 8.0 (Supplementary Fig. S2A), a large effect of
pHwas observed on the self-association (Fig. 5). Thus, by lowering the
pH towards the pI, the lag phase was reduced and the ΔA′350/Δt value
greatly increased. At pH 8.0, with a theoretical net charge of ~−9.2 no
measurable ΔA′350/Δt value was observed within the time-scale of
3 h.
The ionic strength (range 0.1 M and 0.4 M NaCl) has a certain effect
on the rate of cleavage of MBP-G46S-hPAH (Supplementary Fig. S1A),
but a more dramatic effect on the lag phase and the ΔA′350/Δt value of
G46S-hPAH self-association (Table 2), demonstrating the importance of
the global charge in the process.
3.7. Effect of temperature and protein concentration
Whereas the rate of the cleavage was only slightly slower at 15 °C
(t1/2 of 13.3 min) than at 25 °C (t1/2 of 11.3 min) (Supplementary Fig.
S1B), the self-association was largely affected by the reaction
temperature. Thus, on increasing the temperature the lag phase
decreases and the rate of self-association (ΔA′350/Δt) increases
(Table 2) with an apparent activation energy (Ea) of 134 kJ mol−1.
When the cleavage reaction was followed at the standard assay
conditions, but with variable concentrations of fusion protein at a
constant ratio of factor Xa:G46S-hPAH=1:150 (by weight), the half-
time was almost the same in the range of 0.37 to 0.74 mg ml−1
(Supplementary Fig. S2B). A more pronounced effect was observed on
the lag phase and the rate of self-association (ΔA′350/Δt) (Table 2).
3.8. The effect of substrates and phosphorylation of Ser16
The binding of L-Phe or the pterin cofactor BH4 at the active site
triggers global conformational changes in the WT tetramer, including
the R-domain [8]. Here, however, we observed no signiﬁcant modula-
tion of the self-association of G46S-hPAH in the presence of 75 μMBH4,
whereas 1 mM L-Phe slightly reduced the lag phase and increased the
ΔA′350/Δt value (Table 2).When the fusion proteinwas phosphorylated
Fig. 3. Size-exclusion chromatography of WT-hPAH and the mutant G46S-hPAH. (A) The chromatogram of WT-hPAH with 4 main peaks, where peak 1 represents higher-order
oligomeric forms (eluted in the void volume), peak 2 a presumably octameric form, peak 3 the tetramer (~365 kDa) and peak 4 the dimer (~209 kDa). (B) The chromatogram of the
mutant form G46S-hPAH where the broad peak 1 represents higher-order oligomeric forms, peak 3 and 4 the tetramer and dimer, respectively. The apparent molecular mass of the
enzyme forms were estimated using the elution position of standard molecular mass markers as a reference (not shown). The two dashed lines indicate the collected tetramers used
in further experiments. The proteins were expressed as MBP fusion proteins in E. coli under identical expression conditions (24 h, 28 °C). The chromatography was performed on a
HiLoad Superdex 200 HR column (1.6 cm×60 cm), equilibrated and eluted with 20 mMNa-Hepes, 0.2 MNaCl, pH 7.0 at a ﬂow rate of 0.38 ml ml−1 at 4 °C; detection was at 280 nm.
The inset in panels A and B represent the SDS-PAGE analyses demonstrating the purity of the tetrameric fusion proteins. LaneM, low-molecular-mass standard (106.5, 97.6, 50.2, 36.9
and 28.9 kDa); lane 3, the respective tetrameric form enzymes (peak 3) of the size-exclusion chromatography.
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inhibited, with a longer lag phase and a decreased ΔA′350/Δt value
(Fig. 6A). The time-courses for the cleavage of the phosphorylated and
non-phosphorylated MBP-G46S-hPAH were essentially identical (Sup-
plementary Fig. S2C), and the substrates were without effect on the
cleavage of MBP-G46S-hPAH (Supplementary Fig. S2D).
3.9. Effects of heat-shock proteins
Molecular chaperones facilitate the proper folding of many newly
synthesized proteins as well as rescue proteins that are misfolded, e.g.
due to mutations. Chaperone proteins also exhibit the unique property
to inhibit self-association of certain client proteins [36]. From Fig. 6 it is
seen that the Hsp70/Hsp40 chaperone system inhibits the self-
association of G46S-hPAH in a dose-dependent manner. At the lowest
molar ratio (1:20) of Hsp70/Hsp40 there is no effect on the ΔA′350/Δt
value, whereas at the higher ratio (1:2) the heat-shock proteins
markedly prolong the lag phase and decrease the ΔA′350/Δt value
(Fig. 6B). A similar effect was observed for Hsp90 at a molar ratio of 1:2
(Fig. 6C). In control experiments with ovalbumin, no such effects were
observed. Moreover, for both chaperones the addition of ATP did not
further enhance the modulatory effects observed in the absence of
nucleotide (data not shown). The chaperones did not contain cleavage
sites for factor Xa restriction protease and were without effect on the
cleavage of MBP-G46S-hPAH (Supplementary Fig. S2E).Table 1
Kinetic properties of tetrameric wild-type hPAH (MBP-WT-hPAH) and G46S-hPAH (MBP-G
BH4 L-Phe
Vmax
(nmol Tyr min−1 mg−1)
Km
(μM)
Vmax
(nmol Tyr min−1 mg−1)
[S]0.5
(μM)
MBP-WT-hPAH 3346±151 43±5 2360±33 106±2
MBP-G46S-hPAH 4227±187 42±5 3677±104 74±5
The catalytic activity was measured as described in the Materials and methods section at 25
variable). [S]0.5 represents the L-Phe concentration at half-maximal activity and kcat/[S]0.5 the
molecular mass of 94 kDa.3.10. Effects of pharmacological and chemical chaperones
The pterin cofactor BH4 has been shown to increase the stability
versus limited proteolysis by trypsin of WT-hPAH [37], as well as of a
number of PKU mutant proteins in vitro, and to make them less
vulnerable to degradation pathways when expressed in cells [38].
Since the structural basis of the stabilizing effect is quite well
understood [37–39] the cofactor is currently used as a pharmacolog-
ical chaperone in the treatment of a subgroup of PKU/HPA patients
[40]. However, as seen from Table 2, BH4 did not have any protective
effect on the self-association of G46S-hPAH.
A recent screening of over 1000 pharmacological agents has
identiﬁed two small-molecule binders (3-amino-2-benzyl-7-nitro-4-
(2-quinolyl)-1,2-dihydroisoquinolin-1-one and 5,6-dimethyl-3-(4-
methyl-2-pyridinyl)-2-thioxo-2,3-dihydrothieno[2,3-d]pyrimidin-4
(1H)-one) as potential therapeutic agents to treat PKU [41]. Here we
have found that only 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-
dihydroisoquinolin-1-one, at a comparable concentration (100 μM),
partly inhibits the in vitro self-association of G46S-hPAH (Fig. 6D).
The use of osmolytes can produce a chemical chaperoning effect in
vitro and thus be able to rescue folding defects in proteins involved in
conformational disorders [42,43]. In this study we have tested
glycerol, trimethylamine N-oxide (TMAO) and (−)-epigallocatechin
gallate (EGCG), but only glycerol showed a protective effect, while the
other two compounds promoted the self-association (Table 2). The46S-hPAH) fusion proteins.
kcat/[S]0.5
(μM−1 min−1)
nH Vi
(nmol Tyr min−1 mg−1)
Ki
(μM)
Fold activation
R(ν+L-Phe/ν -L-Phe)
2.09 2.5±0.1 1072±218 3190±644 3.9
4.67 1.2±0.1 1521±131 1911±241 1.1
°C; the substrate concentrations were 1 mM L-Phe (BH4 variable) and 75 μM BH4 (L-Phe
“catalytic efﬁciency”. The “catalytic efﬁciency”was calculated on the basis of a subunit
Fig. 4. The self-association of tetrameric G46S-hPAH following cleavage of theMBP fusion
protein by factor Xa. (A) Time-course for the cleavage of tetrameric MBP-G46S-hPAH by
the restriction protease factor Xa. The cleavage was performed at standard assay
conditions (0.74 mg ml−1 fusion protein, 5.0 μg ml−1 factor Xa, 20 mM Na-Hepes, 0.1 M
NaCl, pH7.0 and 25 °C). 50% cleavagewas obtained at ~11 min (t1/2). The datawasﬁtted to
a single exponential decay curve. The inset represents a 10% SDS-PAGE analysis of the
cleavage reaction. Aliquots (4 μg protein) were withdrawn at 0, 10, 20 and 30 min (lanes
2–5, respectively), and at 1, 1.30, 2, 2.30 and 3 h (lanes 6–10, respectively). Lane 1, low-
molecular-mass marker (104.4, 83.2, 49.3, 36.9 and 28.9 kDa). (B) Self-association of the
releasedenzymewas followed in real-time by light scattering, asmeasuredby the increase
in the apparent absorbance at 350 nm (A′350=log [Io/(Ip+f ∙ Id)]) using an Agilent 8453
Diode Array Spectrophotometer. The change in light scatteringwas expressed asΔA′350 by
subtracting the background absorbance in the absence of the added factor Xa. The data
points correspond toG46S-hPAH fusionprotein following cleavageby factorXa (●), and in
the absence of factor Xa (○);WT-hPAH fusion protein following cleavage by factor Xa (▲)
and in theabsenceof factorXa (Δ). Somedatapointswereomitted for clarity. The reactions
were performed at standard assay conditions. Error bars represent mean±SD, n=3–5
independent experiments. The inset represents SDS-PAGE analysis of the G46S-hPAH
fusion protein at t=0 (lane 2), and following its cleavage by factor Xa at t=180 min (lane
3). The reactionmixture (after 180 min)was subjected to ultracentrifugation at 200,000 g
and both the supernatant (lane 4) and pellet (lane 5)were recovered and analyzed by 10%
SDS-PAGE. Lane 1, low-molecular-mass marker (104.4, 83.2, 49.3, 36.9 and 28.9 kDa).
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Table 2
The effect of solvent conditions, protein concentration, substrates and chemical
chaperones on the self-association of tetrameric G46S-hPAH.
Lag phase
(min)
ΔA′350/Δta
(AU min−1)
(ΔA′350)max
(AU)
[NaCl]
(mM)
100 41.9±2.1 0.026±0.003 1.24±0.04
200 112.1±3.3 0.007±0.001 0.49±0.09
400 118.5±2.1 0.000±0.000 0.03±0.01
Temperature
(°C)
15 87.5±8.0 0.006±0.002 0.49±0.17
25 41.9±2.1 0.026±0.003 1.24±0.04
[G46S-hPAH fusion protein]
(mg ml−1)
0.37 79.5b 0.014b 0.85b
0.49 44.3b 0.017b 0.91b
0.74 41.9±2.1 0.026±0.003 1.24±0.04
L-Phe
(mM)
0 41.9±2.1 0.026±0.003 1.24±0.04
1 38.7±4.3 0.035±0.009 1.30±0.14
BH4
(μM)
0 41.9±2.1 0.026±0.003 1.24±0.04
75 45.7±4.0 0.021±0.008 1.22±0.15
Glycerol
(%)
0 41.9±2.1 0.026±0.003 1.24±0.04
1 49.6±3.3 0.020±0.004 1.13±0.16
2.5 55.9±1.3 0.011±0.001 0.84±0.04
5 95.3±5.1 0.004±0.001 0.33±0.08
Trimethylamine N-oxide 0 41.9±2.1 0.026±0.003 1.24±0.04
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tested were without effect on the cleavage of MBP-G46S-hPAH
(Supplementary Fig. S2D and F).(TMAO)
(mM)
5 39.8b 0.032b 1.35b
150 31.8b 0.039b 1.59b
250 30.5±3.5 0.048±0.008 1.68±0.19
(−)-Epigallocatechin gallate
(EGCG)
(G46S-hPAH:EGCG)
1:0 41.9±2.1 0.026±0.003 1.24±0.04
1:0.1 28.6±1.3 0.038±0.001 1.27±0.01
1:1 23.3±2.4 0.113±0.014 2.37±0.14
a ΔA′350/Δt is the rate of formation of higher-order oligomers/polymers as obtained
from the slope of the linear growth phase of each light scattering curve. Values are
shown as mean±SD (n=3–5).
b SD not determined.3.11. Effects ofWT-hPAHdimer andΔC24-hPAHdimer on the self-association
of G46S-hPAH dimer
Since the G46S-hPAH tetramer self-associates to higher-order
oligomers at a 2-fold higher rate than the dimer (Fig. 7A), it was of
interest to see if a molar excess of the WT-hPAH dimer, which does not
self-associate beyond the tetramer (data not shown), has any effect on theself-association of G46S-hPAH dimer. From Fig. 7B it is seen that theWT-
hPAHdimer at a 5-foldmolar excessmarkedly shortens the lag phase and
increases the ΔA′350/Δt value about 2-fold, presumably by promoting the
formation of G46S-WTheterotetramers (see Discussion). By contrast, a 5-
fold molar excess of the truncated ΔC24-hPAH dimer, lacking the
tetramerization domain, only slightly shortens the lag phase, whereas
the rate of self-association (ΔA′350/Δt) is almost the same as for the G46S-
hPAHdimeraloneor in thepresenceof a5-foldmolar excess of ovalbumin
(Fig. 7B). A dimericmutant form (T427P-hPAH),with a reduced tendency
to form tetramer [19], promotes a lower rate of self-association of the
G46S-hPAH dimer than the WT-hPAH dimer (Fig. 7B). Moreover, the
G46S-hPAH dimer in the presence of a 5-fold molar excess WT-hPAH
dimer and 1 mM L-Phe, displayed almost the same lag phase as for the
G46S-hPAH dimer alone and only a slightly increased ΔA′350/Δt value
(Fig. 7C). In this case the presence of L-Phe promotes the formation of
WT tetramer [17]. The presence of 1 mM L-Phe has a negligible effect on
the self-association pattern of the G46S-hPAH dimer alone (Fig. 7C)
indicating that the G46S dimer↔G46S tetramer equilibrium is less
responsive to L-Phe than that of WT-hPAH.
Fig. 6. Effect of phosphorylation at Ser16 and chaperones on the self-association of tetrameric G46S-hPAH. (A) The time-course for the self-association of phosphorylated enzyme
(▲) and non-phosphorylated enzyme (●). The non-phosphorylated fusion protein control was obtained by incubating the enzyme in the absence of added PKA catalytic subunit,
under otherwise identical conditions of the phosphorylated enzyme. Results are representative of two independent experiments. (B) The effect of Hsp70/Hsp40 (molar ratio 100:1)
on the self-association of G46S-hPAH at different concentrations (expressed as molar ratios of chaperone:G46S-hPAH fusion protein): 0:1 (●), 1:20 (▲), 1:10 (□), 1:5 (◊) and 1:2
(▼). (C) The effect of Hsp90 on the self-association of G46S-hPAH at different concentrations (expressed as molar ratios of chaperone:G46S-hPAH fusion protein): 0:1 (●), 1:20 (▲),
1:10 (□),1:5 (◊) and 1:2 (▼). (D) The effect of a pharmacological chaperone on the time-course of the self-association. The data points represent G46S-hPAH in the absence of any
added compound (●), in the presence of 0.83% DMSO (▲) or of 100 μM 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-1-one (in 0.83% DMSO) (■). The self-
association reactions were performed at standard assay conditions (0.74 mg ml−1 fusion protein (7.85 μMmonomer), 5.0 μg ml−1 factor Xa, 20 mM Na-Hepes, 0.1 M NaCl, pH 7.0
and 25 °C). Some data points were omitted for clarity. Error bars represent mean±SD, (n=3).
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Thioﬂavin-T (ThT) is a dye that when bound to amyloid ﬁbrils
displays an enhanced ﬂuorescence at 482 nm, but nonspeciﬁc binding
to some non-amyloid proteins has also been reported [23]. Binding of
ThT to MBP-WT-hPAH results in a ﬂuorescence enhancement (ΔThT)
beyond that of MBP alone, but did not signiﬁcantly increase (P=0.13)
upon cleavage by factor Xa (Fig. 8A). The MBP-G46S-hPAH fusion
protein revealed a signiﬁcantly higher ΔThT-value than MBP-WT-
hPAH (pb0.01), and factor Xa cleavage further increased the
ﬂuorescence enhancement (pb0.01). About 50% of the total ΔThT-
value (at 3 h) was observed during the lag period (~42 min) in which
no light scattering (and ﬁbril formation) was observed (Fig. 8B).
Moreover, during the period of exponential increase in light scattering
the ΔThT represented only 37% of the total ﬂuorescence response.
Thus, the ThT ﬂuorescence enhancement of G46S-hPAH vs the WT-
hPAH protein is dominated by the cleavage of the fusion protein and a
related conformational change.
ANS is a spectroscopic probe that has afﬁnity for hydrophobic
clusters which are not tightly packed in a fully folded structure, or
become exposed in partially unfolded structures [44]. ANS binds to
G46S-hPAH fusion protein (Fig. 8C, trace 5) with an increase in the
ﬂuorescence intensity and a maximum at ~478 nm (blue shift). Sincethis ﬂuorescence response is higher than that observed for the WT-
hPAH fusion protein (Fig. 8C, trace 3), the mutant form has more
hydrophobic clusters exposed than the WT-hPAH. However, after
cleavage the ﬂuorescence intensity of the mutant form G46S-hPAH
(Fig. 8C, trace 7) is only slightly higher than that of the fusion protein
(Fig. 8C, trace 5). TheMBP fusion partner has a negligible contribution to
the ANS ﬂuorescence (Fig. 8C, trace 2).
3.13. Self-association of the isolated regulatory domain
To further assess the importance of the R-domain for the self-
association of full-length G46S-hPAH, we generated WT and G46S
truncated forms including the N-terminal residues 2–120 (R-domain)
and examined their oligomeric state as MBP fusion proteins and
propensity to self-associate on factor Xa cleavage. On bacterial
expression as MBP fusion proteins and afﬁnity puriﬁcation the WT
form was recovered in high yield as a mixture of dimer and monomer
(Supplementary Fig. S3A),whereas the recovery of themutant formwas
very low with higher-order oligomers as the predominating species
(Supplementary Fig. S3B). Moreover, SDS-PAGE revealed that the
mutant form was signiﬁcantly more proteolysed than the WT form
(Supplementary Fig. S3A and B, inset). On cleavage of the dimeric fusion
proteins by factor Xa both proteins self-associate with a similar time-
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Fig. 7. The self-association of G46S-hPAH dimers and the effect of WT-hPAH dimers and L-Phe. (A) The time-course for the self-association of G46S-hPAH tetramers (●) and dimers
(▲) following cleavage of the respective fusion proteins by factor Xa. (Δ) G46S-hPAH dimer fusion protein in the absence of factor Xa. (B) The self-association of G46S-hPAH dimers
in the absence of any added protein (▲), and in the presence of a 5-fold molar excess (5×) ofWT-hPAH dimer (■), or of 5×ΔC24-hPAH dimer (∇), or of 5×T427P-hPAH dimer (♦) or
of 5×ovalbumin (○). (C) The effect of L-Phe on the self-association of G46S-hPAH dimers in the absence and presence of WT-hPAH dimers. G46S-hPAH dimers in the absence of any
added protein and L-Phe (▲) or with 1 mM L-Phe (Δ); G46S-hPAH dimers in the presence of a 5-fold molar excess of WT-hPAH dimers with no L-Phe (■) or with 1 mM L-Phe (□).
(D) Schematic presentation of the G46S-WT homo- and heterotetramer formation. The reactions in (A–C) were performed at standard assay conditions (0.74 mg ml−1 fusion
protein, 5.0 μg ml−1 factor Xa, 20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 and 25 °C) and the WT-hPAH, ΔC24-hPAH and T427P-hPAH enzyme forms were added as already factor Xa
cleaved forms. Some data points were omitted for clarity. Error bars represent mean±SD, (n=3).
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light scattering (Fig. 8D). Self-association of the WT protein was
inhibited by both substrates (L-PheNBH4), whereas self-association of
the G46Smutant R-domain remained unaffected. In both conditions the
L-Phe substrate had no effect on the cleavage by factor Xa (Supplemen-
tary Fig. S3C and D). The formation of higher-order oligomers gave only
a minor enhancement of the ThT ﬂuorescence (Fig. 8A) and no ﬁbrils
were detected on EM (data not shown).3.14. Ultrastructure of G46S-hPAH polymers
In order to get information on the structure of the higher-order
oligomers that are formed after cleavage of the G46S-hPAH fusion
protein, negative staining EM was performed. For the WT-hPAH no
signiﬁcant difference was observed in the EM pattern when comparing
time points 0 and 180 min (data not shown). By contrast, the G46S-
hPAH(Fig. 9A–E) revealed a variety of higher-order structures in a time-
dependent fashion. At the end of the delay period small clusters of
higher-order oligomeric structures of tetrameric G46S-hPAH were
observed (Fig. 9B), followed in time by the appearance of linear
polymers (Fig. 9C) (correlating with increased light scattering). These
ﬁbrils can bundle together and form branches thereby formingextensive network structures (Fig. 9D). EM also revealed that some of
the longﬁbrils display an apparent twisted conﬁguration (Fig. 9E).Using
highmagniﬁcation images (insetof panel Fig. 9E and Supplementary Fig.
S4) the diameters of the ﬁbrils were determined as ~145 Å (the
narrowest region) and ~300 Å (the broadest region), using a correction
of 15% for the ﬂattening on the electron microscope grid [45].
Interestingly, dimeric G46S-hPAH also generates ﬁbrils with a pro-
nounced tendency to network formation (Fig. 9D), which is inhibited by
a 5-fold molar excess of WT-hPAH dimer (Fig. 9F). Additionally, the
pharmacological chaperone 3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-
1,2-dihydroisoquinolin-1-one inhibits the formation of ﬁbrils by
tetrameric G46S-hPAH (Fig. 9G).4. Discussion
4.1. Self-association of G46S-hPAH in vitro
The isolated tetrameric/dimeric MBP-(pep)Xa-G46S-hPAH fusion
protein is recovered in a soluble metastable form, stabilized by MBP
as a chaperone. When cleaved by the restriction protease factor Xa
the released free enzyme is destabilized and forms different types of
higher-order oligomers and polymers (ﬁbrils), as determined by
Fig. 8. The binding of thioﬂavin-T (ThT) and ANS. The binding of ThT and ANS to the uncleaved and cleaved MBP fusion proteins of truncated (residues 2–120, R-domain) and full-
length forms of WT and G46S mutant hPAH. (A) ThT ﬂuorescence enhancement (ΔThT) was measured on samples at the beginning of the cleavage reaction of the respective fusion
proteins by factor Xa and at the end point (t=3 h). The response was normalized by subtracting the background ﬂuorescence of ThT and light scattering contribution, and the values
represent means±SD of three independent experiments (*Pb0.01, **P=0.13). (B) Time-course of the ThT ﬂuorescence enhancement following cleavage of the MBP-G46S-hPAH,
including the lag phase (~42 min) and the exponential self-association (78 min), as measured by light scattering and EM (78 min). The start and maximum of light scattering from
Fig. 4B is indicated, as well as the change in ThT ﬂuorescence (ΔThT) at selected time points, with the percentage of cleavage speciﬁed (Fig. 4A). (C) ANS ﬂuorescence emission
spectra observed during the cleavage of MBP-G46S-hPAH fusion protein by factor Xa, i.e. at t=0min (trace 5), at t~42 min (trace 6) and at t=3 h (trace 7). The corresponding
spectra for the cleavage of MBP-WT-hPAH fusion protein are shown for comparison at t=0min (trace 3) and t=3 h (trace 4). The MBP protein was used as a control (trace 2) and
the emission spectrum of buffer with ANS is shown (trace 1). The excitation wavelength was 385 nm. (D) The self-association of a truncated form (residues 2–120, R-domain) ofWT-
hPAH and its G46S mutant form and the effect of the substrate (L-Phe). The time-course of the self-association of WT-hPAH (2–120) dimeric protein following cleavage of the fusion
protein by factor Xa in the absence (●) and presence of 150 μM L-Phe (○); G46S-hPAH (2–120) dimer fusion protein following cleavage by factor Xa in the absence (▼) and presence
of 150 μM L-Phe (∇). The assays were performed at standard assay conditions and error bars represent mean±SD, n=3 independent experiments.
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formation of polymers involves at least three elementary processes:
(i) the cleavage of the fusion protein with release of the free enzyme
tetramer/dimer,
MBP−ðpepÞXa−G46S−hPAH
↓ Factor Xa
G46S−hPAH + MBP
ð1Þ
and (ii) self-association with the formation of higher-order oligo-
mers/short polymers [(G46S-hPAH)n], detectable by EM (Fig. 9B) and
to some extent by light scattering at 350 nm,
n⋅G46S−hPAH
↓
ðG46S−hPAHÞn
ð2Þand (iii) the autocatalytic formation of larger structures [(G46S-
hPAH)m·n], detectable by light scattering and EM (Fig. 9C and E),
m⋅ðG46S−hPAHÞn
↓
ðG46S−hPAHÞm⋅n
ð3Þ
On cleavage, the light-scattering versus time proﬁle (Fig. 4B) can
be divided into a delay period (lag phase) and a growth phase with an
autocatalytic formation of higher-order oligomers/polymers that is
expressed as ΔA′350/Δt in the relatively linear part of the light
scattering increase. At the end point a decrease in light scattering was
observed at acidic pH, low ionic strength and temperature N15 °C,
caused by the sedimentation of protein at 1 g. By comparing the time-
course for the cleavage (Fig. 4A)with the delay time (Fig. 4B), it can be
concluded that the cleavage is not rate-limiting in the overall reaction
leading to the formation of hPAH polymers, most clearly seen at a low
temperature (Supplementary Fig. S1B and Table 2). The delay time
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neutral salt ionic strength and temperature (Fig. 5 and Table 2).
Moreover, the experimental conditions which favor a short delay time
also promote a high rate of the autocatalytic process.
4.2. The effects of chaperones
Since the ﬁrst report on PKU patients responding to oral administra-
tion of BH4 by lowering their blood Phe levels [46], the cofactor has been
successfully used for the long-term treatment of HPA patients as an
alternative to dietary treatment [47,48]. Basedon theBIOPKUdbdatabase
(www.bh4.org/BH4DatabasesBiopku.asp) [48] BH4-responsiveness is
expected in about 50% of all patients with PAH deﬁciency [48].
Interestingly, the responsive mutations are preferentially located to the
R-domain, possibly related to its structural and physico-chemical
properties (see below), and the effect on its stability by the speciﬁc
interaction with the 1′,2′-dihydroxypropyl side-chain of BH4, when
bound at the active site of WT-hPAH [16,37]. A positive clinical response
to BH4 has been reported even in a patient with severe PKU and the
genotype G46S/S303A [47], but it was concluded that the S303A allele
was responsible for the observed decrease in plasma Phe level caused by
oral BH4. The present in vitro study (Table 2) further supports the
conclusion that the G46S allele is non-responsive to BH4.
Due to the mutant selectivity and the high cost of BH4 alternative
pharmacological chaperones have been explored. A recent screening of
over 1000 pharmacological agents has identiﬁed a small-molecule
binder (3-amino-2-benzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoqui-
nolin-1-one) that efﬁciently enhances the thermal stability of WT-
PAH andmisfoldedmutant forms in the R-domain (I65T and R68S), and
signiﬁcantly increases the activity and steady-state PAHprotein levels in
transiently transfected cells [41]. Here we have found that this small-
molecule binder, used at a comparable concentration (100 μM), partly
inhibits the self-association of G46S-hPAH, as measured by light
scattering (Fig. 6D) and completely inhibits the ﬁbril formation
(Fig. 9G).
Glycerol and trimethylamine N-oxide (TMAO) have been shown to
correct folding/assembly defects of some neurodegenerative and
metabolic conformational disorders [49–53]. In this study glycerol had
a protective effect, with a delayed lag phase and decreased ΔA′350/Δt
value, whereas TMAOpromoted the self-association (Table 2). A similar
promotive effect was observed for (−)-epigallocatechin gallate (EGCG)
(Table 2), themajor polyphenol in green tea thatwas recently shown to
inhibit the ﬁbrillogenesis of amyloidogenic polypeptides [54].
4.3. The self-association of G46S-hPAH generates non-amyloid ﬁbrils
With reference to the ThT ﬂuorescence response (Fig. 8A and B) and
the ultrastructures observedby EM (Fig. 9), three lines of evidence point
to the formation of non-amyloid ﬁbrils. First, in the self-association of
G46S-hPAH the initial part (~51%) of the hyperbolic time-course for ThT
ﬂuorescence enhancement occurs in the lag phase (~42 min) where no
increase in light scattering or formation of ﬁbrils was observed. In the
self-association of proteins forming amyloid-like ﬁbrils the ThT
ﬂuorescence enhancement is related to the ﬁbril formation [55]. Thus,
the initial ﬂuorescence enhancement of G46S-hPAH is related to the
main cleavage of the fusion protein (~89%), presumably reﬂecting a
conformational change in its R-domain, since no ﬂuorescence enhance-
ment was observed on cleavage of the WT-hPAH fusion protein
(Fig. 8A). Such unspeciﬁc binding of ThT has been observed for someFig. 9. Electron micrographs of negatively stained G46S-hPAH before and after cleavage of i
before cleavage, and (B) after cleavage for 42 min (~ the end of lag phase, as shown in Fig. 4B)
the dimeric MBP-G46S-hPAH in the absence (D) and presence of a 5-fold molar excess of di
(inset) at high resolution. (G) The effect of the pharmacological chaperone 3-amino-2-b
tetrameric G46S-hPAH at t=3 h of cleavage. The proteins were negatively stained with aqu
Short ﬁbrils in B and F are indicated by arrows. Scale bars: 500 nm (A–C, F and G), 1 μm (Dother proteins [23,55]. In addition, studies on amyloid-like peptides
revealed apoor correlationbetweenThTﬂuorescence enhancement and
the formation of amyloid-like structures [56]. Secondly, the ΔThT value
increased by only 37% during the autocatalytic formation of ﬁbrils
(Fig. 8B), partly explained by the residual cleavage of the fusion protein.
Thirdly, the ﬁbrils generated by G46S-hPAH are highly branched (Fig. 9
and Supplementary Fig. S4A) forming networks, and the diameters of
individual ﬁbrils range from ~145 to 300 Å, whereas amyloid and
amyloid-likeﬁbrils appear byEMas rigid, nonbranching structures from
~60 to 130 Å in diameter [57].
The self-association of G46S-hPAH demonstrates some apparent
similarities with that of sickle cell hemoglobin (deoxy-HbS). Deoxy-
HbS and G46S-hPAH are bothmisfolded tetrameric proteins, and their
self-association is caused by mutations affecting a single surface
exposed amino acid (E6V in the β-chain of HbS and G46S in the R-
domain of hPAH). The twomutant proteins also display similar kinetic
patterns of the self-association process, as measured by light
scattering, and they polymerize into a number of ultrastructures as
a function of time, initiated by factor Xa cleavage of MBP-G46S-hPAH
and by deoxygenation of HbS, respectively [58]. The G46S-hPAH ﬁbrils
and those derived from deoxy-HbS also share common properties. At
the present resolution (160,000×) the typical ﬁbrillar structures
formed by tetrameric G46S-hPAH (Fig. 9E, inset and Supplementary
Fig. S4A) show the above described periodic variation in apparent
diameter, i.e. from ~145 Å (the narrowest region) to ~300 Å (the
broadest region). Some of the structures have the appearance of
twisted ﬁbrils (Fig. 9C and Supplementary Fig. S4A). By comparison,
the corresponding dimensions of the deoxy-HbS ﬁbrils were reported
to be 180 and 230 Å [45,59]. However, the self-association of the two
proteins involves different molecular mechanisms.
4.4. Structural insight into the self-association of G46S-hPAH
InWT-PAH the R-domain has some unique structural and physico-
chemical properties, which may explain why mutations in this
domain affect the stability of the enzyme. First, the 3D structure [34]
has demonstrated an overall high crystallographic B-factor of the R-
domain (Fig. 2B). In the full-length enzyme the R-domain is also
characterized by a particularly low thermal stability, as compared to
the C-domain [60,61]. The R-domain is partly stabilized by its
interaction with the 1′,2′-dihydroxypropyl side-chain of the pterin
cofactor BH4 when bound at the active site [16,37]. Secondly, by using
the TANGO algorithm for sequence-dependent prediction of the
propensity to aggregate [62], the β1-strand (residues I35–L41) and
the β2-strand (residues E76–T81) were predicted to promote
aggregation, whereas the G46S substitution did not change this
prediction. However, since the WT-hPAH tetramer/dimer, in contrast
to the G46S-hPAH tetramer/dimer, does not self-associate at standard
experimental conditions (Fig. 4B), the predicted aggregation propen-
sity cannot explain the difference. Of more importance is the
prediction (Fig. 2C) that the G46S mutation results in an extension
of α-helix 1 by four residues. Such a change of the Cα backbone
conformation and the α–β sandwich structure of theWT enzymemay
promote new intermolecular contacts and self-association via the
mutually misfolded regions of their R-domains (Supplementary Fig.
S4B). Thirdly, the inhibitory effect of phosphorylation of Ser16
(Fig. 6A) also indicates that the Cα backbone conformation of the R-
domain is important for the self-association process. Moreover, MD
simulations of WT-hPAH have revealed that this phosphorylationts MBP fusion protein by factor Xa. (A) The tetrameric MBP-G46S-hPAH fusion protein
, and (C) for 2 h (~maximum light scattering, Fig. 4B). (D and F) The result of cleavage of
meric WT-hPAH (F). (E) The twisted ﬁbrils and a single ﬁbril of tetrameric G46S-hPAH
enzyl-7-nitro-4-(2-quinolyl)-1,2-dihydroisoquinolin-1-one on the self-association of
eous uranyl acetate and analyzed in Jeol 1230 Electron Microscope operated at 80 kV.
) and 100 nm (E).
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(residues 1–33) [16], and FT-IR spectroscopy of the isolated WT R-
domain (residues 2–110) has suggested that it induces an apparent
increase in the α-helix content [15]. In addition, deamidation of labile
asparagine residues in hPAH— notably Asn32 in the R-domain [63] —
also affects the G46S-hPAH self-association. Accordingly, the non-
deamidated form of G46S-hPAH (2 h induction) showed a higher
tendency to self-associate (with a slightly shorter lag phase and a
higher rate of self-association), as compared with the deamidated
G46S-hPAH form (24 h induction) (Supplementary Fig. S5). Studies
on the isolated R-domain (residues 2–120) (Fig. 8D) further
emphasize the importance of its conformation in the self-association
process. The dimeric and monomeric forms of this truncated protein
display a high propensity to self-associate, even in their WT forms,
and the G46S mutation slightly increased this propensity.
The ﬁnding that the G46S-hPAH dimer also self-associates beyond
the tetrameric state, although at a slower rate than the tetramer
(Fig. 7A), requires a special comment. Since theWT-PAH exists in a two-
state TM↔DM equilibrium [8], it is likely that a similar equilibrium
exists for theG46S-hPAHmutant. As seen from Fig. 7B, the presence of a
superstoichiometric amount of WT dimer during the cleavage of the
MBP-G46S-hPAH dimer supports the formation of hybrid WT–G46S
heterotetramer, which self-associates at an enhanced rate compared to
G46S-hPAH dimer alone. In this case, however, EM studies demonstrat-
ed predominantly amorphous aggregates (Figs. 7D and 9F). Based on
these results one might expect that in a heterozygous WT/G46S
genotype, the fraction of the G46S-hPAH dimer could form WT–G46S
heterotetramers that would promote the self-association and the
degradation of the WT subunit. However, in WT-hPAH the TM↔DM
equilibrium is shifted towards the tetrameric form in the presence of L-
Phe [17], whereas in G46S-hPAH the TM↔DM equilibrium is less
responsive to L-Phe, as there is only a minor enhancement of the self-
association of the G46S-hPAH dimer in the presence of 1 mM L-Phe
(Fig. 7C). Because the two equilibria respond differently to L-Phe, the
WT-hPAH dimer will formWT-hPAH tetramers in the presence of L-Phe
and will not be available to form WT–G46S heterotetramers that were
responsible for the observed enhancement of the self-association of the
G46S-hPAH dimer in the presence of the WT-hPAH dimer. The
concentration of L-Phe (50–100 μM in the hepatocyte of normal
individuals), depends on the metabolic state and extracellular concen-
tration of L-Phe in the blood [64]. In a homozygous G46S phenotype the
L-Phe will not have any signiﬁcant effect on the TM↔DM equilibrium
(Fig. 7C). Thus, our results suggest that the self-association of G46S-
hPAH is favored by the tetrameric structure, and the propensity of the
G46S-WT hybrids to self-associate is deﬁned by the conformational
state of the G46S subunits.
The relation between self-association of a protein, its fundamental
physico-chemical intrinsic properties (e.g. hydrophobicity, secondary
structure propensity, charge and hydrophobic/ hydrophilic patterns),
and extrinsic factors have been extensively studied [65–67]. All the
data presented in this study (pH, ionic strength, phosphorylation state
of Ser16) indicate that the net charge of the protein, or its R-domain, is
a main modulator of the self-association of G46S-hPAH in vitro, as
measured by light scattering (Table 2).
4.5. Potential in vivo implications
In our previous transfection studies in HEK293 cells the expression
level of G46S-hPAH was only ~3% of WT-hPAH (immunoreactive PAH
protein) when related to the mRNA levels, compatible with the severe
form of PKU observed in the homozygous patient [12]. The present in
vitro studies offer an explanation for the accelerated degradation of the
mutant protein, although we do not know how G46S self-associates in
the complex and crowded macromolecular environment of the
hepatocyte. Since there is no reported link between any liver
dysfunction or amyloid pathology and severe forms of PKU, it is unlikelythat self-associated,misfoldedhPAHmutant proteins exert a toxic effect
on the liver. Based on inhibition of the self-association of tetrameric
G46S-hPAH in vitro by substoichiometric concentrations of the heat-
shock protein Hsp90 (Fig. 6C), and to some extent by Hsp70/Hsp40
(Fig. 6B), themutant is a likely client protein of themolecular chaperone
systems in vivo, as observed for the chaperonins GroESL on co-
expression with several PKU/HPA mutant proteins in E. coli [5,68,69].
However, the accelerated degradation of G46S-hPAH in HEK293 cells
[12] indicates that the physiological level of chaperones in these cells
(and in hepatocytes) is not sufﬁcient to rescue this misfolded protein.
Therefore, the main question to be answered relates to the mechanism
bywhichG46S-hPAHand relatedmisfoldedandunstable hPAHproteins
are degraded in vivo. AlthoughWT-hPAH is poly/multi-ubiquitinated in
vitro [70], no signiﬁcant stabilizing effect of proteasome inhibitors have
been observed in cases of selected missense mutations [4]. Therefore,
the accelerated turnover observed upon their expression in eukaryotic
cells may be explained by an alternative quality control mechanism.
Previous studies on the turnover of WT-hPAH in cultured hepatoma
cells gave an estimated half-life of 8.2 h [71], i.e. similar to that of a
number of other cytosolic liver proteinswith a slow turnover, which are
considered to be degraded by autophagosome pathway [72]. Intracel-
lular self-association of a number of misfolded proteins has been
connected with the formation of aggresomes, which are ultimately
degraded by autophagolysosomes, in a process that also involves
ubiquitination [73].
4.6. Relevance for the study of misfolding PKU/HPA mutations
The tetrameric form of recombinant WT-hPAH has a small margin
of stability. Even a low concentration of a mild denaturant (urea)
allows the enzyme to explore a range of different structural states and
induces its self-association [74]. Therefore, it is not unexpected to ﬁnd
a high frequency of misfolding hPAH mutations associated with PKU/
HPA, resulting in a variety of molecular subtypes showing different
conformational and stability properties. Thus, these misfolded hPAH
proteins represent a phenotypically heterogeneous groupwhich often
has a propensity to self-associate and to form higher-order oligomers
when overexpressed in prokaryotic systems, and are rapidly degraded
when expressed in eukaryotic cells. Upon overexpression in E. coli,
these misfolded mutant proteins are often stabilized by MBP as a
fusion partner, and the metastable fusion proteins are frequently used
in in vitro studies to elucidate the molecular basis of the functional
impairment in PAH deﬁciency [9,68,69]. However, the present study
shows that the physico-chemical properties of the metastable MBP-
mutant-hPAH fusion protein are not representative for those of the
mutant protein. Our current experimental approach, therefore, should
be a useful supplement in systematic in vitro studies of misfolded
PAH/HPA-associated mutant proteins, as well as for the assessment of
the capability of molecular and pharmacological chaperones to
prevent their self-association and stabilize their native states. This
experimental approach may also provide valuable mechanistic
insights into the frequently observed and poorly understood
compound heterozygous forms of PKU/HPA [75].
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Supplementary Fig. S1. The effect of NaCl concentration (A) and temperature (B) on t1/2 
cleavage of tetrameric MBP-G46S-hPAH fusion protein by the restriction protease factor Xa. 
Error bars represent standard mean ± SD. 
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Supplementary Fig. S2. Time-course for the cleavage of tetrameric MBP-G46S-hPAH fusion 
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protein by the restriction protease factor Xa at different pH values (A) or different fusion protein 
concentrations (B). In addition, the effects of phosphorylation (C), the presence of substrate (L-
Phe), cofactor (BH4), glycerol and TMAO (D), molecular chaperones (E), and pharmacological 
chaperones (F) are shown. The data were fitted to a single exponential decay curve. The time-
course of cleavage was performed at standard assay conditions (0.74 mg·ml-1 fusion protein, 5.0 
μg·ml-1 factor Xa, 20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 and 25 oC). 
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Supplementary Fig. S3. The WT and G46S truncated forms (residues 2-120, R-domain). (A) 
Size exclusion chromatography of WT-hPAH (2-120) expressed as a MBP fusion protein in E. 
coli. Peak 1, higher-order oligomeric forms (eluted in the void volume); peak 2, dimeric form (~ 
156 kDa); peak 3, monomeric form (~ 65 kDa) and peak 4, degradation products (~ 39 kDa). (B) 
Size exclusion chromatography of G46S-hPAH (2-120) expressed as a MBP fusion protein in E. 
coli. Peak 1, higher-order oligomeric forms (eluted in the void volume); peak 2, dimeric form (~ 
148 kDa) and peak 4, degradation products (~ 39 kDa). The molecular mass of the enzyme forms 
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were estimated using the elution position of standard molecular mass markers as a reference (not 
shown). 10.7 mg and 9.3 mg fusion protein were applied to the column in (A) and (B), 
respectively. The chromatography was performed on a HiLoad Superdex 200 HR column (1.6 
cm × 60 cm), equilibrated and eluted with 20 mM Na-Hepes, 0.2 M NaCl, pH 7.0 at a flow rate 
of 0.38 ml·min-1 at 4 °C and detection was at 280 nm. The inset in panels (A) and (B) represent a 
SDS-PAGE analysis demonstrating the purity of the fusion proteins after two steps of 
purification (amylose affinity chromatography and size-exclusion chromatography). Lane M, 
low-molecular-mass standard (106.5, 97.6, 50.2, 36.9 and 28.9 kDa); lane 2, the respective 
dimeric form enzymes (peak 2); lane 3, monomeric form (peak 3) and lane 4, degradation 
products (peak 4) after the size-exclusion chromatography. (C) Time-course for the cleavage of 
dimeric WT-hPAH (2-120) in the absence () and presence of 150 µM L-Phe () by the 
restriction protease factor Xa. (D) Time-course for the cleavage of dimeric G46S-hPAH (2-120) 
in the absence (▼) and presence of 150 µM L-Phe () by the restriction protease factor Xa. 
Data were fitted to a single exponential decay curve. The time-course of cleavage was performed 
at standard assay conditions (0.74 mg·ml-1 fusion protein, 5.0 μg·ml-1 factor Xa, 20 mM Na-
Hepes, 0.1 M NaCl, pH 7.0 and 25 oC). 
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Supplementary Fig. S4. G46S-hPAH fibril formation. (A) Electron micrograph of a negatively 
stained twisted fibril of G46S-hPAH. The broadest part (∗), narrowest part (∗∗), and branching 
(∗∗∗) of the fibril are indicated. (B) Schematic representation of a potential mechanism of self-
association resulting in the formation of branched fibrils. 
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Supplementary Fig. S5. Effect of deamidation on the self-association of tetrameric G46S-
hPAH. The time-course for the self-association of a non-deamidated (2 h induction) (▲) and a 
deamidated (24 h induction) () tetrameric G46S-hPAH. The self-association reactions were 
performed at standard assay conditions (0.74 mg⋅ml-1 fusion protein (7.85 µM monomer), 5.0 
μg⋅ml-1 factor Xa, 20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 and 25 ºC). Some data points were 
omitted for clarity. Error bars represent mean ± SD, (n = 3). 
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Abstract 
The proposal that mammalian phenylalanine 
hydroxylase (PAH) has an allosteric regulatory binding 
site for L-phenylalanine (L-Phe), in addition to the 
catalytic site, has been a controversial issue for 30 
years. In the present study a truncated maltose binding 
protein tagged construct of the human enzyme (MBP-
(pepXa)-hPAH2-120), comprising the regulatory (R) 
domain, was expressed in E. coli and recovered in a 
metastable state as a dimer and monomer. Upon 
cleavage of the fusion proteins by factor Xa both forms 
of hPAH2-120 self-associate and form unstructured 
oligomers as observed by electron microscopy. This 
self-association revealed a stereospecific inhibition (> 
95%) by L-Phe with a [L]0.5 value of 23.3 ± 0.5 µM L-
Phe for the dimer and 15.1 ± 2.4 µM L-Phe for the 
monomer. Interestingly, the self-association of the 
dimer of a conformationally variant mutant form 
(G46S) revealed no inhibition by L-Phe, indicating that  
the L-Phe binding site in the R-domain is sensitive to 
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the conformation of its βαββαβ motif (ACT domain). 
Moreover, several independent lines of direct 
experimental evidence from recent studies support the 
conclusion that the binding site is not available in the 
native full-length tetrameric/dimeric enzyme, as a result 
of a conformational change in the R-domain and/or a 
steric hindrance due to interdomain interactions. 
 
Introduction 
The ~ 50 kDa monomer of wild-type (WT) 
mammalian phenylalanine hydroxylase (PAH) 
assembles in vivo and on overexpression in bacteria to 
form tetramers and dimers, in equilibrium. The 3D 
structures of human phenylalanine hydroxylase (hPAH) 
and rat phenylalanine hydroxylase (rPAH) have 
revealed that the protomer consists of three structural 
and functional domains, i.e. a regulatory (R, residues 1-
117), a catalytic (C, residues 118-410) and an 
oligomerization (O, residues 411-452) domain with a 
tetramerization motif (Erlandsen et al. 1997; Fusetti et 
al. 1998; Kobe et al. 1999). On the basis of the 3D 
structures of the C+O domains of hPAH and the R+C 
domains of rPAH a composite full-length (R+C+O) 
model has been assembled for the PAH tetramer 
(Flatmark and Stevens 1999) organized as an 
asymmetric dimer of dimers. The N-terminal R-domain 
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has an α-β sandwich (βαββαβ) motif composed of a 
four-stranded antiparallel β-sheet flanked on one side 
by two short α-helices and the other side by the C-
domain (Fig. 1a, b), and the motif has been classified as 
an ACT domain (Aravind and Koonin 1999; Kobe et al. 
1999). However, PAH differs from other archetypical  
Fig. 1 3D structure of PAH protomer (rPAH1-429), sequence 
and secondary structure assignment of the N-terminal 
regulatory domain (R-domain) of hPAH and the 
localization/interactions of the G46 residue in the R-domain. a 
Ribbon representation of the regulatory/catalytic domain 
crystal structure of rPAH (PDB ID: 1PHZ) in the monomeric 
form with the regulatory domain shown in green, the catalytic 
domain in red, the iron as a yellow sphere and G46 in stick 
model (pointed arrow). b Sequence of the N-terminal 
regulatory domain of hPAH (SwissProt P00439) with 
elements of secondary structure (determined from the 
coordinates of the combined PAH structures (Flatmark and 
Stevens 1999) with the program DSSP (Kabsch and Sander 
1983)) indicated above the sequence and numbered 
sequentially from the N-terminus (Kobe et al. 1999). c Close-
up of the location of G46 in the regulatory domain of rPAH, 
at the end of the loop between β-strand 1 and α-helix 1, where 
it H-bonds to K50. The Cα-atom trace is shown in green 
ribbon, with the relevant residues in stick model and water 
molecules as red spheres. The figures were created using 
PyMOL, version 1.1 (DeLano Scientific) (Delano 2002) (a 
and c). 
 
ACT domains in proteins binding regulatory amino 
acids, since there are no contacts between the ACT 
domains in the dimeric and tetrameric structures of 
mammalian PAH (Flatmark and Stevens 1999). As seen 
from Table 1 the possible regulatory function of a 
second L-phenylalanine (L-Phe) binding site in 
mammalian PAH has over the years been a 
controversial issue. Among the supportive evidence was 
the demonstration of an in vitro binding of [14C]-L-Phe 
to recombinant WT and mutant forms (G46S, A47V, 
T63P/H64N, I65T and R68S) of the isolated R-domain 
(hPAH2-120), expressed as maltose binding protein 
(MBP) fusion proteins (Gjetting et al. 2001). More 
recently 1H-15N heteronuclear single-quantum 
coherence (HSQC) NMR studies of a dimeric isolated 
R-domain (rPAH1-117) revealing chemical shift 
perturbations in the presence of L-Phe, that are 
consistent with its binding at a specific site (Li et al. 
2010b). Some of these binding studies have been 
challenged (Liberles et al. 2005; Siltberg-Liberles and 
Martínez 2009), partly due to the fact that the MBP 
fusion proteins utilized (Gjetting et al. 2001) were 
predominantly dimers, and therefore not considered 
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representative for the situation in the full-length enzyme 
where no contacts between the proposed binding sites in 
the ACT domain of the different protomers occurs 
(Flatmark and Stevens 1999). 
  In the present study, therefore, the R-domain 
(residues 2-120) of the recombinant WT and a 
conformationally variant mutant form (G46S) (Leandro 
et al. 2011) were isolated as MBP-(pep)Xa-hPAH2-120 
fusion proteins with the goal to: (i) isolate their 
oligomeric forms; (ii) demonstrate that the R-domain is 
in a metastable state as fusion protein and self-
associates upon cleavage of the fusion protein forming 
unstructured higher-order oligomers; (iii) show that L-
Phe inhibits the propensity of WT, but not a G46S 
mutant form, to self-associate; (iv) demonstrate that the 
inhibition of self-association by L-Phe of the 
monomeric form is stereospecific and of relatively high 
affinity. To address these aspects, we used a combined 
approach of real-time light-scattering, thioflavin-T and 
ANS fluorescence-based binding assays and electron 
microscopy (EM) structural analyses. 
 
Materials and Methods 
Materials 
TB1 cells, the prokaryotic expression vector pMAL-
c2/pMAL-hPAH and the amylose resin were obtained 
from New England Biolabs (USA). The restriction 
protease factor Xa was obtained from Protein 
Engineering Technology ApS (Aarhus, Denmark). 
Thioflavin-T (ThT) and 8-anilino-1-
naphthalenesulfonic acid (ANS) were obtained from 
Sigma-Aldrich. 
 
Site-specific mutagenesis  
The WT regulatory (R) domain (WT-hPAH2-120) and 
its G46S mutant form (G46S-hPAH2-120) were obtained 
by introducing a stop signal in codon 121 of hPAH, by 
site-directed mutagenesis (QuikChangeR II, Stratagene), 
using the pMAL-WT-hPAH (Martínez et al. 1995) and 
pMAL-G46S-hPAH constructs (Eiken et al. 1996) as 
template, respectively. Primers 5′-
GACACAGTGCCCTGGTAACCAAGAACCATTCA
AGAGC-3′ (forward) and 5′-
GCTCTTGAATGGTTCTTGGTTACCAGGGCACTG
TGTC-3′ (reverse) used for mutagenesis were provided 
by Eurogentec, Seraing, Belgium (the mismatch 
nucleotides are shown in bold type). The authenticity of 
the mutagenesis was verified by DNA sequencing as 
described previously (Eiken et al. 1996).  
 
Expression and isolation of fusion proteins 
The WT and G46S mutant form were expressed in 
E. coli as fusion proteins (MBP-(pep)Xa-hPAH2-120) 
(Martínez et al. 1995). The bacteria were grown at 37 
ºC and the induction by 1 mM isopropyl-thio-β-D-
galactoside was performed for 8 h at 28 ºC. The fusion 
proteins were purified by affinity chromatography 
(amylose resin) and centrifuged in a TL-100 
Ultracentrifuge (Beckman, USA) for 20 min at 50,000g 
before size-exclusion chromatography (SEC) as 
described (Martínez et al. 1995). SEC was performed at 
4 ºC using a HiLoad Superdex 200 HR column (1.6 
cm×60 cm) prepacked from Amersham Biosciences 
(GE Healthcare, Uppsala, Sweden). The mobile phase 
consisted of 20 mM Na-Hepes and 0.2 M NaCl, pH 7.0 
and the flow rate was 0.38 ml⋅min-1. The dimeric and 
monomeric fusion proteins were concentrated by 
Centriplus 30 filter (Amicon, MA, USA). The 
concentration of purified fusion proteins was measured 
using the absorption coefficient A280 (1 mg⋅ml-1⋅cm-1) = 
1.34. A colorimetric method (Bradford 1976) was in 
some cases also used to measure enzyme 
concentrations, with bovine serum albumin as the 
standard.
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Table 1 Experimental evidence interpreted as supportive and non supportive of a second regulatory binding site 
for L-Phe in mammalian PAH. 
Evidence Reference 
 
Supportive 
1. Tryptophan is a substrate, but does not activate the rPAH-TM a 
 
2. Equilibrium binding of [14C]-L-Phe to rPAH-TM giving a stoichiometry 
of L-Phe:subunit ~ 1.5:1 
 
3. R-domain of rPAH19-428-DM has a βαββαβ motif (ACT domain) 
similar to its distant homolog prephanate hydratase b 
 
4. Equilibrium binding of [14C]-L-Phe to MBP-hPAH2-120-DM giving 
half maximal binding at ~ 130 µM b 
 
5. Gel filtration and 1H-15N HSQC NMR studies of rPAH2-117 in the presence of L-
Phe reveal changes in peak elution and chemical shift perturbations, 
respectively, consistent with L-Phe binding at a specific site 
 
Non supportive 
1. Equilibrium binding of [14C]-L-Phe to rPAH-TM giving a stoichiometry 
of L-Phe:subunit ~ 0.8:1 
 
2. Equilibrium binding of [3H]-L-noradrenaline to hPAH-TM giving  
a stoichiometry of L-noradrenaline:subunit of ~ 0.5:1 and a Hill coefficient of 
1.9 c  
 
3. Differential scanning calorimetry supports the binding of L-Phe 
to the catalytic domain of hPAH-TM with a stoichiometry of 
L-Phe:subunit ~ 1:1 
 
4. 3D structural analysis of  hPAH121-427-DM, lacking the R-domain, 
demonstrates a global conformation change on binding L-Phe 
at the active site 
 
5. Full-length hPAH-DM is not activated by L-Phe a 
 
6. Isothermal titration calorimetry demonstrates the binding of L-Phe 
to hPAH-TM with a stoichiometry of  L-Phe:subunit 1.2 ± 0.1:1 and a kD = 13.6 
µM 
 
 
(Shiman 1980) 
 
(Parniak and Kaufman 1981; 
Phillips et al. 1984) 
 
(Kobe et al. 1999) 
 
 
(Gjetting et al. 2001) 
 
 
(Li et al. 2010b) 
 
 
 
 
 
(Shiman 1980) 
 
 
(Martínez et al. 1990) 
 
 
 
(Thórólfsson et al. 2002) 
 
 
 
(Andersen et al. 2003) 
 
 
 
(Bjørgo et al. 2001) 
 
(Flydal et al. 2010) 
 
aPreincubation with L-Phe activates the tetrameric enzyme several fold. The abbreviations TM and DM represent tetrameric 
and dimeric forms of the enzyme, respectively. 
bThe ACT domain of prephenate hydratase binds L-Phe with high affinity at its dimer interphase, involving the sequence 
motifs G191LLV and E218SRP (Tan et al. 2008); the corresponding sequence motifs in rPAH(hPAH) are G46AL and E66SRP. 
cThe analog binds at the active site iron with positive cooperativity (nH = 1.9), forming a charge transfer complex (Martínez et al. 
1990), and induces a global conformational change (Solstad et al. 2003). 
 
 
Cleavage of MBP-hPAH2-120 fusion proteins and assay 
of self-association by light scattering 
Before cleavage of the MBP-hPAH2-120 fusion 
proteins by factor Xa they were subjected to high-speed 
ultracentrifugation at 210,000g for 15 min at 4 ºC. In 
the standard assay at 20 mM Na-Hepes, 0.1 M NaCl, 
pH 7.0 and 25 °C the concentration of the fusion protein 
was 0.74 mg⋅ml-1, and the concentration of factor Xa 
was adjusted to give a final ratio (by weight) of 1:150 
relative to the fusion protein. Self-association of the 
factor Xa released R-domain was followed in real-time 
by light scattering, as measured by the increase in the 
apparent absorbance at 350 nm (A′350 = log [Io /(Ip + f ∙Id 
)] using an Agilent 8453 Diode Array 
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Spectrophotometer with a Peltier temperature control 
unit. The change in light scattering was expressed as 
ΔA′350 by subtracting the background absorbance in the 
absence of added factor Xa. The rate of forming higher-
order oligomers was expressed as ∆A′350/∆t and was 
obtained from the slope of the linear growth phase of 
each light scattering curve. In each experiment a 
parallel time-course cleavage analysis was conducted to 
rule out any effect of the cleavage rate. 
In order to study the inhibitory effect of L-Phe on 
the self-association of WT-hPAH2-120 and the mutant 
form G46S-hPAH2-120, the fusion proteins were 
preincubated for 5 min at standard assay conditions 
with L-Phe (0-1 mM) before the cleavage was initiated 
with factor Xa. The inhibition of the self-association 
was analyzed by nonlinear regression analysis using the 
SigmaPlot® Technical Graphing Software and a reverse 
Hill equation (four parameter logistic equation): υ = 
Vmin + ((Vmax − Vmin)/(1 + (L/[L]0.5)s), (DeLean et al. 
1978; Oz-Gleenberg et al. 2007; Prinz 2010) where υ is 
the rate of formation of higher-order oligomers 
(∆A′350/∆t); L, the ligand (L-Phe) concentration; Vmax, 
the rate of self-association when the ligand is absent; 
Vmin, the rate of self-association for infinite 
concentration of the ligand; [L]0.5 is the apparent 
equilibrium dissociation constant ~ IC50 (50 % 
inhibition), and s, a pseudo-Hill coefficient (sigmoid 
factor) that determines the steepness of the curve. 
 
SDS-PAGE analyses 
The purification of the fusion proteins and the 
efficiency of its cleavage by factor Xa, was analyzed by 
SDS-PAGE in a 10 % (w/v) polyacrylamide gel 
(Laemmli 1970). The gels were stained by Coomassie 
Brilliant Blue R-250, scanned using VersaDoc 4000 
(Bio-Rad) and quantification of the protein bands was 
obtained by using the Quantity One 1-D Analysis 
Software (Bio-Rad, Hercules, CA, USA). 
 
ANS binding assay 
Fluorescence-based 8-anilino-1-naphthalenesulfonic 
acid (ANS) binding studies were performed as 
described by Aukrust et al (Aukrust et al. 2006). 
Briefly, 1.3 µM hPAH2-120 was incubated with 60 µM 
ANS in 20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 at room 
temperature for 5 min in the dark. The fluorescence 
emission spectra were recorded between 400 and 600 
nm (6 nm slit width) at 25 ºC using an excitation 
wavelength of 385 nm (6 nm slit width) on a Perkin-
Elmer LS-50B luminescence spectrometer (Perkin-
Elmer, Waltham, MA, USA) and by averaging four 
scans. 
 
Thioflavin-T binding assay 
Fluorescence-based thioflavin-T (ThT) binding 
studies were performed according to a standard protocol 
(Eisert et al. 2006). Briefly, the ThT measurements 
were made by taking reaction aliquots and diluting them 
to 1.3 μM hPAH2-120 in 20 mM Na-Hepes, 0.1 M NaCl, 
pH 7.0 containing 20 μM ThT. Immediately following 
sample preparation the fluorescence was measured on a 
Perkin-Elmer LS-50B luminescence spectrometer at 25 
ºC using an excitation wavelength of 440 nm and 
emission of 482 nm, with slit widths of 3 and 7 nm for 
excitation and emission, respectively, and by averaging 
four scans. The reported values (ΔThT) have been 
corrected by subtracting the background fluorescence of 
ThT in the absence of protein and with the protein in 
the absence of ThT (light scattering). 
 
Negative staining of WT-hPAH2-120 oligomers and 
electron microscopy 
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For the negative staining EM of WT-hPAH2-120 
oligomers, Formvar-coated 200 mesh nickel grids 
(Electron Microscopy Sciences, Fort Washington, 
USA) were used. The grids were further coated with 
carbon, stored dust-free in Petri dishes kept at low 
humidity, and glow-discharged for 15 s prior to use. 
Negative staining was carried out by first applying 5 µl 
of a protein solution on the specimen grid. Following 
absorption for 60 s, the sample drop was removed by 
blotting with filter paper, and the grid was stained twice 
with 2 % (w/v) aqueous uranyl acetate. After 
application, the first drop (10 µl) was blotted off 
immediately, whereafter a fresh drop of the stain was 
added to the grid for 15 s. After final blotting and 
drying, the specimens were observed in a Jeol 1230 
Electron Microscope operated at 80 kV. 
 
Computational Analysis 
The effect of the G46S mutation on the free energy 
of folding (∆∆G) was predicted using the structural 
coordinates of (∆C428-452)-rPAH (PDB ID: 1PHZ) 
and the Concoord/PBSA server 
(http://ccpbsa.biologie.uni-
erlangen.de/ccpbsa/index.php) (Benedix et al. 2009). In 
order to assess the effect on G46S mutation on the 
secondary structure of the hPAH protein an algorithm 
based on helix-coil transition theory, AGADIR, was 
used to predict helical propensity (http://agadir.crg.es/) 
(Lacroix et al. 1998). WT-hPAH2-120 predicted 
isoelectric point (pI) is 6.1 and a global net charge of -
1.7 at pH 7 (calculated using the EMBL IEP Service, 
http://www3.embl.de/cgi/pi-wrapper.pl). 
 
Results 
 
Expression and isolation of the MBP-hPAH2-120 fusion 
proteins 
On expression of WT MBP-(pep)Xa-hPAH2-120 and 
its mutant form G46S, the affinity purified fusion 
proteins were separated into their oligomeric forms by 
SEC. The chromatogram of the WT-hPAH2-120 form 
(Fig. 2) revealed four peaks where peak 1 represented 
higher-order oligomeric forms (eluted at or near the 
void volume), and peak 2 and peak 3 represented the 
dimeric and monomeric forms, respectively. For the 
G46S-hPAH2-120 fusion protein only the dimeric form 
was recovered at sufficiently high yield for further 
analyses. Moreover, SDS-PAGE revealed that the 
mutant form was more partly proteolysed than the WT 
form (data not shown). 
 
 
Fig. 2 Size-exclusion chromatography of the WT R-domain 
(WT-hPAH2-120) expressed as a MBP fusion protein in E. coli. 
Peak 1, higher-order oligomeric forms (eluted in the void 
volume); peak 2, dimeric form (~ 156 kDa); peak 3, 
monomeric form (~ 65 kDa) and peak 4, degradation products 
(~ 39 kDa). The molecular mass of the enzyme forms were 
estimated using the elution position of standard molecular 
mass markers as a reference (not shown). 10.7 mg of fusion 
protein were applied to the column. The chromatography was 
performed on a HiLoad Superdex 200 HR column (1.6 cm×60 
cm), equilibrated and eluted with 20 mM Na-Hepes, 0.2 M 
NaCl, pH 7.0 at a flow rate of 0.38 ml·min-1 at 4 °C and 
detection was at 280 nm. The inset represents a SDS-PAGE 
analysis demonstrating the purity of the fusion proteins after 
two steps of purification. Lane M, low-molecular-mass 
standard (106.5, 97.6, 50.2, 36.9 and 28.9 kDa); lane 2, 
dimeric form (peak 2); lane 3, monomeric form (peak 3) and 
lane 4, degradation products (peak 4) after the size-exclusion 
chromatography. 
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The hPAH2-120 fusions proteins comprising the 
hPAH regulatory domain (residues 2-117) and 
including also residue W120 were used, as this residue 
has been used as a valuable conformational probe for 
the full-length WT and truncated forms of enzyme 
(Knappskog and Haavik 1995; Stokka and Flatmark 
2003). However, no change in tryptophan fluorescence 
was detected in absence and presence of L-Phe. The 
hPAH2-120 fusions proteins were also used in order to 
compare the results of the cleaved forms obtained here 
with the results of the fusion proteins obtained by 
Gjetting et al. that comprise residues 2-120 (Gjetting et 
al. 2001). 
 
Cleavage of the MBP fusion proteins 
At the standard assay conditions the cleavage of the 
WT-hPAH2-120 fusion protein by factor Xa was very 
similar for the dimeric (Supplementary Fig. S1) and the 
monomeric fusion protein, with t1/2 (time at 50 % 
cleavage) of ~ 11 min. The presence of L-Phe had no 
significant effect on the cleavage reaction of WT-
hPAH2-120 by factor Xa (Supplementary Fig. S1), as 
well as on the cleavage of G46S-hPAH2-120 (data not 
shown). 
 
Self-association of dimeric and monomeric forms of 
WT-hPAH2-120 
On cleavage of the dimeric and monomeric MBP-
hPAH2-120 fusion proteins by factor Xa (pH 7.0, 0.1 M 
NaCl and 25 oC) the proteins self-associate (Fig. 3) with 
a similar time-course, including a delay period (lag 
phase), a growth phase of increasing light scattering 
(∆A′350/∆t) of 3.9 ± 0.1 × 10-3 and 1.3 ± 0.1 × 10-3 
AU⋅min-1, for dimeric (Fig. 3a) and monomeric (Fig. 
3b) forms, respectively. In the absence of added factor 
Xa no change in light scattering was observed within 
the time scale of 3 h. 
 
Fig. 3 The self-association of dimeric (a) and monomeric (b) 
WT-hPAH2-120 following cleavage of the MBP fusion protein 
by factor Xa, and the effect of L-Phe. a The time-course of the 
self-association of dimeric WT-hPAH2-120 protein following 
cleavage of the fusion protein by factor Xa was followed in 
real-time by light scattering, as measured by the increase in 
the apparent absorbance at 350 nm (ΔA′350). The data points 
correspond to cleavage in the absence of any added compound 
() and in the presence of 1 mM L-Phe (▲). () represents 
dimeric WT-hPAH2-120 fusion protein in the absence of factor 
Xa. b The time-course of the self-association of monomeric 
WT-hPAH2-120 protein following cleavage of the fusion 
protein by factor Xa in the absence of any added compound 
() and in the presence of 1 mM L-Phe (▲). () represents 
monomeric WT-hPAH2-120 fusion protein in the absence of 
factor Xa. The reactions were performed at standard assay 
conditions (0.74 mg⋅ml-1 fusion protein, 5.0 μg⋅ml-1 factor Xa, 
20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 and 25 oC). Some data 
points were omitted for clarity. Error bars represent mean ± 
SD, (n = 3). 
 
 
Inhibition of self-association by L-Phe and 
stereospecificity 
The self-association of the dimeric WT-hPAH2-120 is 
inhibited in a stereospecific manner by phenylalanine; 
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100 μM L-Phe almost completely inhibited the self-
association of the dimeric R-domain whereas 100 μM 
D-Phe revealed almost no effect (Fig. 4a). A similar 
relation was observed for the monomeric form (data not 
shown). Whereas the inhibition of the dimeric form 
(Fig. 5a) revealed a [L]0.5 value of 23.3 ± 0.5 μM L-Phe, 
that of the monomeric form (Fig. 5b) was 15.1 ± 2.4 
μM L-Phe (Table 2). By contrast, the self-association of 
the dimeric form of the G46S mutant revealed no 
inhibition by L-Phe (Fig. 4b). The effect of other 
hydrophobic L-amino acids (e.g. L-alanine) were test, 
but no inhibition of the self-association of WT-hPAH2-
120 was observed, even at higher concentrations of the 
amino acids (1 mM) (data not shown). 
 
Binding of ANS and ThT 
ANS is a spectroscopic probe that has affinity for 
hydrophobic clusters which are not tightly packed in a 
fully folded structure or become exposed in partially 
unfolded structures (Semisotnov et al. 1991). ANS 
binds to dimeric WT MBP-hPAH2-120 fusion protein 
(Fig. 6a) and its factor Xa cleaved form (t = 3 h) (Fig. 
6b) with an increase in the fluorescence intensity and a 
blue shift (maximum at ~ 478 nm). Similar spectra were 
obtained in the absence and presence of 1 mM D-Phe 
whereas L-Phe revealed a concentration dependent 
decrease and red shift of the fluorescence spectra (Fig. 
6a, b). Similar results were obtained for the monomeric 
WT-hPAH2-120 as a fusion protein (Fig. 6c) and after its 
cleavage by factor Xa (Fig. 6d). The MBP fusion 
partner alone has a negligible contribution to the ANS 
fluorescence, and there was no additional effect of L-
Phe (Fig. 6a). At the standard assay conditions the 
higher-order oligomers, related to the increase in light-
scattering, revealed only a minor enhancement of the 
ThT fluorescence (Supplementary Fig. S2). 
 
 
Fig. 4 a The stereospecific inhibition of the self-association of 
WT-hPAH2-120 by phenylalanine. The time-course of the self-
association of dimeric WT-hPAH2-120 protein following 
cleavage of the fusion protein by factor Xa in the absence () 
and presence of 100 µM L-Phe (▲) or 100 µM D-Phe (). b 
The self-association of dimeric WT-hPAH2-120 and its G46S 
mutant form and the effect of L-Phe. The time-course of the 
self-association of WT-hPAH2-120 dimeric protein following 
cleavage of the fusion protein by factor Xa in the absence () 
and presence of 150 µM L-Phe (); G46-hPAH2-120 dimer 
fusion protein following cleavage by factor Xa in the absence 
() and presence of 150 µM L-Phe (). Some data points 
were omitted for clarity. The assays were performed at 
standard assay conditions and error bars represent mean ± SD, 
n = 3 independent experiments. 
 
 
Ultrastructure of WT hPAH2-120 oligomers 
In order to get information on the morphology of the 
higher-order oligomers of dimeric WT hPAH2-120 that 
are formed on factor Xa cleavage of the fusion protein, 
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Table 2 L-Phe inhibition of the self-association of dimeric and monomeric WT-hPAH2-120.  
 
 
 
 
 
The effect of L-Phe concentration on the rate of forming higher-order oligomers (∆A′350/∆t) was determined as described in 
the Materials and methods section at standard conditions (0.74 mg⋅ml-1 fusion protein, 5.0 μg⋅ml-1 factor Xa, 20 mM Na-
Hepes, 0.1 M NaCl, pH 7.0 and 25 oC) with varying concentrations of L-Phe (0−1 mM). 
aV represents the rate of forming higher-order oligomers (∆A′350/∆t). b[L]0.5 corresponds to IC50 (50 % inhibition). 
 
negative staining EM was performed on aliquots 
removed during the cleavage reaction. At the final time 
point (t = 180 min) the EM micrographs (Fig. 7) 
revealed that the self-association of the WT protein 
generated unstructured higher-order oligomers, but no 
fibrils were observed. 
 
 
Discussion 
In a previous study (Gjetting et al. 2001), the 
binding of [14C]-L-Phe to the isolated R-domain 
(hPAH2-120), expressed as a MBP fusion protein was 
performed on dimeric fusion proteins stabilized by 
MBP as a chaperone. Whereas the WT form revealed an 
apparent half maximal binding at ~ 130 µM L-Phe, five 
mutants (G46S, A47V, T63P/H64N, I65T and R68S) 
were reported to bind L-Phe with a variably reduced 
affinity. Since the semi-quantitative binding data were 
obtained only on dimeric fusion proteins, the 
interpretation of the data and their relevance for the 
full-length enzyme has later been questioned (Liberles 
et al. 2005; Siltberg-Liberles and Martínez 2009). In the 
present study, we have found (Figs. 3a, 5a) that L-Phe 
also binds to the MBP-free dimeric form of WT R-
domain (hPAH2-120), by inhibiting its self-association to 
higher-order oligomeric forms. The affinity ([L]0.5 = 
23.3 ± 0.5 µM L-Phe) was higher than previously 
reported for the dimeric fusion protein (Gjetting et al. 
2001). More important was the finding that L-Phe binds  
to the monomeric form (Figs. 3b, 5b), with an even
 
Fig. 5 The effect of L-Phe concentration on the inhibition of 
the self-association of dimeric (a) and monomeric (b) WT-
hPAH2-120. The inhibitory effect of L-Phe on the self-
association of WT-hPAH2-120 was assayed at standard 
conditions (0.74 mg⋅ml-1 fusion protein, 5.0 μg⋅ml-1 factor Xa, 
20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 and 25 oC) with 
varying concentrations of L-Phe (0−1 mM) and the rate of 
forming higher-order oligomers (∆A′350/∆t) was obtained from 
the slope of the linear growth phase of each light scattering 
curve. The L-Phe dose-dependent inhibition curves of the self-
association were generated by nonlinear regression analysis of 
the experimental data using the four parameter logistic 
equation (see Materials and methods). The insets represent the 
data obtained in the concentration range 0−250 µM L-Phe. 
Enzyme Vmax
a 
(× 10-3 AU⋅min-1) 
Vmin 
(× 10-3 AU⋅min-1) 
[L]0.5b 
(µM) 
Pseudo-Hill 
Coefficient (s) 
WT-hPAH2-120 dimer 3.6 ± 0.1 0.06 ± 0.05 23.3 ± 0.5 4.8 ± 0.5 
WT-hPAH2-120 monomer 1.3 ± 0.1 0.04 ± 0.05 15.1 ± 2.4 1.3 ± 0.2 
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Fig. 6 The binding of ANS to dimeric and monomeric WT-hPAH2-120. a ANS fluorescence emission spectra of the dimeric WT-
hPAH2-120 fusion protein in the absence of ligand (trace 1), with 100 µM L-Phe (trace 3), 1 mM L-Phe (trace 4), and 1 mM D-Phe 
(trace 2). The MBP protein was used as a control in the absence (trace 5) and in the presence of 1 mM L-Phe (trace 6) and the 
emission spectrum of buffer with ANS is shown (trace 7). b ANS fluorescence emission spectra observed after cleavage of the 
dimeric WT-hPAH2-120 fusion protein by factor Xa (t = 3 h) in the absence of ligand (trace 1), with 100 µM L-Phe (trace 4), 1 
mM L-Phe (trace 5), 100 µM D-Phe (trace 2), 1 mM D-Phe (trace 3) and the emission spectrum of buffer with ANS (trace 6). c 
ANS fluorescence emission spectra of the monomeric WT-hPAH2-120 fusion protein in the absence of ligand (trace 1), with 100 
µM L-Phe (trace 3), 1 mM L-Phe (trace 4), 1 mM D-Phe (trace 2) and the emission spectrum of buffer with ANS (trace 5). d 
ANS fluorescence emission spectra observed after cleavage of the monomeric WT-hPAH2-120 fusion protein by factor Xa (t = 3 
h) in the absence of ligand (trace 1), with 100 µM L-Phe (trace 3), 1 mM L-Phe (trace 4), 1 mM D-Phe (trace 2) and the emission 
spectrum of buffer with ANS (trace 5). The excitation wavelength was 385 nm. 
 
higher affinity ([L]0.5 = 15.1 ± 2.4 µM L-Phe). Thus, an 
interaction between two R-domains in a dimer is not 
required for the binding of L-Phe as is the case for the 
binding of this amino acid to the archetypical regulatory 
ACT domain of the distant homologous enzyme 
prephenate dehydratase (Aravind and Koonin 1999; Tan 
et al. 2008). That L-Phe binds to hPAH2-120 also in the 
fusion protein (before factor Xa cleavage) was shown 
by its quenching of the ANS fluorescence enhancement 
observed on binding the hydrophobic fluorescence 
probe to the fusion protein (Fig. 6). Moreover, in both 
assay systems the measured responses to L-Phe were 
stereospecific (Figs. 4a, 6), and also specific for  
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Fig. 7 Electron micrograph of negatively stained dimeric WT-
hPAH2-120 after cleavage of its MBP fusion protein by factor 
Xa (t = 3 h). The proteins were negatively stained with 
aqueous uranyl acetate and analyzed in Jeol 1230 Electron 
Microscope operated at 80 kV. The dark arrow points to large 
unstructured oligomers and the light arrow to small roughly 
spherical structures. Scale bar: 500 nm. 
 
phenylalanine in a physiological concentration range 
(data not shown). 
In contrast to the WT-hPAH2-120, a conformationally 
variant mutant form (G46S) revealed no inhibition by L-
Phe of its self-association induced by factor Xa 
cleavage, indicating that the binding site in the R-
domain is sensitive to the conformation of its βαββαβ 
sandwich motif (ACT domain). The residue G46 is 
positioned at the entry of α-helix 1 (A47-E57) in a five 
residue (L41-G46) loop structure (loop 1), linking β-
strand 1 and α-helix 1 (Fig. 1c). The substitution 
G46→S was found to be destabilizing (ΔΔG = 4.1 
kcal·mol-1), using a structure-based method for the 
estimation of the free energy of folding (Benedix et al. 
2009), and predicted to promote a N-terminal extension 
of α-helix 1 by four residues, or one turn, using the 
AGADIR algorithm (Lacroix et al. 1998). Thus, the 
change of the Cα backbone conformation and the α-β 
sandwich structure of the WT R-domain, induced by the 
G46→S mutation, are likely to promote the formation 
of new intermolecular contacts of the domain, including 
its binding of L-Phe. It may also partly explain why L-
Phe does not bind to this site in the full-length 
oligomeric WT enzyme. 
Comparing the 3D structural data of the R+C 
domains of rPAH (PDB ID: 1PHZ) (Kobe et al. 1999) 
with the data obtained from infrared spectroscopy 
analyses of the hPAH R-domain (comprising residues 
2-110) (Chehin et al. 1998), suggests that the degree of 
ordered structure in the isolated R-domain is slightly 
different from that in the intact phenylalanine 
hydroxylase, by a decrease in the α-helix content. This 
structure is able to bind L-Phe, in contrast to the G46S 
mutant form that is predicted to extend the α-helix 1, 
impairing the L-Phe binding. 
Recent studies on a dimeric R-domain (rPAH1-117) 
involving gel filtration and 1H-15N HSQC NMR 
analyses also support a binding site for phenylalanine in 
the R-domain (Li et al. 2010b). However, as seen from 
Table 1, there is mounting experimental evidence 
supporting the conclusion that the L-Phe binding site in 
the isolated R-domain is not available in the native full-
length tetrameric/dimeric enzyme. The strongest 
evidence is the isothermal titration calorimetry 
measurements demonstrating that L-Phe binds to full-
length hPAH tetramer with a stoichiometry of L-
Phe:subunit = 1.2 ± 0.1:1 and a kD of 13.6 μM (Flydal et 
al. 2010). By contrast, full-length PAH tetramer 
isolated from C. elegans (cePAH) demonstrated two 
binding sites (L-Phe:subunit = 2.1 ± 0.05:1) with 
slightly different affinities, interpreted as a potential 
binding site in the R-domain (kD of 8.2 μM) in addition 
to the active site (kD of 15.0 μM) (Flydal et al. 2010). 
Although the modeled tetrameric structures of cePAH 
and hPAH are very similar, a unique pocket and 
putative L-Phe binding site was found only in cePAH 
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close to the interface between an R-domain and an 
adjacent C-domain, lined by the ACT-domain motifs 
G41AL/E61SRP (Flydal et al. 2010). In the modeled 
tetrameric structures the accessibility of this site in 
hPAH was found to be sterically hindered by the large 
side-chains of K215 and Y216 in the adjacent C-domain, 
in contrast to cePAH where the corresponding residues 
are Q215 and N216 (Flydal et al. 2010). The functional 
significance of the second binding site of L-Phe in 
cePAH and its absence in full-length mammalian PAH 
is, however, an evolutionary challenging issue. Whereas 
cePAH has a major anabolic function, related to the 
synthesis of a melanin-like pigment (Calvo et al. 2008), 
mammalian PAH has an essential catabolic function in 
the regulation of the L-Phe homeostasis. 
L-Phe plays a major role in the regulation of the 
catalytic activity of tetrameric mammalian PAH which 
is activated several-fold by preincubation with the 
substrate (Shiman and Gray 1980). The related 
hysteretic conformational isomerization is an 
intrinsically complex process (Andersen et al. 2003; 
Flatmark and Stevens 1999; Li et al. 2010a), and the 
molecular mechanism of substrate activation is not fully 
understood. We consider that the experimental evidence 
presented in Table 1 (namely the recent isothermal 
titration calorimetry data) do not support a separate 
allosteric binding site for L-Phe as originally proposed 
by Shiman and Gray (Shiman and Gray 1980), but the 
conclusion that the conformational isomerization and 
catalytic activation is initiated by binding of L-Phe to 
the active site, as the “epicentre” of the related 
conformational hysteresis. Our previous 3D structural 
analyses of a truncated form (∆N1-102/∆C428-452)-
hPAH, lacking the R-domain, have demonstrated that 
binding of the analog 3-(2-thienyl)-L-alanine and L-
norleucine at the active site triggers structural changes 
throughout the entire catalytic domain (Andersen et al. 
2003), which partly activates the enzyme (Stokka and 
Flatmark 2003). This truncated form is in its unliganded 
form already highly activated (Knappskog et al. 1996), 
due to removal of the autoinhibitory sequence of the R-
domain (Jennings et al. 2001). The 3D structural 
conformational changes observed in the isolated C-
domain upon substrate binding, has recently been 
confirmed by hydrogen/deuterium exchange and mass 
spectrometry analyses of rPAH (Li et al. 2010a). In the 
full-length tetrameric hPAH the substrate analog L-
noradrenaline binds covalently at the active site, with 
positive cooperativity (nH = 1.9), and it is associated 
with a conformational change (Martínez et al. 1990). 
hPAH is an enzyme that demonstrates a low stability 
towards chemical denaturation (Kleppe et al. 1999) and 
a low thermal stability, even at physiological 
temperature, in the absence of its stabilizing natural 
pterin cofactor (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4) (Martínez et al. 2008). By 
differential scanning calorimetry it has been shown that 
the thermal unfolding of the full-length tetramer occurs 
with two transition temperatures, i.e. Tm ∼ 45oC 
assigned to the unfolding of the four R-domains and Tm 
∼ 54 oC assigned to the unfolding of two C-domains, 
followed by an irreversible protein denaturation 
(Thórólfsson et al. 2002). Disease causing missense 
mutations in hPAH, distributed by the overall structure 
of the protomer (http://www.pahdb.mcgill.ca/) (Scriver 
et al. 2003), often results in misfolded proteins and have 
an additional destabilizing effect both in vitro and in 
vivo (Erlandsen and Stevens 1999; Pey et al. 2007). It 
has been suggested (Gersting et al. 2008) that these 
mutations, independent of their position, have a major 
impact on the folding of the inherently unstable R-
domain. Here we have found that L-Phe binding to the 
isolated R-domain has a stabilizing effect, and a loss of 
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this ability in the full-length WT enzyme may 
contribute to explain its low stability. 
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Supplementary Fig. S1 Time-course for the cleavage of dimeric WT-hPAH2-120 fusion protein by the restriction 
protease factor Xa in the absence of any compound (), with 1 mM L-Phe (▲) and 1 mM D-Phe ().The data were 
fitted to a single exponential decay curve. The time-course of cleavage was performed at standard assay conditions 
(0.74 mg·ml-1 fusion protein, 5.0 μg·ml-1 factor Xa, 20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 and 25 oC). 
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Supplementary Fig. S2 The binding of ANS to the uncleaved and cleaved MBP fusion proteins of dimeric and 
monomeric WT-hPAH2-120. The ThT fluorescence enhancement (∆ThT) was measured on samples at the beginning 
of the cleavage reaction of the respective fusion proteins by factor Xa and at the end point (t = 3 h). The MBP 
protein was included as a control. The response was normalized by subtracting the background fluorescence of ThT 
and light scattering contribution, and the values represent means ± SD of three independent experiments. 
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Abstract 
The mononuclear non-heme iron(II)-containing enzyme 
phenylalanine hydroxylase (PAH) catalyzes the 
conversion of L-phenylalanine (L-Phe) to L-tyrosine in 
the presence of the pterin cofactor (6R)-L-erythro-
5,6,7,8-tetrahydrobiopterin and dioxygen as co-
substrates. The high-resolution structure of the dimeric 
catalytic core domain (∆N102/∆C24-hPAH) have 
revealed that substrate binding triggers a 
conformational isomerization including a Cα 
displacement of ~10 Å for Y138 and ~21 Å of its side-
chain hydroxyl group from a surface position in a 
flexible loop to a partially buried position within a 
hydrophobic core at the active site. In this study, we 
have compared the tolerance for substitutions of Y138 
in the dimeric catalytic core domain and the full-length 
tetrameric enzyme. The catalytic efficiency 
(kcat/[S]0.5,Phe) of the Y138F/A/E/K substitutions was 
found to be equally reduced (38 – 95 %) in the two 
enzyme forms (r2 = 0.99), whereas the coupling 
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efficiency was slightly affected only in the Y138E/K 
substitutions of the full-length enzyme. Our data lend 
support to the conclusion that the repositioning of the 
flexible loop and Y138, as observed in the 3D structure 
of the catalytic core domain, is representative for the 
full-length enzyme. Moreover, in the full-length 
tetramer the L-Phe-triggered conformational 
isomerization, as measured by surface plasmon 
resonance spectroscopy, revealed an increased 
equilibrium signal amplitude in the Y138A mutation 
and a correlated fold increase in catalytic activation, 
whereas both were slightly reduced by the K and E 
substitutions. Thus, Y138 plays a regulatory role both 
in the L-Phe triggered conformational isomerization 
related to catalytic activation and in positioning the 
substrates for catalysis. 
 
Introduction 
   Phenylalanine hydroxylase (PAH, phenylalanine 4-
monooxygenase, EC 1.14.16.1) catalyzes the 
stereospecific hydroxylation of L-phenylalanine (L-Phe)  
to L-tyrosine, the first and rate-limiting step in the  
 
 
Abbreviations : 6-MPH4, 6-methyl-5,6,7,8-tetrahydropterin; 
BH4, (6R)-L-erythro-5,6,7,8-tetrahydrobiopterin; CvPAH, 
Chromobacterium violaceum PAH; hPAH, human 
phenylalanine hydroxylase; MBP, maltose binding protein; L-
Phe, L-phenylalanine; L-Tyr, L-tyrosine; nH, Hill coefficient; 
rPAH, rat phenylalanine hydroxylase; RU, resonance units; 
SEC, size-exclusion chromatography; SPR, surface plasmon 
resonance; THA, 3-(2-thienyl)-L-alanine; WT, wild-type. 
 
140 
 
catabolism of L-Phe (for reviews, see [1-4]). The 
enzyme uses a five-coordinated Fe(II) to activate 
dioxygen in the tightly coupled hydroxylation of L-Phe 
with the pterin cofactor (6R)-L-erythro-5,6,7,8-
tetrahydrobiopterin (BH4) as the electron donor. 
Mammalian PAH is a homotetramer (in equilibrium 
with a dimeric form) with the protomer (452 residues) 
consisting of three structural and functional 
subdomains: a N-terminal regulatory domain (residues 
1-117), a catalytic core domain (residues 118-410), and 
a C-terminal oligomerization domain (residues 411-
452), with a dimerization and a tetramerization motif 
(for review, see [1]). The full-length enzyme has been 
resistant to crystallization, but high-resolution 
structures of a truncated tetrameric form (ΔN102-
hPAH) lacking the N-terminal regulatory domain [5] 
and a truncated dimeric form (ΔC24-rPAH) lacking 24 
C-terminal residues of the tetramerization motif [6], 
have allowed the generation of a modeled structure of 
the ligand-free tetrameric full-length hPAH [1]. 
Moreover, the structures have indicated a functional 
role of the conformational changes which occur at the 
active site upon substrate binding, by an apparently 
induced-fit mechanism [7-10]. Thus, upon L-Phe 
binding to the binary cofactor complex (ΔN102/ΔC24-
hPAH-Fe(II)·BH4) hinge-bending motions results in a 
displacement of a flexible surface loop (Fig. 1A and B) 
[8,9] and a relocation of the side-chain of Y138 to a 
partially buried position at the active site (Fig. 1C). 
Additionally, these structures have provided insights 
into the roles of active site residues and conformational 
changes in substrate recognition and catalysis, leading 
to the proposal of a catalytic mechanism for PAH [8]. 
This functional model has more recently been extended 
to the full-length form of the structurally and 
functionally related enzyme rat tyrosine hydroxylase 
(rTH) in a structure-based mutagenesis study [11]. The 
3D structure of a tetrameric N-terminal truncated form 
of rTH (ΔN155/158-rTH), lacking residues 1-155/158, 
has also revealed a flexible loop structure, comprising 
residues 177-191 [12,13], where residues 180-185 
correspond to residues 134-139 in the homologous loop 
of PAH. Mutation of F184 in rTH (~ Y138 in hPAH) in 
the center of the loop to an A resulted in a ~ 6-fold 
reduction in both catalytic and coupling efficiency, and 
it was proposed that a motion of the flexible loop may 
be involved in the rate-limiting step of the TH reaction 
[11]. The functional importance of the L-Phe-induced 
displacement observed for the flexible surface loop in 
hPAH (conserved in mammalian PAHs) and relocation 
of the Y138 hydroxyl group to a partially buried 
position at the active site [8,9] has, however, yet to be 
addressed experimentally. 
   To further probe the functional role of Y138 we have 
generated mutations of this residue (Y138F/A/E/K) in 
the dimeric catalytic core domain (ΔN102/ΔC24-
hPAH) and in the full-length tetrameric hPAH. The 
functional impact was assessed by steady-state kinetic 
analysis, by measuring the coupling efficiency of the 
hydroxylation reaction and by monitoring the substrate-
induced conformational isomerization (hysteresis) of 
the full-length tetramer in real-time by surface plasmon 
resonance (SPR) spectroscopy. A comparison of the 
functional perturbations of the two enzyme forms lends 
support to the conclusion that Y138 in the flexible loop 
has an equally important catalytic function in the 
dimeric catalytic core domain and in the full-length 
tetrameric enzyme. Moreover, in the full-length 
tetramer Y138 also plays a regulatory role in the L-Phe 
triggered conformational isomerization of the enzyme, 
related to its catalytic activation. 
 
Experimental Procedures 
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Fig. 1. The localization and interactions of the Y138 residue in the catalytic core domein of human phenylalanine hydroxylase. 
(A) Electrostatic surface potential of the binary ∆N102/∆C24-hPAH-Fe(II)⋅BH4 complex (PDB i.d. 1j8u) and (B) electrostatic 
surface potential of the ternary ∆N102/∆C24-hPAH-Fe(II)·BH4·THA complex (PDB i.d. 1kw0). The Cα backbone of the loop 
surrounding Y138 (residues 134-139) and the Y138 side-chain is shown in stick model. Red and blue represent negative and 
positive potentials, respectively. (C) A stereo view of the Y138 interactions in the hydrophobic core at the active site of the 
ternary complex ∆N102/∆C24-hPAH-Fe(II)·BH4·THA (PDB i.d. 1kw0), where it forms an intramolecular hydrogen bond to a 
water molecule (Wat 2, red sphere), which is also hydrogen bonded to O2’ of the dihydroxypropyl side chain of BH4. The figures 
were created using PyMOL, version 1.1 (DeLano Scientific) [29]. 
 
Materials 
   The primers for site-directed mutagenesis were 
obtained from Eurogentec (Seraing, Belgium) and 
MWG-Biotech AG (Ebersberg, Germany). The 
QuikChange® II site-directed mutagenesis kit was from 
Stratagene (La Jolla, CA, USA). The BigDye® 
Terminator v3.1 Cycle Sequencing Kit used to prepare 
DNA for sequencing was delivered by Applied 
Biosystems, and the DNA sequencing was carried out 
on an ABI 3730xl DNA Analyzer (Applied 
Biosystems). The restriction protease factor Xa was 
obtained from Protein Engineering ApS (Aarhus, 
Denmark). The reagents and the sensor chip CM5 used 
in the surface plasmon resonance (SPR) analyses were 
purchased from Biacore AB (Uppsala, Sweden). (6R)-
L-erythro-5,6,7,8-tetrahydrobiopterin was delivered by 
Dr. B. Schircks Laboratory (Jona, Switzerland). 
 
Site-specific mutagenesis 
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   The mutations Y138 → F/A/K/E were introduced into 
the cDNAs of the WT-hPAH and double truncated form 
∆N102/∆C24-hPAH using the QuikChange® II site-
directed mutagenesis kit. The pMAL-hPAH [14] and 
the pMAL-∆N102/∆C24-hPAH plasmids [15], 
containing a cleavage site for factor Xa, were used as 
the template and the specific oligonucleotides primers 
listed in Supplementary Table S1 were used for 
mutagenesis. The constructs were sequenced in both 
directions to verify the introduction of the desired 
mutations. 
 
Expression and purification of hPAH 
   The WT-hPAH, the double truncated form 
∆N102/∆C24-hPAH and respective mutant fusion 
proteins were expressed in Escherichia coli (TB1 cells) 
with maltose binding protein (MBP) as the fusion 
partner [14]. The bacteria were harvested after 8 h of 
induction with 1 mM isopropyl-thio-β-D-galactoside 
(IPTG) at 28 ºC, and the tetrameric and dimeric fusion 
proteins were purified by affinity chromatography to 
homogeneity as previously described [14]. The fusions 
proteins were cleaved for 4 h at 4 ºC by the restriction 
protease factor Xa (Protein Engineering Technology 
ApS, Aarhus, Denmark) using a protease to substrate 
ratio of 1:200 (by mass) followed by size-exclusion 
chromatography (SEC) at 4 ºC using a Hiload Superdex 
200 HR column (1.6 cm×60 cm), prepacked from 
Amersham Biosciences (GE Healthcare, Uppsala, 
Sweden), equilibrated and eluted with 20 mM Na-
Hepes, 0.2 M NaCl, pH 7.0 at a flow rate of 0.38 
ml⋅min-1. The isolated WT-hPAH tetramers (and 
corresponding full-length tetrameric mutants) and 
∆N102/∆C24-hPAH dimers (and corresponding double 
truncated dimeric mutants) were collected. Protein 
concentrations were determined using the absorption 
coefficient A280 (1 mg⋅ml-1⋅cm-1) of 1.0 for the WT-
hPAH [14] and of 1.24 for the ∆N102/∆C24-hPAH, 
determined according to the method of Gill and von 
Hippel [16] in 20 mM Na-Hepes, 200 mM NaCl, pH 
7.0, with and without 6 M guanidium chloride. For the 
isolated Y138F/A/K/E-hPAH full-length mutants, A280 
(1 mg⋅ml-1⋅cm-1) of 0.92 was used and for the isolated 
∆N102/∆C24-Y138F/A/K/E-hPAH double truncated 
mutants, A280 (1 mg⋅ml-1⋅cm-1) of 1.19 was used, both 
determined by the method of Gill and von Hippel [16]. 
   Protein purity was analyzed by SDS-PAGE in a 10 % 
(w/v) polyacrylamide gel [17]. The gels were stained by 
Coomassie Brilliant Blue R-250, scanned using 
VersaDoc 4000 (Bio-Rad) and quantification of the 
protein bands was obtained by using the Quantity One 
1-D Analysis Software (Bio-Rad, Hercules, CA, USA). 
 
Assay of enzymatic activity and coupling efficiency 
   The catalytic activity was assayed at 25 ºC in a 
medium containing 100 mM Na-Hepes, pH 7.0, 5 mM 
DTT, 0.04 mg⋅ml-1 catalase, 100 µM ferrous 
ammonium sulfate, 0.5 mg⋅ml-1 bovine serum albumin, 
0.3−0.9 µM subunit of tetrameric hPAH or dimeric 
∆N102/∆C24-hPAH and variable concentrations of L-
Phe and pterin cofactor BH4. After 5-min preincubation 
with L-Phe, the reaction was initiated by adding BH4 
with DTT, and allowed to proceed as described [18]. 
The amount of L-Tyr formed after one minute 
(standard), or other selected time points, was measured 
by HPLC with fluorimetric detection [14]. The steady-
state kinetic parameters were calculated by non-linear 
regression analysis using the SigmaPlot® Technical 
Graphing Software and the modified Hill equation of 
LiCata and Allewel [19] for cooperative substrate 
binding as well as substrate inhibition [18], i.e. the 
velocity ν = {Vmax + Vi([S]x/Kxi)}/{1 + (Kh/[S]h) + 
([S]x/Kxi)} [19]. The exponent x is a second Hill 
coefficient which allows for the possibility that the 
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substrate inhibition may also be cooperative, and by 
varying the value of x between 1 and 3, x = 2 gave the 
best fit for our values. [S]0.5 is taken as the 
concentration of substrate at one-half the calculated 
Vmax. In order to study the effect of preincubation with 
L-Phe on the specific activity (fold activation), 1 mM L-
Phe was added either at the start of the preincubation 
period or together with 75 µM BH4 at the initiation of 
the hydroxylation reaction. 
   The coupling efficiency of the hydroxylation reaction 
was measured in a mixture containing 0.3−1.5 µM 
hPAH, 200 µM NADH, 0.05 µg⋅µl-1 catalase, 10 units 
superoxide dismutase, 10 µM ferrous ammonium 
sulfate, 1 mM L-Phe, excess dihydropteridine reductase 
in 187 mM Hepes buffer, pH 7 at 25 ºC [9]. The 
reaction was started by adding 100 µM BH4, and the 
oxidation of NADH was followed in real-time at 340 
nm, using an Agilent 8453 Diode Array 
spectrophotometer with a Peltier temperature control 
unit. At selected time points aliquots of the reaction 
mixture were mixed with acidic ethanol (stop solution), 
and the amount of L-Tyr formed was measured by 
HPLC with fluorimetric detection [20]. The degree of 
coupling was expressed as the molar ratio of L-Tyr 
formation to BH4 oxidation (measured as oxidized 
NADH, using the molar extinction coefficient, ε = 6220 
M-1⋅cm-1). 
 
Surface plasmon resonance analysis 
   Real-time interaction analysis between immobilized 
enzyme and L-Phe was measured by surface plasmon 
resonance (SPR) spectroscopy [21-23] using the 
Biacore 3000 biosensor system (BiaCore AB, Uppsala, 
Sweden). The full-length enzymes, diluted in 10 mM 
sodium acetate buffer (pH 5.5) to a final concentration 
of 0.23 mg⋅ml-1, were immobilized covalently to the 
hydrophilic carboxymethylated dextran matrix of a 
CM5 sensor chip by the standard primary amine 
coupling reaction. The system was equilibrated with 
HBS-EP (10 mM Hepes, 150 mM NaCl, 3.4 mM 
EDTA and 0.005 % (v/v) of the surfactant P20, pH 7.4) 
at a flow rate of 5   µl⋅min-1 at 25 ºC [21]. Various 
concentrations of L-Phe in HBS-EP buffer were injected 
over immobilized hPAH, and the sensorgrams were 
analyzed by simple Langmuir response isotherms 
[21,23]. The equilibrium responses (∆RUeq at t = 3 min) 
as a function of the free analyte (L-Phe) concentration 
was used to determine the concentration at half 
maximal response ([L]0.5) and the maximum ∆RUeq-
value by nonlinear regression analysis using the 
SigmaPlot® Technical Graphing Software. The 
experimental error for replicate injections of the analyte 
was < 4%. The SPR responses were expressed as 
∆RU/(ng protein/mm2) where 1000 RU corresponds to 
~ 1 ng protein/mm2 of immobilized protein [24]. 
 
Computational and structural analysis 
   The effect of Y138F/A/E/K mutations in the catalytic 
core domain, ∆N102/∆C24-hPAH, on the free energy of 
folding (∆∆G) was predicted for its unliganded and 
substrate bound conformational states using the 
coordinates of Protein Data Bank codes PDB i.d. 1pah 
and 1kw0, respectively, and the algorithm 
Concoord/PBSA [25] available at 
(http://ccpbsa.biologie.uni-
erlangen.de/ccpbsa/index.php). Experimental B-factors 
of Cα atoms in the truncated form ∆C24-rPAH (PDB 
i.d. 1phz) were obtained using the algorithm 
MolMovDB [26,27] 
(http://molmovdb.mbb.yale.edu/molmovdb/). To 
identify the location of potential hinge-bending regions 
in PAH we subjected the crystal structure of unliganded 
rPAH (PDB i.d. 2phm) to further analysis using the 
HingeMaster software program that predicts the 
144 
 
location of hinges in a protein by integrating existing 
hinge predictors (TLSMD, StoneHinge, FlexOracle and 
HingeSeq) with a family of novel hinge predictors 
based on grouping residues with correlated normal 
mode motions (http://molmovdb.org/cgi-bin/submit-
flexoracle.cgi) [28]. Structural images were generated 
with PyMol [29] available at (http://www.pymol.org/). 
 
Results 
 
Expression and isolation of WT-hPAH and 
∆N102/∆C24-hPAH and their Y138F/A/E/K mutant 
forms 
   The fusion proteins of WT-hPAH and ∆N102/∆C24-
hPAH and their Y138F/A/E/K mutant forms were 
expressed at comparable high yields in E. coli and 
isolated by affinity chromatography and SEC. Cleavage 
of the fusion proteins and the subsequent isolation of 
their oligomeric forms by SEC resulted in mg quantities 
of soluble tetrameric and dimeric forms, respectively, 
with identical electrophoretic mobilities on SDS-PAGE 
for the WT and mutant forms (Supplementary Fig. S1A 
and B). 
 
The effect of Y138F/A/E/K mutations on the free energy 
of folding 
   Using the coordinates of the ligand-free double 
truncated ∆N102/∆C24-hPAH-Fe(II) dimeric form 
(PDB i.d. 1pah) and the structure based method for 
prediction of the free energy of folding [25] of mutant 
proteins, substitutions of the surface located Y138 
(solvent accessibility ~80%) with F (aromatic without 
the hydroxyl group), A (small, uncharged), E (acidic) 
and K (basic) residues were found not to have any 
significant effect on its stability (Fig. 2A). By contrast, 
using the coordinates of its ternary complex 
∆N102/∆C24-hPAH-Fe(II)⋅BH4·THA (PDB i.d. 1kw0)  
 
Fig. 2. (A) Estimation of the free energy of folding (∆∆G) of 
the mutant proteins (Y138F/A/E/K) using the 
Concoord/PBSA algorithm [25] with the coordinates of the 
unliganded double truncated ∆N102/∆C24-hPAH dimeric 
form (PDB i.d. 1pah) (black bars), and the coordinates of the 
ternary complex ∆N102/∆C24-hPAH-Fe(II)⋅BH4·THA (PDB 
i.d. 1kw0) (gray bars). The two horizontal dashed lines 
represent the standard deviation of the method (σ = 1.04 
kcal·mol-1). (B) Combined hinge prediction scores of the R-C 
domain structure in the non-phosphorylated form of rPAH 
(PDB i.d. 2phm) using the HingeMaster server [28] as a 
function of amino acid residue number with particular hinge 
bending regions indicated. 
 
the A, K and E substitutions of the active site located 
Y138 (solvent accessibility ~22%) were predicted to 
have an increasingly (A<K<E) destabilizing effect (Fig. 
2A). A similar comparison could, however, not be made 
for the two truncated forms ∆C24-rPAH-Fe(III) (PDB 
i.d. 1phz) and ∆N102-hPAH-Fe(III) (PDB i.d. 2pah), 
since no electron density was observed for the residues  
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137-142 of the flexible loop in these structures 
(Supplementary Fig. S2). 
 
The effect of Y138F/A/E/K mutations on the steady-state 
kinetic parameters 
   The steady-state kinetic parameters of the dimeric 
catalytic core domain and the tetrameric WT-hPAH and 
their Y138F/A/E/K mutant forms were determined with 
L-Phe and BH4 as the variable substrates (Table 1). The 
dimeric WT catalytic core domain revealed a 4-fold 
higher catalytic efficiency (kcat/[S]0.5,L-Phe) than the WT 
full-length tetrameric enzyme, and was not further 
activated by preincubation with L-Phe. Moreover, it 
demonstrated a more pronounced substrate inhibition 
than the tetrameric enzyme (Fig. 3A and B), which 
complicated the determination of the kinetic 
cooperativity with respect to L-Phe (see Methods 
section). The substitutions Y138F/A/E/K reduced the 
catalytic efficiency to 62, 38, 19 and 10 % of WT, 
respectively, and except for the Y→A substitution the 
Km value for BH4 was increased (Table 1). 
   L-Phe plays a major role in the regulation of the 
catalytic activity of the full-length tetrameric PAH 
which is activated several-fold by preincubation with 
the substrate and displays a positive kinetic 
cooperativity with respect to L-Phe (for review, see [1-
4]). The tetrameric WT-hPAH revealed a Hill 
coefficient of nH = 1.95 ± 0.17 and a [S]0.5-value of   
170 ± 10 µM with a 5.3-fold enhancement of the 
catalytic activity (activation) on a 5-min preincubation 
with 1 mM L-Phe at 25 ºC (Table 1). The substitutions 
Y138F/A/E/K lowered the catalytic efficiency 
(kcat/[S]0.5,L-Phe) to 56, 38, 18 and 5 % of WT, 
respectively, but the Km value for BH4 did not change 
significantly (Table 1). Interestingly, the Y138A 
tetramer revealed a slightly decreased [S]0.5 value (144 
± 9 µM) for L-Phe and a higher fold activation (9.2-
fold) on preincubation with 1 mM L-Phe, whereas in the 
Y138E/K mutations the [S]0.5,L-Phe value increased and 
the fold activation by substrate was reduced (Table 1). 
All the mutant tetramers revealed a lower Hill 
coefficient than WT-hPAH (Table 1), most pronounced 
for the Y138E/K mutant forms. 
   From Fig. 4 it is seen that a high correlation (r2 = 
0.99) was observed between the effect of the mutations 
on the catalytic efficiency (kcat/[S]0.5,Phe) of the catalytic 
core domain and the full-length tetrameric enzyme. 
Moreover, as seen from Table 2 the hydroxylation 
reaction was fully coupled in the catalytic core domain 
mutants whereas a slight uncoupling was observed for 
the Y138A/E/K mutations of the full-length tetrameric 
enzyme. 
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The Y138F/A/E/K mutations perturb the L-Phe-induced 
conformational isomerization of the full-length 
tetrameric enzyme 
   The L-Phe triggered activation of the tetrameric 
enzyme is characterized by a reversible conformational 
isomerization, a characteristic feature of this hysteretic 
enzyme. Surface plasmon resonance (SPR) and intrinsic 
tryptophan fluorescence spectroscopy have previously 
been used to monitor in real-time this process which 
occurs on a s-to-min time scale [21-23,30]. Here, the 
full-length tetrameric WT-hPAH and its mutant forms 
were immobilized at high ∆RU-values in the range of 
32000-38000 RU, i.e. 32-38 ng bound tetramer/mm2. 
As previously described [22,23] a time-dependent 
increase in the SPR signal response to L-Phe injection 
was observed for the full-length WT-hPAH tetramer 
and in all the mutant forms, with ∆RUeq reached at ~3 
min (individual sensorgrams not shown). However, the 
maximum ∆RUeq value (∆RUmax), calculated from the 
respective L-Phe vs ∆RUeq response isotherms varied 
(Fig. 5A). Thus, the ∆RUmax was increased in the 
Y138A mutant form whereas it was slightly reduced in 
the Y138E/K mutants. Moreover, from Fig. 5B it is 
seen that the fold increase in the catalytic activity on 
preincubation with 1 mM L-Phe (fold activation) (Table 
1) correlates (r2 = 0.96) with the ∆RUeq of the SPR 
signal response at the same L-Phe concentration. 
   Since the catalytic core domain ∆N102/∆C24-hPAH 
is already in an activated state, it did not demonstrate 
any hysteresis, but only a minor time independent SPR 
response to L-Phe binding (~0.05 RU/ng subunit/mm2) 
[23]. 
 
 
Fig. 3. The effect of substrate (L-Phe) concentration on the 
catalytic activity of the dimeric catalytic core domain 
∆N102/∆C24-hPAH () and of the full-length tetrameric 
WT-hPAH (). The hPAH activity was assayed at standard 
conditions (0−4 mM L-Phe, 75 µM BH4 and 25 ºC). (B) 
Close-up of the data shown in A obtained in the concentration 
range 0−500 µM L-Phe, demonstrating a positive 
cooperativity for the full-length tetrameric WT-hPAH. 
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Fig. 4. Secondary plot demonstrating the positive correlation 
between the catalytic efficiency (kcat/[S]0.5) of the 
Y138F/A/E/K mutations in the dimeric catalytic core domain 
(∆N102/∆C24-hPAH) and the full-length tetrameric WT-
hPAH. The primary data are given in Table 1. The values for 
the catalytic efficiency were normalized with the WT full-
length and WT catalytic core domain as a reference (1.0). 
Error bars represent SD; the correlation coefficient was r2 = 
0.99. 
 
Discussion 
   The existence of coupled residue motions on various 
time scales in enzymes is now well accepted, and their 
detailed characterization has become an essential 
element in understanding the role of protein dynamics 
in catalysis. So far, only a small number of enzymes 
have been shown to rely on essential coupled residue 
motions for catalysis (for reviews, see [31] and [32]). 
Based on combined enzyme kinetic and biophysical 
studies on the full-length tetrameric mammalian PAH 
there is broad agreement that its catalytic activation by 
L-Phe, preceding the chemical steps of the reaction, can 
be presented by the following equation, 
 
                         k1                 k2 
 PAH + Phe ↔ PAH·Phe ↔  PAH*·Phe  (1) 
  
                         k-1                 k-2 
where PAH represents the ligand-free state of the 
enzyme, PAH·Phe its low-activity binary enzyme- 
 
Fig. 5. The equilibrium L-Phe binding isotherm of full-length 
tetrameric WT-hPAH and respective mutant forms as 
measured by surface plasmon resonance (SPR). (A) The SPR 
response isotherm for immobilized full-length tetrameric WT-
hPAH (), Y138F-hPAH (▼), Y138A-hPAH (), Y138E-
hPAH () and Y138K-hPAH () to increased concentrations 
of L-Phe. The truncated form ∆N102/∆C24-hPAH (catalytic 
core enzyme) was immobilized to the reference cell. The 
experiments were performed at 25 ºC in HBS-EP buffer (10 
mM Hepes, 150 mM NaCl, 3.4 mM EDTA and 0.005 % (v/v) 
of the surfactant P20, pH 7.4). The experimental error for 
replicate injections of the analyte was < 4%. The curve fitting 
of the binding isotherms was calculated by non-linear 
regression analysis using SigmaPlot® Technical Graphing 
Software with a r2 = 0.99. (B) Secondary plot demonstrating 
the relationship between the fold activation and the substrate-
induced global conformational change (∆Req) of full-length 
tetrameric WT-hPAH and respective mutant forms as 
measured by SPR. The primary data are given in Table 1 and 
Fig. 5A. The fold activation was measured with and without a 
5-min preincubation step of the enzyme with the substrate L-
Phe (1 mM). The relative values of the SPR signal amplitude 
corresponds to the ∆RUeq values for the equilibrium L-Phe 
binding isotherms at 1 mM L-Phe, with the wild-type as a 
reference (1.0). A strong positive correlation (r2 = 0.96) 
between the fold activation and the global conformational 
change is observed. 
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substrate complex and PAH*·Phe the binary complex 
of the high-activity state in which a relatively slow (s-
to-min time scale) conformational isomerization has 
occurred [21-23,33], with k2,obs << k1,obs, characteristic 
of a hysteretic enzyme. The substrate triggered 
isomerization has been followed in real-time by 
intrinsic tryptophan fluorescence and SPR spectroscopy 
[21-23], and found to be correlated (r2 = 0.93 - 0.96) to 
the degree of catalytic activation [22,33]. Moreover, the 
high-resolution structures of the ligand-free form, the 
binary (with BH4) and the ternary (with BH4 and 3-(2-
thienyl)-L-alanine (THA)) substrate complexes of its 
catalytic core domain (ΔN102/ΔC24-hPAH-Fe(II)) 
have provided insights into potentially catalytically 
related motions [7-9]. In this enzyme form substrate 
binding triggers structural changes throughout the entire 
catalytic domain [8,9], including the active site (Fig. 1), 
which is considered to represent the “epicenter” of the 
conformational transition [8,9]. Substrate binding also 
results in a change in the co-ordination of the catalytic 
ferrous iron and a reorientation of residues lining the 
active site [7-9], representing major contributions to 
catalysis [8,9,34]. One of the most prominent motions is 
observed for the flexible surface loop (residues 131-
155) with a maximum Cα displacement of ~10 Å for 
Y138 [8,9], bringing its hydroxyl group ~21 Å closer to 
the iron atom (Oη only 6.5 Å away) (Fig. 1 A and B). 
The phenolic group packs (interactions within 4.0 Å) 
within a hydrophobic pocket consisting of the side-
chains of L248, W326, V379 as well as the main-chain 
of P279 and the aromatic group of the substrate (Fig. 
1C), and its position stabilized by hydrogen bonding to 
the pterin cofactor and hydrophobic contacts (Fig. 1C). 
The question is, however, to what extent this relocation 
of the mobile surface loop and Y138 is representative 
for the full-length enzyme. 
   The 3D structure of the ligand-free truncated dimeric 
form ΔC24-rPAH-Fe(III), with an intact regulatory 
domain but lacking 24 residues of the C-terminal 
tetramerization motif [6] (PDB i.d. 1phz), is the closest 
representative for the ligand-free full-length dimeric 
WT-PAH, also with respect to catalytic activity and 
regulatory properties [23]. Thus, L-Phe triggers a 
similar reversible conformational isomerization as in 
the full-length enzyme and demonstrates a catalytic 
activation by L-Phe preincubation [23]. The 3D 
structure of ΔC24-rPAH-Fe(III) also identified the 
flexible surface loop (residues 131-155) with a high 
crystallographic B-factor (Supplementary Fig. S2), as in 
the catalytic core domain structure, but with an 
unassigned electron density for the center residues 137-
142. Moreover, two potential hinge-bending regions are 
predicted within the loop (Fig. 2B). These structural 
properties imply that the Y138 loop in ∆C24-hPAH-
(Fe(III) has the flexibility required for its relocation to 
the active site on substrate binding, as observed in the 
∆N102/∆C24-hPAH-Fe(II) catalytic core domain (Fig. 
1A-C), which may be extended to include the full-
length enzyme. This conclusion is further supported by 
the kinetic analyses of the Y138F/A/E/K mutations in 
the full-length tetrameric hPAH (Table 1 and Fig. 4) 
demonstrating, with minor differences, similar kinetic 
effects as observed for the dimeric catalytic core 
domain. Additionally, Y138 shows a regulatory role in 
the L-Phe triggered conformational isomerization and 
catalytic activation of the tetrameric enzyme. 
   In the structurally and functionally related enzyme 
tyrosine hydroxylase (rTH), the mutation F184A (~ 
Y138 in hPAH) in the homologous 14 residue flexible 
loop structure (residues 177-191) of the full-length 
enzyme was found to result in a 95 % reduction in Vmax 
and 84 % reduction in the coupling efficiency, using the 
pterin cofactor analog 6-MPH4 as the electron donor, 
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and it was concluded that the F184 loop controls the 
coupling of L-Tyr hydroxylation to tetrahydropterin 
oxidation [11]. Thus, the reported kinetic effects of the 
F184A mutation in rTH are far more dramatic than 
those observed here for the Y138A substitution in 
hPAH using the natural cofactor BH4 (Tables 1 and 2), 
the preferred electron donor in studies on coupling 
efficiency [35]. Although the catalytic mechanism of 
PAH and TH is considered to be essentially the same, 
the regulatory properties of the two enzymes are quite 
different [1,36,37]. In striking contrast to PAH no 
catalytic activation of TH is observed on preincubation 
with its substrate, and a potential conformational 
change upon substrate (L-Tyr) binding has not been 
demonstrated experimentally [37]. Here, our mutation 
analyses have revealed a regulatory role of Y138 also in 
the catalytic activation of the full-length enzyme (Fig. 
5) since its substitution with F/A/E/K perturbs the L-
Phe induced isomerization equilibrium. Thus, the 
propensity to adopt to its catalytically most active 
isomeric conformation (∼PAH*·L-Phe in eqn. 1), as 
measured by ΔRUmax of the equilibrium SPR signal 
response, is promoted by the Y→A substitution (Fig. 
5A), and the related fold catalytic activation [22] is 
enhanced in a proportional way (Fig. 5B). These effects 
of the Y138A mutation indicate that the substitution of 
the bulky aromatic side-chain may allow an easier 
access of this residue to the hydrophobic active site 
pocket (Fig. 1C), and thus promote the substrate-
induced conformational isomerization (Fig. 5), although 
it simultaneously negatively impacting the catalytic 
reaction (Table 1). In the Y138F substitution no 
significant change was observed in the [S]0.5,Phe value, 
the Km for the cofactor and the fold activation by 
substrate preincubation, but the Vmax value decreased by 
38 % (truncated form) and 34 % (full-length form) with 
L-Phe as the variable substrate (Table 1). In this case a 
loss of the water (WAT2) mediated hydrogen bond (2.7 
Å), linking the side-chain of Y138 with BH4 O2' (Fig. 
1C and Fig. S3) [8,9], may cause a structural 
destabilization of the active site interactions. Although 
WAT2 in the WT structure may have a stabilizing 
effect on the active site structure, this iron co-ordinated 
water does not seem to be of importance in the catalytic 
reaction [8,38]. As expected from the computed ΔΔG 
values for the mutations (Fig. 2) the most perturbing 
effects on substrate activation and catalytic efficiency 
was observed when Y138 is substituted with the 
hydrophilic and charged amino acids (K and E), 
presumably explained by an unfavorable 
polarity/charge effect and steric conflict with the side-
chains of residues lining the active site. 
   The catalytic mechanism of PAH is sequential and all 
three substrates (BH4, L-Phe and O2) are bound at the 
active site before any L-Tyr is released [35,39]. Our 
crystal structure analyses of the binary hPAH-
Fe(II)·BH4 and ternary hPAH-Fe(II)·BH4·THA 
complexes of the catalytic core domain [7,8] have 
demonstrated that an open co-ordination position on the 
iron becomes available for dioxygen only in the 
presence of both reduced pterin cofactor (BH4) and 
substrate (THA). The proposed reaction scheme [8] has 
later been supported by steady-state kinetic analyses 
using a monomeric bacterial enzyme (CvPAH) which is 
devoid of the complex regulatory properties of the 
mammalian enzyme [1]. The catalytic mechanism was 
found to be fully ordered, with reduced pterin cofactor 
binding the active site first, L-Phe second and O2 last 
[39]. Interestingly, the overall fold of CvPAH 
resembles the catalytic domain in hPAH [40], and has a 
~ 10-fold higher specific activity [39,40]. The finding 
that the hydroxylation of L-Phe catalyzed by the 
Y138F/A/E/K mutant forms of the catalytic core 
enzyme are all fully coupled (Table 2), and almost fully 
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coupled in the full-length enzyme, indicates that the 
reduced pterin cofactor is protected from oxidation as in 
the WT form. The Y138 loop behaves like a “lid” 
domain, whose proper closure restricts the accessibility 
of bulk solvent. Our data suggest that the reduced 
catalytic efficiency (kcat /[S]0.5,Phe) measured for all the 
mutant forms (Table 1) reflect a perturbation of the 
precise positioning of active site residues (Fig. 1C), and 
a destabilization of the transition state complex. 
   A destabilization of the active site structure which 
involves Y138 may also occur in some mutations 
associated with phenylketonuria (PKU). Past magnetic 
circular dichroism and X-ray absorption spectroscopy 
of the full-length tetrameric WT-rPAH have confirmed 
the 3D structure analyses of the catalytic core enzyme 
[8,9] that the substrate triggered conformational 
isomerization brings the catalytic ferrous iron and the 
substrates in proper position for activation of dioxygen 
and catalysis [34]. One PKU mutant (E280K) was 
found to result in a destabilization of the active site 
structure, leading to a partly uncoupled hydroxylation 
reaction and a 60-fold reduction of the specific activity 
[34]. Interestingly, in our 3D structure of the ternary 
complex of the WT catalytic core enzyme, the side-
chain of E280 forms a stabilizing hydrogen bond with 
the amide N of Y138 (Supplementary Fig. S3). The 
E280K substitution may abolish this hydrogen bond 
which at least partly explains the kinetic effects of the 
mutation. 
   In summary, the high-resolution crystal structures of 
mammalian PAH have revealed a unique active-site 
design, and together with biochemical/biophysical data 
indicated the importance of conformational changes in 
the mechanism of PAH catalysis. Here, our 
Y138F/A/E/K mutations in the catalytic domain have 
provided functional insights into the 
crystallographically observed substrate triggered 
repositioning of a flexible surface loop with the center 
residue Y138 moving from a surface position to a 
partially buried position at the active site. In the full-
length tetrameric enzyme the mutations perturb both the 
L-Phe triggered global conformational isomerization 
(catalytic activation), including the repositioning of the 
loop, and the formation of a precise orientation of 
catalytic groups and residues necessary for catalysis. 
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Supplementary Fig. S1. 10 % SDS-PAGE analysis of the purified recombinant hPAH proteins. (A) Full-length 
tetrameric WT-hPAH and respective tetrameric mutant forms. Lane 1, WT-hPAH; lane 2, Y138F-hPAH; lane 3, 
Y138A-hPAH; lane 4, Y138E-hPAH; lane 4, Y138K-hPAH. (B) Double truncated dimeric catalytic core 
∆N102/∆C24-hPAH and respective double truncated dimeric mutant forms. Lane 1, low-molecular-mass standard; 
lane 2, ∆N102/∆24-hPAH; lane 3, ∆N102/∆C24-hPAH-Y138F; lane 4, ∆N102/∆C24-hPAH-Y138A; lane 5, 
∆N102/∆C24-hPAH-Y138E; lane 6, ∆N102/∆C24-hPAH-Y138K. 
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Supplementary Fig. S2. Crystallographic B-factor values of Cα carbons of the rPAH (PDB i.d. 1phz). No electron 
density was observed for the residues 137-142 in the 24-residue flexible loop structure. 
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Supplementary Fig. S3. Potential stabilizing hydrogen bonds between Y138 and Wat 2 in the ternary complex 
hPAH-Fe(II)·BH4·THA (PDB i.d. 1mmk) of the catalytic domain of hPAH. The Cα backbone of the loop 
surrounding Y138 and the loop surrounding E280 as well as the Y138 and E280 side-chains are shown in stick 
model. The water molecule Wat 2 and the iron are shown as red and magenta spheres, respectively. The figure was 
created using PyMOL version 1.1 (DeLano Scientific) [1]. 
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Supplementary Table S1. 
Oligonucleotides used for site-directed mutagenesis. Mismatch nucleotides are shown in boldface. 
Primer Sense PAH cDNA positiona Sequence (5ʹ→3ʹ) 
Y138F Forward 628-648 CTCAGCTTTGGAGCGGAACTG 
Y138F Reverse 628-648 CAGTTCCGCTCCAAAGCTGAG 
Y138A Forward 628-648 CTCAGCGCTGGAGCGGAACTG 
Y138A Reverse 628-648 CAGTTCCGCTCCAGCGCTGAG 
Y138K Forward 622-653 CAGATTCTCAGCAAAGGAGCGGAACTGGATGC 
Y138K Reverse 622-653 GCATCCAGTTCCGCTCCTTTGCTGAGAATCTG 
Y138E Forward 622-653 CAGATTCTCAGCGAGGGAGCGGAACTGGATGC 
Y138E Reverse 622-653 GCATCCAGTTCCGCTCCCTCGCTGAGAATCTG 
aData are taken from [2]. 
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Phenylketonuria (PKU), the most common inborn error of metabolism, was one of the first 
genetic diseases to be explained at the metabolic level, and the first to provide a chemical 
explanation for mental retardation and a basis for an efficient dietary treatment (for review, see 
(Scriver 2007)). Since the first description of the disorder by Asbjørn Følling in the 1930s 
(Følling 1934), a large collection of data on the disease and the protein has been gathered, 
shifting the PKU paradigm from a biochemical enzyme deficiency to a protein misfolding 
disease with a loss of function. Thus, a large number of mutations result in a reduced folding 
efficiency and a reduced thermal/chemical stability of the enzyme, which leads to an increased 
turnover when expressed in mammalian cells (Eiken et al. 1996; Pey et al. 2007; Gersting et al. 
2008; Martínez et al. 2008; Gersting et al. 2010; Muntau and Gersting 2010). Human PAH 
comprises a series of features that made it an excellent model system for studying the underlying 
causes and potential therapeutic tools of cytosolic misfolding diseases. It is an allosteric 
multimeric protein that is regulated by several mechanisms, including post-translational 
modifications, which may lead to functionally important conformational changes (Flatmark and 
Stevens 1999; Li et al. 2010). Human PAH has a small margin of stability versus chemical 
denaturation (Kleppe et al. 1999), which may explain the observed high frequency of misfolding 
of the mutant proteins. The large genotypic heterogeneity, together with the oligomerization 
equilibrium (between tetramers, dimers and higher-order oligomeric forms) of hPAH and its 
intrinsic property to form hybrid forms adds an additional dimension to the molecular 
heterogeneity that might have impact in the catalytic/regulatory properties and protein 
misfolding in the cell. Here, our current results contribute to elucidate specific aspects of PAH 
and PKU related to: (i) the phenomenon of interallelic complementation as observed in 
heterozygous and compound heterozygous patients when hybrid proteins are formed 
(heterotetramers); (ii) the misfolding of hPAH mutant forms characterized by a high tendency to 
self-associate (e.g. G46S), in particular the misfolding of the R-domain, an ACT domain module 
with a putative binding site for L-Phe and (iii) the role of a flexible surface/active site loop in the 
mechanisms of catalysis and catalytic activation of the enzyme. 
Interallelic complementation (IC) in PKU was first suggested by Kaufman and collaborators 
(Kang et al. 1970; Kaufman et al. 1975) in parents of PKU patients (carriers), which 
demonstrated a lower hepatic PAH activity than expected from the average activity of the wild-
type and mutant homozygous enzymes. In the following years IC has been considered as an 
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additional factor contributing to the high phenotypic diversity observed in PKU patients (Scriver 
and Waters 1999), and genotype-phenotype correlations have been difficult to predict in some 
compound heterozygous combinations (e.g. I65T, R158Q, R261Q, R270K, V388M, R408Q, 
Y414C) (Lichter-Konecki et al. 1994; Burgard et al. 1996; Kayaalp et al. 1997; Guldberg et al. 
1998; Rivera et al. 2000). Compound heterozygous patients carrying these mutations revealed a 
more severe metabolic/clinical phenotype than expected from the predicted residual activity 
(PRA) of the homoallelic state. In these patients a negative IC phenomenon was proposed as a 
plausible contributing factor to the observed discrepancies, as the interactions between the 
different mutant protomers may result in hybrid enzymes with reduced enzymatic activity and/or 
stability. Although interactions between wild-type and some mutant subunits (F39L, K42I, L48S, 
I65T, A104D and R157N) have been shown by the yeast two-hybrid system (Waters et al. 2001), 
the enzymatic heteroallelic state was not evaluated and individual hybrid forms were not 
isolated. 
Our studies concerning candidate mutations for negative IC in the Portuguese 
hyperphenylalaninemic (HPA) population (I65T, R261Q, R270K and V338M) (Part III, section 
1) have revealed that combinations among them or with the WT (for the V388M mutation) 
showed a decrease in the enzymatic activity, when compared to the predicted values obtained in 
the homoallelic state (PRA). In these studies we were able to mimic the actual situation 
occurring in heterozygous and compound heterozygous individuals, where a mixture of hPAH 
homotetramers, heterotetramers and dimers is likely to exist. However, the isolation of individual 
hybrid proteins and the possible existence of heterodimers were still unresolved. 
In studies of wild-type and truncated forms of hPAH (Part III, section 2) we were able to 
show that heterodimers were not formed, but only heterotetramers, if the mutant retains a WT-
like C-terminal domain structure. This indicates a co-translational dimerization process, 
explaining why monomers have so far not been reported for WT-hPAH, and a post-translational 
formation of heterotetramers. This was corroborated by in vitro studies of pre-formed dimers of 
WT and a misfolding mutant G46S that self-associates in vitro, forming fibrils (Part IV, section 
1). The presence of WT dimers resulted in an enhancement of the self-association of the G46S 
mutant dimers by forming WT/G46S heterotetramers that resulted in the formation of amorphous 
aggregates. However, the presence of L-Phe avoids this self-association, preventing a negative IC 
in this situation, in what might seem a paradox. This is because the tetramer ↔ dimer 
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equilibrium of the G46S mutant does not respond to the L-Phe level, in contrast to the WT 
protein, and therefore the WT equilibrium is shifted towards the WT homotetramer. We also 
reported the first isolation of a hybrid hPAH protein, the WT/∆N102-hPAH heterotetramer (Part 
III, section 2). The hybrid protein revealed kinetic and regulatory properties, as well as 
conformational changes that were influenced by interactions between the two homodimers 
within the heterotetramer, and therefore the dimers were not acting as isolated units. 
 Besides the restricted phenylalanine-free diet, BH4 supplementation is currently approved for 
the treatment of a subset of mutations (BH4-responsive) (Levy et al. 2007). The supplementation 
with the approved commercial form (sapropterin dihydrochloride) allows adjustments towards a 
less restrictive diet for these patients and in some of them the possibility of a normal diet (Blau 
2010). However, a number of inconsistencies have been reported for BH4 supplementation, 
where compound heterozygous patients carrying two known BH4 responsive mutations revealed 
an absence or only a partial response to the cofactor (Muntau et al. 2002; Desviat et al. 2004; 
Erlandsen et al. 2004; Karačić et al. 2009). Negative IC was proposed as one possible 
explanation (Trefz et al. 2009), and a number of these inconsistencies in BH4-responsive 
genotypes of compound heterozygous patients (e.g. I65T/R261Q, I65T/V388M) (Trefz et al. 
2009) represent a combination of mutations where we have shown a negative IC at the level of 
enzymatic activity (Part III, section 1). 
Nowadays, the full genotype is considered important to evaluate BH4-responsiveness. Owing 
to the large number of compound heterozygous patients (∼75% of the PKU patients) it will be 
interesting to extent these studies to determine the effect of BH4 on hybrid assembly and stability 
properties, as until now these studies have been limited to homotetrameric enzymes. A mouse 
model for compound heterozygous BH4-responsive mutations has been described (Lagler et al. 
2010) and will also contribute to understand the mechanisms underlying BH4-responsiveness in 
compound heterozygous patients. 
Hybrid hPAH proteins should also be taken into account in the development of new 
therapeutic strategies, as the emerging pharmacological chaperones (Pey et al. 2008). They will 
also be important in studies on the genotype-phenotype correlations, elucidating the frequency of 
formation of these hybrid protein forms and their properties, with particular emphasis when one 
of the mutations is an aggregation-prone protein. 
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A large number of mutations result in the misfolding/aggregation/degradation of hPAH 
(Eiken et al. 1996; Bjørgo et al. 1998; Pey et al. 2007; Gersting et al. 2008). The small margin of 
stability of hPAH (Kleppe et al. 1999) is probably related to its high structural flexibility, which 
is of functional importance e.g. in terms of catalytic activation by its substrate (L-Phe), where 
large conformational changes are observed (Stokka and Flatmark 2003; Li et al. 2010). The high 
number of point mutations that lead to protein misfolding could also be related to the reduce 
thermal stability of the R-domain of the protein (an ACT module) (Thórólfsson et al. 2002). 
Our studies on the missense mutation G46S in the R-domain (Part IV, section 1) have 
revealed a self-association which lead to the formation of large, twisted non-amyloid fibrils. The 
in vitro studies were made possible by the expression of the mutant as a maltose binding protein 
(MBP) fusion, which allowed its recovery in a metastable form. Removal of the MBP partner 
resulted in self-association of both the tetramer and the dimer, and we were thus able to study the 
modulation of the self-association process at a series of experimental conditions. The G46S self-
association process is highly dependent on the net charge of the protein, and it could be 
modulated with an increased delay and/or a decrease in the level of self-association by chemical 
chaperones (glycerol), the proposed pharmacological chaperone 3-amino-2-benzyl-7-nitro-4-(2-
quinolyl)-1,2-dihydroisoquinolin-1-one (Pey et al. 2007) and by the heat-shock proteins 
Hsp70/Hsp40 and Hsp90. As far as we know there are no reports on liver dysfunction or in vivo 
fibril formation in individuals with PKU/HPA, and although the mutant protein being a client 
protein for the molecular chaperone systems it is rapidly degraded when expressed in HEK293 
cells (Eiken et al. 1996). However, the cellular mechanism by which G46S and other misfolded 
hPAH proteins are degraded in vivo remains to be further analyzed. Moreover, the experimental 
approach developed in this study can in the future be applied to the study of other mutant 
proteins, especially aggregation-prone mutations. 
The R-domain has been implicated in the conformational instability of the hPAH protein, 
even when the mutations are localized in the other domains (Gersting et al. 2008). In the 3D 
structure, the R-domain of one subunit makes contacts with the catalytic domain of the neighbor 
subunit and with the active site of his own subunit, through the IARS sequence. Therefore, 
misfolding mutations in the catalytic domain can be transmitted to the intrinsically unstable R-
domain. In our studies we expressed and isolated the WT R-domain and its G46S mutant form 
(residues 2-120) (Part IV, section 2), and observed that not only the mutant domain self-
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associates but also the WT R-domain. However L-Phe inhibits in a stereospecific way the self-
association of the WT, but not of the mutant G46S. These data lead us to revisit the controversial 
regulatory binding site for the substrate in human PAH. 
The R-domain of PAH contains an ACT module which in other ACT domain-containing 
proteins is known to have a regulatory function by binding of small molecules (e.g. amino acids, 
pyrimidines), usually at ACT module dimer interface in proteins forming dimers or higher order 
oligomers (Siltberg-Liberles and Martínez 2009). In hPAH there are no contacts between the 
four R-domains in the tetrameric enzyme, and therefore the ACT module in hPAH exists as a 
monomeric entity. However, a second binding site (putatively at the interface between the R-
domain and the adjacent catalytic domain) has been shown in PAHs from lower eukaryotes, e.g. 
in the Caenorhabditis elegans PAH (CePAH) tetrameric enzyme, which does not display a 
catalytic activation and a positive cooperativity in response to L-Phe binding (Flydal et al. 2010). 
However, all the data collected in our studies and from other groups (Flydal et al. 2010; Li et al. 
2011 for latest developments), seem to support the conclusion that the R-domain of full-length 
hPAH has lost the regulatory binding site with the evolutionary emergence of the regulatory 
properties (activation and cooperativity), due to conformational changes in the R-domain and/or 
a steric hindrance due to interdomain interactions (Flydal et al. 2010). Nevertheless, the isolated 
R-domain of hPAH is able to bind L-Phe, and in our studies this binding has a stabilizing effect. 
Therefore, the gain of regulatory properties and the loss of ability to bind L-Phe may explain the 
low stability of the R-domain in the full-length WT human PAH. The function played by the 
ACT domain in the hPAH regulation, conformational changes upon L-Phe triggered catalytic 
activation at the active site and protein misfolding is an area that should deserve more attention 
in the following years. 
 PAH has been shown to undergo large conformational changes during the catalytic cycle, and 
catalytic activation by L-Phe binding is one of the main regulatory mechanisms in this enzyme 
(Flatmark and Stevens 1999). Binding of L-Phe at the active site triggers reversible molecular 
motions that are transmitted from this “epicenter” to the entire protein, resulting in an activation 
of the enzyme and a positive cooperativity of substrate binding to the tetrameric form (Bjørgo et 
al. 2001; Flatmark et al. 2001; Stokka and Flatmark 2003; Stokka et al. 2004). The lack of a full-
length crystal structure has precluded a structural explanation of the activation mechanism, but 
the structures of a truncated form, representing the catalytically active C-domain, have 
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highlighted the conformational changes in the catalytic domain associated with substrate binding 
(Andersen et al. 2002; Andersen et al. 2003). Thus, the crystal structures of the substrate-free 
and the ternary enzyme-substrate complex have provided “snapshots” of the enzyme during the 
catalytic cycle. The largest molecular motion observed was a relocation of a flexible 
surface/active site loop, containing Tyr138 (large Cα displacement) to a partially buried position 
at the active site upon substrate binding. Our comparative steady-state kinetic analyses (Part V, 
section 1) of the truncated (C-domain) and full-length Y138X mutant forms support the 
conclusion that this conformational change and relocation of Tyr138 is representative also for the 
full-length enzyme, and that it participates in the positioning of substrates for catalysis. Our 
studies also revealed an additional role of the Tyr138 loop in the conformational isomerization of 
the full-length enzyme that lead to catalytic activation upon L-Phe binding. Substitution of Tyr 
with a small amino acid (Ala) at residue 138 may allow an easier access of this residue to the 
active site and thus promoting the conformational isomerization as measured by surface plasmon 
resonance, but it has a negative impact on catalysis. Our studies and those of other groups 
(Andersen et al. 2003; Stokka and Flatmark 2003; Thórólfsson et al. 2003; Stokka et al. 2004; Li 
et al. 2010) point to a mechanism for the catalytic activation which involves local 
conformational changes triggered at the active site (“epicenter”) upon L-Phe binding, which 
propagate throughout the entire protein with repositioning of the R- and C-domains. However, 
the protein motions which occur during the catalytic cycle are far from being solved, both in 
terms of 3D structure and protein motions at the backbone and residue level. 
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